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Adiposity-related chronic diseases, including type 2 dia-betes mellitus, cardiovascular diseases (CVDs), and can-
cers, cause >17 million global deaths each year.1 Consumption 
of sugar-sweetened beverages (SSBs) increases adiposity and 
long-term weight gain.2–4 In addition, SSB intake appears to 
increase the risk of diabetes mellitus independently of adipos-
ity,5 likely related to adverse metabolic and glucose-insulin 
effects. Yet, despite dramatic increases in both global sales 
of SSBs6 and the global pandemic of obesity,7,8 comprehen-
sive quantitative estimates of the impact of SSB intake on 
obesity-related diseases in nations worldwide by age and sex 
have not been available. Few published reports of country-
level SSB consumption exist,9–18 and these previous national 
reports have used disparate data sources and methods that 
are not easily compared. In addition, previous studies have 
not systematically assessed how SSB intake impacts major 
chronic diseases worldwide by region, country, age, and sex. 
Comprehensive, accurate estimates of the burdens of chronic 
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obesity-related diseases attributable to SSB consumption, 
including the uncertainty in such estimates, are essential for 
informed national, regional, and global policies.
As part of our work in the 2010 Global Burden of Diseases 
Nutrition and Chronic Diseases Expert Group (NutriCoDE), 
we systematically reviewed, compiled, and extracted national 
data on SSB consumption worldwide and addressed issues of 
consistency, comparability, bias, and missingness in the col-
lated data. We also derived and incorporated into our analysis 
the best available estimates of the effects of SSB intake on obe-
sity and diabetes mellitus, and of obesity on diabetes mellitus, 
CVD, and cancers, including heterogeneity in these effects by 
age and sex. Our analysis further included data on age-, sex-, 
and cause-specific mortality in all nations worldwide. We used 
a comparative risk assessment analytic framework to quantify 
global, regional, and national disease burdens related to SSB 
consumption, assessing both the direct and obesity-mediated 
effects of SSBs on chronic disease.
Methods
To quantify the number of adult deaths worldwide related to SSB 
intake, we used a comparative risk assessment framework19–21 that 
captures geographical, sex, and age variation in SSB consumption, in 
the effects of SSB consumption on diabetes mellitus and body mass 
index (BMI), in the effects of BMI on disease outcomes, and in cause-
specific mortality (Table 1, Figure 1). We estimated both the direct 
effects of SSB consumption on diabetes mellitus burdens and the 
BMI-mediated effects of SSB consumption on CVD, diabetes mel-
litus, and cancer burdens.
Global SSB Consumption Data by Country, Age, 
and Sex
As part of the Global Burden of Diseases, Risk Factors, and Injuries 
2010 study, we identified national surveys or, if unavailable, subna-
tional surveys on SSB intake in adults through systematic searches of 
multiple literature databases and direct contact with experts world-
wide, as described elsewhere.26 SSBs were defined as any sugar-
sweetened sodas, fruit drinks, sports/energy drinks, sweetened iced 
tea, or homemade SSBs such as frescas, which contained at least 50 
kcal per 8-oz serving; 100% fruit juice was excluded. In total, we 
compiled data on SSBs from 62 dietary surveys including 611 971 
individuals conducted between 1980 and 2010 across 51 countries 
(Table I in the online-only Data Supplement).26 Eighty-eight per-
cent of the surveys were nationally representative, and all but one 
had data on both men and women. Forty-five surveys (72%) were 
from low- and middle-income countries, and 18 (28%) were from 
high-income countries. Together, these surveys provided data on SSB 
intake in countries representing 63% of the world’s adult population 
(Table 1).26 We also identified annual country-level data relevant to 
SSB intake between 1980 and 2010 for 187 countries in our analysis 
by using food balance sheet data on per capita sugar availability from 
the United Nations Food and Agriculture Organization.27
From each survey, we extracted data on survey location, time 
period, representativeness, sampling design, dietary assessment 
method, and the age- and sex-specific distributions (mean, standard 
deviation) of SSB intake and corresponding strata-specific sample 
size, using a standardized electronic spreadsheet. We evaluated the 
quality of population sampling and diet assessment methods and 
checked data for plausibility. SSB consumption data were adjusted 
for total energy by using the residual method to reduce measure-
ment error and account for differences in physical activity and 
metabolic rate.28
To combine individual-level intake data with country-level food 
availability data, to address issues of data incomparability, and to 
capture the uncertainty in estimates of beverage intake attributable to 
measurement error, sampling uncertainty, and modeling uncertainty, 
we used established age-integrating Bayesian hierarchical modeling 
methods. The primary model inputs were survey-level quantitative 
data, including country-, time-, age-, and sex-specific consumption 
levels (mean and standard deviation); data on the numbers of subjects 
in each strata; survey-level indicator covariates for sampling repre-
sentativeness, dietary assessment method, and type of dietary metric; 
country-level year-specific data relevant to sugar availability from 
the United Nations Food and Agriculture Organization; and country, 
region (21 regions), and superregion (7 groupings of regions) random 
effects (Table 1).19,26 Model outputs were country-, age-, sex-, and 
year-specific estimates of mean SSB consumption and its uncertainty. 
In our present analysis, we used data on SSB consumption produced 
by this model for the year 2010.
Direct and BMI-Mediated Effects of SSB Intake on 
CVD, Diabetes Mellitus, and Cancers
We incorporated into our analysis the best available estimates for 
etiologic effects of SSBs on BMI and type 2 diabetes mellitus and of 
BMI on CVD (ischemic heart disease, stroke), type 2 diabetes mel-
litus, and cancers (esophageal, colon, pancreatic, breast, uterine, kid-
ney, gall bladder; Tables 1 and 2).24,29
Effects of SSB Intake on BMI
Long-term effects of SSB intake on BMI in adults were derived from 
meta-analysis of 3 large prospective US cohort studies that have eval-
uated the effects of changes in SSB intake on changes in weight gain, 
namely, the Nurses’ Health Study, the Nurses’ Health Study II, and 
the Health Professionals Follow-up Study, with a combined sample 
size of 120 877 participants (Table 1). Each serving per day increase 
in SSB intake was associated with a 0.10 (95% confidence interval 
[CI], 0.05–0.15) kg/m2 increase in BMI in individuals with BMI <25 
and a 0.23 (95% CI, 0.14–0.32) kg/m2 increase in BMI in individu-
als with BMI ≥25 (Table 2).29 These estimates are consistent with a 
recent meta-analysis of 7 prospective cohorts (174 252 individuals) 
that reported an 0.12- to 0.22-kg increase in weight per serving per 
day of SSBs over a 1-year period, and a meta-analysis of 5 trials (292 
participants) that found a 0.85-kg (95% CI, 0.50–1.2 kg) increase in 
body weight when SSBs were added to the diet.30 These estimates 
are also broadly supported by results from 2 recent large randomized 
trials of the effects of SSB intake on weight gain in children, one of 
which reported BMI reductions of ~0.57 kg/m2 for a 1.7 servings/d 
reduction in SSB intake over a 1-year period, and the other of which 
reported significant reductions in weight gain, body fat change, and 
BMI z score for each 104-kcal reduction in sugary beverage intake 
per day over an 18-month period.2,3
Effects of SSB Intake on Diabetes Mellitus
Effects of SSB consumption on diabetes mellitus were based on a 
meta-analysis of 8 prospective cohorts with a total of 310 819 par-
ticipants and 15 043 cases of type 2 diabetes mellitus (Tables 1 and 
2).31 In this meta-analysis, individuals in the highest category of SSB 
intake (1–2 servings/d) had a 26% greater risk of developing type 2 
diabetes mellitus in comparison with those in the lowest category of 
SSB intake (none or <1 serving per month; risk ratio, 1.26; 95% CI, 
1.12–1.41). The association between SSB intake and risk of type 2 
diabetes mellitus in this meta-analysis was consistent across sex and 
ethnic groups, which included blacks, whites, and Asians. Although 
there was heterogeneity among studies (I2=66%), all but one showed 
positive associations between SSB intake and risk of type 2 diabetes 
mellitus, with the strength of the association increasing with study 
size and duration. Three cohorts included adjustment for BMI, most 
appropriate for our modeling of direct (nonobesity-mediated) effects, 
but these also adjusted for total energy intake, which could result 
in underestimation of true effects. Results from this meta-analysis 
are supported by other large studies, including a subcohort of the 
European Prospective Investigation into Cancer and Nutrition, which 
included 15 374 participants and 11 684 cases of type 2 diabetes mel-
litus, and reported a hazard ratio of 1.18 (95% CI, 1.06–1.32) for the 
association of SSBs with type 2 diabetes mellitus.22,32
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Sensitivity Analyses
To determine whether relative risks for individual dietary components 
derived from prospective cohorts might overestimate the impact on 
chronic disease attributable to residual confounding by other dietary 
factors, we performed 3 sensitivity analyses based on studies of over-
all dietary patterns.29 In brief, we compared the predicted risk of coro-
nary heart disease (CHD) calculated from the effects of individual 
dietary components on CHD from cohort data with the observed risk 
of CHD in dietary pattern studies, including (1) prospective cohort 
studies on the association of overall dietary patterns with incident 
CHD, (2) randomized controlled feeding trials quantifying the effects 
of overall dietary patterns on SBP and low-density lipoprotein choles-
terol, and (3) a large randomized clinical trial evaluating the impact of 
an overall dietary pattern on incident CVD events.
Effects of BMI on CVD, Diabetes Mellitus, and 
Cancers
Evidence for effects of BMI on CVD, diabetes mellitus, and site-
specific cancers was obtained from published analyses of large inter-
national pooling studies24,25 (Tables 1 and 2). The effects of BMI on 
CVD and diabetes mellitus were obtained from pooled analysis of 
163 international cohorts with 2.43 million participants and 70 000 
cases. At the reference median age of 60, the relative risk of BMI 
on CVDs, such as ischemic heart disease, stroke, and hypertensive 
heart disease ranged from 1.44 (95% CI, 1.40–1.48) to 1.90 (95 % 
CI, 1.17–3.07) per 5 kg/m2 increase in BMI, and the corresponding 
pooled effect for diabetes mellitus was 2.32 (95% CI, 2.04–2.63). The 
effects of BMI on 7 site-specific cancers (breast, uterine, esophageal, 
pancreatic, colon, kidney, and gall bladder) were based on pooled 
analysis of 221 international cohorts with 282 137 cases.25 The effects 
of SSB on CVD and cancers were assumed to be mediated only 
through changes in BMI, whereas the effects of SSB on diabetes mel-
litus were assumed to be mediated through both BMI- and non-BMI–
related pathways.31,33–35
A J-shaped relationship between BMI and all-cause mortality has 
been observed in some population-based studies, and such nonlin-
earities are primarily attributable to effect modification by smoking 
or reverse causation attributable to underlying chronic disease (such 
as chronic respiratory disease or cancer) in which weight loss may 
precede death by a decade or more. Among the international pooling 
projects used in estimating the etiologic effects of BMI on CVD and 
diabetes mellitus for the present analysis, 21 kg/m2 was the lowest 
empirically observed minimum beyond which no additional benefits 
of lowering BMI were found.24 In our analyses, we therefore restricted 
benefits of SSB reduction up to a BMI of 21 kg/m2, beyond which we 
did not include additional benefits of further weight reduction.
We used the same risk estimates in men and women and across 
different races based on evidence that proportional effects of BMI 
are generally similar by sex and race,24,36 with the exception of spe-
cific cancers for which we used separate risk estimates in men ver-
sus women based on evidence for differing effects of BMI by sex25 
(Table 2). In our analysis, we included age-specific relative risks for 
the effects of BMI on CVD and diabetes mellitus, based on previous 
work demonstrating decreasing proportional effects at older ages.24
Cause-Specific Mortality by Country, Age, and Sex
Data on mortality from 235 causes were compiled as part of the 
2010 GBD study (Table 1).1 In brief, data were obtained on causes 
of death for 187 countries from 1980 to 2010 based on vital registra-
tion, verbal autopsy, mortality surveillance, censuses, surveys, hospi-
tals, police records, and mortuaries; and assessed for completeness, 
diagnostic accuracy, missing data, stochastic variations, and prob-
able causes of death. As described elsewhere, statistical modeling 
strategies estimated cause-specific mortality, including different per-
mutations of covariates and assessment of model performance with 
specific models selected based on data quality and out-of-sample test-
ing of prediction error and the validity of 95% uncertainty intervals 
(UIs).1 Cause-specific mortality fractions within each age-sex group 
were constrained to sum to total mortality based on draws from the 
uncertainty distributions. The final mortality data set included cause-, 
age-, and sex-specific mortality for 187 countries between 1990 and 
2010. In this analysis we used age-, sex-, and country-specific data for 
2010 on deaths attributable to diabetes mellitus (E10–E14), ischemic 
heart disease (International Classification of Diseases, Tenth Revision 
codes I20–I25), ischemic stroke (I63, I65–I67, I69.3), hypertensive 
heart disease (I11), and breast (C50), uterine (C54–C55), esophageal 
(C15), pancreatic (C25), colon (C18–C21), kidney (C64), and gall 
bladder (C23) cancer.
Statistical Analysis
Estimation of Deaths Attributable to SSB Consumption
We quantified disease burdens attributable to SSB consumption 
in 2010 in 187 countries by age and sex by incorporating the data 
described above into a comparative risk assessment analytic frame-
work (Figure 1). We included in our analysis the direct effects of 
SSB on diabetes mellitus and BMI, and the BMI-mediated effects of 
SSBs on diabetes mellitus, CVD (CHD, stroke), and cancers (breast, 
uterine, esophageal, colon, pancreatic, kidney, and gall bladder), as 
well. All analyses evaluated SSB consumption, effects of SSBs on 
diabetes mellitus and BMI, effects of BMI on diseases, and cause-
specific mortality across 16 age- and sex-specific strata within each 
country (men and women ages 20–24, 25–34, 35–44, 45–54, 55–64, 
65–74, 75–84, and 85+ years). We also accounted for stronger effects 
of SSB intake on BMI in overweight versus normal adults29 by parti-
tioning effects in each age-, sex-, and country-specific strata accord-
ing to the proportion of the population who were normal weight or 
overweight.7,8 Our analyses did not involve ecological correlations 
(ie, simple comparisons of SSB intakes and disease rates) because 
these would be limited by substantial confounding. We have instead 
quantitatively assessed and incorporated into our analysis age- and 
sex-specific data on SSB consumption, external evidence on causal 
effects of SSBs on disease risk, and validated data on country-, age-, 
sex-, and cause-specific mortality.
For diabetes mellitus and each BMI-related disease end point, we 
calculated the disease-specific population-attributable fraction attrib-
utable to SSB consumption:
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where x=SSB consumption level; P(x)=current distribution in 
the age and sex stratum; P′(x)=alternative distribution (zero con-
sumption); RR(x)=relative risk of mortality at SSB consumption 
level x; and m=maximum exposure level. Mortality attributable 
to SSB consumption was calculated by multiplying the calculated 
population-attributable fraction by the observed number of cause-
specific deaths (Figure 1). Analyses were done separately for each 
country, age, and sex group, and assessed as both absolute and pro-
portional mortality.
Estimation of DALYs Attributable to SSB Consumption
Disability-adjusted life-years (DALYs) are summary metrics of pop-
ulation health that measure how many years of healthy life are lost 
because of death and disability.37 DALYs are the sum of 2 compo-
nents: the years of life lost attributable to premature mortality and 
the years lived with disability. Years of life lost are computed by mul-
tiplying the number of deaths at each age by a standard life expec-
tancy at that age in the given population. Years lived with disability 
are estimated as the prevalence of different disease sequelae multi-
plied by the disability weight for each sequela.38 Disability weights 
are selected on the basis of surveys of the general population about 
the loss of health associated with the health state related to the dis-
ease sequelae.39 The estimation of cause-specific DALYs by country, 
age, and sex has been described elsewhere.37–39 DALYs attributable to 
SSB consumption were calculated by multiplying the total DALYs 
attributable to CVD, diabetes mellitus, and cancers by the country-, 
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Table 1. Description of Data Sources and Modeling Methods Used to Estimate Adult SSB Consumption Levels, the Effects of SSB Intakes on BMI and  
Diabetes Mellitus, and Total Cause-Specific Mortality by Country, Age, and Sex
Data Source and Description Data Coverage
Statistical Methods Used for Pooling and Modeling Data From Diverse Global Sources
Modeling Approach Covariates Validity
SSB consumption by country, age, and sex Individual-level survey data National food availability data    
  Total consumption of sugar-sweetened beverages 
containing >50 kcal/8-oz serving, including sodas, 
fruit drinks, sports/energy drinks, and sweetened 
iced tea
A total of 780 age- and sex-specific data points, 
88% nationally representative, were collected from 
51 countries and represented 63% of the world’s 
adult population. 16% of all data were from multiple 
dietary recall surveys, 20% of all data were from 
food-frequency questionnaires, 17% of data were 
from single dietary recall surveys, and 47% of data 
were from household availability surveys.
Total annual per capita sugar availability in each of 187 
countries worldwide based on availability of sugar, sugar 
beet, sugar cane, noncentrifugal sugar, and sugar crops. 
These data are based on U.N. Food and Agriculture 
Organization (FAO) food balance sheets which capture a 
country’s net annual food availability, accounting for imports 
and exports.
DisMod3,19 a Bayesian hierarchical method was used to pool 
data from multiple sources and model missing data using 
informative time-varying covariates, borrowing information across 
geographical regions and time periods while also incorporating 
uncertainty attributable to measurement error and model 
specification. Models were fit by using a randomized MCMC 
algorithm based on the Adaptive Metropolis step function.
Both study-specific and national-level covariates were 
incorporated in the model. Study-level covariates 
included information on national representativeness 
of data points, method/metric of data collection, and 
sex. Country-level information included country, region, 
and superregion random effects. Other country-level 
covariates such as gross domestic product were tested 
but did not improve prediction.
Models were assessed for convergence of 
MCMC iterations and were validated by using 
goodness- 
of-fit tests. Final model results were 
assessed for plausibility by subject-matter 
experts.
Relative risks by age and sex      
  Effects of SSB on diabetes mellitus      
   Published meta-analyses of 8 prospective cohort 
studies
Data were from US, European, and Asian cohorts including 310 819 participants and 15 043 cases of type 2 diabetes 
mellitus.*
Systematic review and meta-analysis were used to identify and 
pool relevant data from cohort studies. Given that the effects of 
SSB on incidence of diabetes mellitus are attenuated with age, we 
extrapolated the effect estimate into 10-y age groups from age 
20 to 100 using an age pattern derived from the average percent 
change in relative risk for CVD and diabetes mellitus across 4 
metabolic risk factors.
Included studies considered adjustment for potential 
confounding by age, sex, and various lifestyle factors, 
such as smoking, alcohol use, and physical activity, and 
various dietary habits. For most, a positive association 
persisted, suggesting an independent effect of SSBs on 
incident diabetes mellitus.
Standard methods of assessing publication 
bias, such as Begg and Eggers tests and 
visual inspection of funnel plots indicated 
no evidence of such bias in this analysis. 
Cochrane Q test and the I2 statistic revealed 
statistically significant heterogeneity, which 
was reduced in sensitivity analyses excluding 
smaller studies of shorter duration.
  Linear effects of SSB on BMI      
   Original meta-analysis of 3 prospective cohort 
studies (NHS I, NHS II, HPFS)
Data were from US cohorts including 120 877 participants. The association of change in BMI with change in SSB consumption 
was assessed by using multivariate linear regression accounting 
for within-person repeated measures. Results across the 3 cohorts 
were pooled by an inverse-variance weighted meta-regression as 
described in earlier work.23 Separate linear effects were estimated 
for BMI < 25 and BMI ≥25 because the rate of increase in BMI 
attributable to SSB intake varies based on an individual’s baseline 
BMI.
Analyses were adjusted for age, baseline BMI, and 
changes in other lifestyle behaviors such as diet, 
smoking, physical activity, alcohol consumption, sleep 
duration, and TV watching.
Change in SSB consumption resulted in a 
statistically significant change in BMI across 
all 3 cohorts, and the magnitude of change in 
BMI was consistent across all cohorts. This is 
the only analysis thus far to examine effects 
of change in SSB consumption on change in 
adiposity.
  Effects of BMI on CVD and diabetes mellitus      
   Published pooled analysis of 3 international 
pooling projects (APCSC, PSC, ERFC)
Data were from East Asian, North American, and European pooling projects comprising a total of 163 cohorts, 2.43 
million participants, and 70 000 CVD events.24
Relative risks from the pooling projects were interpolated and 
extrapolated into standard age groups by using log-linear models. 
Age-specific relative risks were pooled using random- 
effects models. Trends in age-specific relative risks from pooled 
analyses were compared with trends in original cohort data to 
ensure validity of pooled results.
Effect modification by race/ethnicity and sex were 
assessed but were not found to be statistically 
significant.
Trends in age-specific relative risks from 
pooled analyses were compared with trends 
in original cohort data to ensure validity of 
pooled results. The I2 test did not reveal 
significant heterogeneity between studies for 
any age group.
  Effects of BMI on site-specific cancers      
   Published meta-analysis of 221 cohort studies. Data were from North American, East Asian, European, and Australian cohorts with a total of 282 137 incident cases 
of cancer >133 000 000 person-years of follow-up.25
Systematic review and random-effects meta-analysis Effect modification by race/ethnicity, sex, and age were 
assessed for cancers other than breast and ovarian, but 
were not found to be statistically significant.
Between-study heterogeneity varied by 
cancer, from low to moderate (0%–55%), 
and there was no evidence of publication bias 
in inspection of funnel plots.
Cause-specific total mortality by country, age, and sex1     
  Vital registration with medical certification of cause 
of death
Data represented 2798 site-years from 130 countries Cause of Death Ensemble Modeling (CODEm), a modeling 
strategy encompassing 4 families of statistical models, was used 
to pool mortality data from diverse sources, aggregate deaths 
hierarchically, and capture uncertainty attributable to model 
parameter estimation, model specification, and fundamental 
sources of error.
Covariates were selected from a database of mortality 
predictors based on the cause of death being modeled. 
Covariates were tested for predictive ability before 
inclusion in a given model.
Models were validated by using out-of-
sample predictive validity tests in which 30% 
of data were withheld from initial model fits. 
Predicted trends were then compared with 
trends in the existing held-out data.
  Verbal autopsy (sample registration, demographic 
surveillance systems)
Data represented 486 site-years from 66 countries, 10% nationally representative
  Cancer registries Data represented 2715 site-years from 93 countries
  Survey/census data Data were from 56 national surveys
  Sibling history Data represented 1557 survey-years from 61 countries
  Burial/mortuary data Data represented 32 site-years from 11 countries
  Hospital records Data represented 21 site-years
  Police records Data represented 1129 site-years from 122 countries
These represent the primary data used in analyses to compute mortality attributable to SSB consumption by age, sex, and country in 2010. BMI indicates body mass 
index; CVD, cardiovascular disease; MCMC, Markov chain Monte Carlo; and SSB, sugar-sweetened beverages.
*Malik et al (2010).5 A meta-analysis of 8 prospective cohorts (310 819 participants, 15 043 incident cases of diabetes mellitus), comparing the highest (1–2 
servings/d) vs lowest (<1 serving/mo) category of intake. Three cohorts included adjustment for BMI, most appropriate for our modeling of direct (non–obesity-
mediated) effects; but these also adjusted for total energy intake, which could result in underestimation of true effects. A more recent meta-analysis of 6 cohorts, 
published after finalization of our dietary RRs, reported a similar pooled dose-response association per daily SSB serving of 1.20 (95% CI, 1.12–1.29).22
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Table 1. Description of Data Sources and Modeling Methods Used to Estimate Adult SSB Consumption Levels, the Effects of SSB Intakes on BMI and  
Diabetes Mellitus, and Total Cause-Specific Mortality by Country, Age, and Sex
Data Source and Description Data Coverage
Statistical Methods Used for Pooling and Modeling Data From Diverse Global Sources
Modeling Approach Covariates Validity
SSB consumption by country, age, and sex Individual-level survey data National food availability data    
  Total consumption of sugar-sweetened beverages 
containing >50 kcal/8-oz serving, including sodas, 
fruit drinks, sports/energy drinks, and sweetened 
iced tea
A total of 780 age- and sex-specific data points, 
88% nationally representative, were collected from 
51 countries and represented 63% of the world’s 
adult population. 16% of all data were from multiple 
dietary recall surveys, 20% of all data were from 
food-frequency questionnaires, 17% of data were 
from single dietary recall surveys, and 47% of data 
were from household availability surveys.
Total annual per capita sugar availability in each of 187 
countries worldwide based on availability of sugar, sugar 
beet, sugar cane, noncentrifugal sugar, and sugar crops. 
These data are based on U.N. Food and Agriculture 
Organization (FAO) food balance sheets which capture a 
country’s net annual food availability, accounting for imports 
and exports.
DisMod3,19 a Bayesian hierarchical method was used to pool 
data from multiple sources and model missing data using 
informative time-varying covariates, borrowing information across 
geographical regions and time periods while also incorporating 
uncertainty attributable to measurement error and model 
specification. Models were fit by using a randomized MCMC 
algorithm based on the Adaptive Metropolis step function.
Both study-specific and national-level covariates were 
incorporated in the model. Study-level covariates 
included information on national representativeness 
of data points, method/metric of data collection, and 
sex. Country-level information included country, region, 
and superregion random effects. Other country-level 
covariates such as gross domestic product were tested 
but did not improve prediction.
Models were assessed for convergence of 
MCMC iterations and were validated by using 
goodness- 
of-fit tests. Final model results were 
assessed for plausibility by subject-matter 
experts.
Relative risks by age and sex      
  Effects of SSB on diabetes mellitus      
   Published meta-analyses of 8 prospective cohort 
studies
Data were from US, European, and Asian cohorts including 310 819 participants and 15 043 cases of type 2 diabetes 
mellitus.*
Systematic review and meta-analysis were used to identify and 
pool relevant data from cohort studies. Given that the effects of 
SSB on incidence of diabetes mellitus are attenuated with age, we 
extrapolated the effect estimate into 10-y age groups from age 
20 to 100 using an age pattern derived from the average percent 
change in relative risk for CVD and diabetes mellitus across 4 
metabolic risk factors.
Included studies considered adjustment for potential 
confounding by age, sex, and various lifestyle factors, 
such as smoking, alcohol use, and physical activity, and 
various dietary habits. For most, a positive association 
persisted, suggesting an independent effect of SSBs on 
incident diabetes mellitus.
Standard methods of assessing publication 
bias, such as Begg and Eggers tests and 
visual inspection of funnel plots indicated 
no evidence of such bias in this analysis. 
Cochrane Q test and the I2 statistic revealed 
statistically significant heterogeneity, which 
was reduced in sensitivity analyses excluding 
smaller studies of shorter duration.
  Linear effects of SSB on BMI      
   Original meta-analysis of 3 prospective cohort 
studies (NHS I, NHS II, HPFS)
Data were from US cohorts including 120 877 participants. The association of change in BMI with change in SSB consumption 
was assessed by using multivariate linear regression accounting 
for within-person repeated measures. Results across the 3 cohorts 
were pooled by an inverse-variance weighted meta-regression as 
described in earlier work.23 Separate linear effects were estimated 
for BMI < 25 and BMI ≥25 because the rate of increase in BMI 
attributable to SSB intake varies based on an individual’s baseline 
BMI.
Analyses were adjusted for age, baseline BMI, and 
changes in other lifestyle behaviors such as diet, 
smoking, physical activity, alcohol consumption, sleep 
duration, and TV watching.
Change in SSB consumption resulted in a 
statistically significant change in BMI across 
all 3 cohorts, and the magnitude of change in 
BMI was consistent across all cohorts. This is 
the only analysis thus far to examine effects 
of change in SSB consumption on change in 
adiposity.
  Effects of BMI on CVD and diabetes mellitus      
   Published pooled analysis of 3 international 
pooling projects (APCSC, PSC, ERFC)
Data were from East Asian, North American, and European pooling projects comprising a total of 163 cohorts, 2.43 
million participants, and 70 000 CVD events.24
Relative risks from the pooling projects were interpolated and 
extrapolated into standard age groups by using log-linear models. 
Age-specific relative risks were pooled using random- 
effects models. Trends in age-specific relative risks from pooled 
analyses were compared with trends in original cohort data to 
ensure validity of pooled results.
Effect modification by race/ethnicity and sex were 
assessed but were not found to be statistically 
significant.
Trends in age-specific relative risks from 
pooled analyses were compared with trends 
in original cohort data to ensure validity of 
pooled results. The I2 test did not reveal 
significant heterogeneity between studies for 
any age group.
  Effects of BMI on site-specific cancers      
   Published meta-analysis of 221 cohort studies. Data were from North American, East Asian, European, and Australian cohorts with a total of 282 137 incident cases 
of cancer >133 000 000 person-years of follow-up.25
Systematic review and random-effects meta-analysis Effect modification by race/ethnicity, sex, and age were 
assessed for cancers other than breast and ovarian, but 
were not found to be statistically significant.
Between-study heterogeneity varied by 
cancer, from low to moderate (0%–55%), 
and there was no evidence of publication bias 
in inspection of funnel plots.
Cause-specific total mortality by country, age, and sex1     
  Vital registration with medical certification of cause 
of death
Data represented 2798 site-years from 130 countries Cause of Death Ensemble Modeling (CODEm), a modeling 
strategy encompassing 4 families of statistical models, was used 
to pool mortality data from diverse sources, aggregate deaths 
hierarchically, and capture uncertainty attributable to model 
parameter estimation, model specification, and fundamental 
sources of error.
Covariates were selected from a database of mortality 
predictors based on the cause of death being modeled. 
Covariates were tested for predictive ability before 
inclusion in a given model.
Models were validated by using out-of-
sample predictive validity tests in which 30% 
of data were withheld from initial model fits. 
Predicted trends were then compared with 
trends in the existing held-out data.
  Verbal autopsy (sample registration, demographic 
surveillance systems)
Data represented 486 site-years from 66 countries, 10% nationally representative
  Cancer registries Data represented 2715 site-years from 93 countries
  Survey/census data Data were from 56 national surveys
  Sibling history Data represented 1557 survey-years from 61 countries
  Burial/mortuary data Data represented 32 site-years from 11 countries
  Hospital records Data represented 21 site-years
  Police records Data represented 1129 site-years from 122 countries
These represent the primary data used in analyses to compute mortality attributable to SSB consumption by age, sex, and country in 2010. BMI indicates body mass 
index; CVD, cardiovascular disease; MCMC, Markov chain Monte Carlo; and SSB, sugar-sweetened beverages.
*Malik et al (2010).5 A meta-analysis of 8 prospective cohorts (310 819 participants, 15 043 incident cases of diabetes mellitus), comparing the highest (1–2 
servings/d) vs lowest (<1 serving/mo) category of intake. Three cohorts included adjustment for BMI, most appropriate for our modeling of direct (non–obesity-
mediated) effects; but these also adjusted for total energy intake, which could result in underestimation of true effects. A more recent meta-analysis of 6 cohorts, 
published after finalization of our dietary RRs, reported a similar pooled dose-response association per daily SSB serving of 1.20 (95% CI, 1.12–1.29).22
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age-, and sex-specific population-attributable fractions, which were 
calculated as described above.37,38
Estimation of Uncertainty
We used Monte Carlo simulation to quantify the uncertainty in the 
attributable deaths and DALYs, propagating the uncertainty from SSB 
intake data (which includes both measurement and sampling error 
and modeling uncertainty), and uncertainty from the relative risks 
into our final estimates. We drew 1000 times from the distribution of 
SSB consumption for each country-age-sex group as characterized by 
its mean and standard error. For each mean exposure, population-rep-
resentative standard deviations were predicted by using coefficients 
from regressions performed on all available dietary survey data in our 
collection, in which standard deviation was the dependent variable 
and mean was the independent variable.40,41 Independent of exposure, 
we generated 1000 draws of the etiologic relative risks of SSB intake 
on diabetes mellitus and BMI, and of BMI on adiposity-related dis-
eases. These simultaneous draws were entered into the analysis to 
generate 1000 mortality estimates for each country-age-sex group, of 
which we report the mean and 95% UIs. All analyses were performed 
by using R software, version 2.15.0.
Results
In 2010, the mean global consumption of SSBs among adults 
was 0.58 servings/d (95% UI, 0.37–0.89). The mean intake 
varied substantially in men and women across different ages 
and world regions, highest in countries in Latin America and 
the Caribbean and lowest in parts of East Asia. Detailed find-
ings on SSB consumption patterns across the world have been 
reported.26
Mortality Related to SSB Consumption
Global Mortality Related to SSB Consumption
In 2010, the model attributed a total of 184 000 (95% UI, 161 000–
208 000) deaths globally to SSB intake (Table 3), representing 
5.3% (95% UI, 5.0%–5.5%) of all diabetes mellitus deaths, 0.4% 
(95%UI, 0.3%–0.6%) of BMI-related CVD deaths, and 0.3% 
(95% UI, 0.2%–0.3%) of all BMI-related cancer deaths. Most 
of these deaths (72.3% or 133 000; 95% UI, 126 000–139 000) 
were attributable to diabetes mellitus, 24.2% (45 000; 95% UI, 
29 000–61 000) were attributable to CVD, and 3.5% (6450; 95% 
UI, 4300–8600) were attributable to BMI-related cancers. Half of 
all SSB-attributable deaths were in women. Three in 4 (75.9%) 
of all deaths attributable to SSB consumption occurred in low- 
and middle-income countries. Globally, absolute mortality from 
SSBs was greatest in adults >65 years of age, at 167 (95% UI, 
141–195) deaths per million adults. Conversely, proportional 
mortality was highest among adults aged 20 to 44 years, in whom 
14.0% (95% UI, 12.9%–15.0%) of all diabetes mellitus– and 
adiposity-related deaths were attributable to SSB consumption.
Figure 1. Schematic diagram of the relationships between the data sources used in the comparative risk assessment modeling 
framework on which this analysis is based. BMI indicates body mass index; CVD, cardiovascular disease; PAF, population-attributable 
fraction; and SSB, sugar-sweetened beverages.
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Regional Mortality Related to SSB Consumption
Across 9 major world regions, Latin America and the 
Caribbean had the highest absolute mortality related to SSB 
consumption (48 000 per million adults; 95% UI, 41 000–
54 000), whereas Australia and New Zealand had the lowest 
(560; 95% UI, 440–700; Table 3). Among age and sex groups 
in these regions, men >65 years in Latin America and the 
Caribbean had the highest SSB-related absolute mortality (582 
deaths per million men; 95% UI, 485–681); women >65 years 
of age in this region were close behind (552 deaths per million 
women; 95% UI, 460–644). Adults 65+ years in the United 
States and Canada had the next highest SSB-attributable mor-
tality: 379 (95% UI, 285–478) per million men and 300 (95% 
UI, 227–386) per million women. Women aged 20 to 44 years 
in Western Europe and Australia/New Zealand had the lowest 
mortality: 2 (95% UI, 1–3) deaths per million.
Although older adults had the highest absolute mortality 
attributable to SSBs, younger adults had the highest propor-
tional mortality (Table 3). Among adults aged 20 to 44 years 
in Latin America/Caribbean, 1 in 7 (13.9%; 95% UI, 11.7%–
16.1%) of all diabetes mellitus– and adiposity-related deaths 
in men and 1 in 9 (10.9%; 95% UI, 9.3%–12.4%) of all such 
deaths in women were attributable to SSBs. Considering only 
deaths attributable to diabetes mellitus, 1 in 3 such deaths in 
men aged 20 to 44 years in both Latin America/Caribbean and 
United States/Canada were attributable to SSBs. Among all 
diabetes mellitus deaths, the percentage related to SSB con-
sumption exceeded 10% among adults aged 20 to 44 years in 
every world region except South Asia.
National Mortality Related to SSB Consumption
Across all countries worldwide, proportional mortality related 
to SSB intake varied substantially (Figure 2, Table II in the 
online-only Data Supplement). Proportional deaths were 
highest in Mexican men aged 20 to 44 years, in whom 1 in 
3 (33.6; 95% UI, 26.4–39.5%) diabetes mellitus– and BMI-
related deaths were linked to SSB consumption. Proportional 
mortality also exceeded 20% in adults aged 20 to 44 years 
in Kiribati, Gabon, Marshall Islands, Belize, Barbados, and 
Tonga. Proportional mortality attributable to SSBs was low-
est in adults aged >65 years in several East Asian countries, 
approaching zero in some cases.
Among larger nations (population >1 million), the SSB-
related mortality rate was highest in Mexico (405 deaths per 
million adults; 95% UI, 345–462) and lowest in Bangladesh 
(1; 95% UI, 0–2 deaths per million adults; Table II in the 
online-only Data Supplement). In total, Mexico had an esti-
mated 24 000 (95% UI, 21 000–28 000) SSB-related deaths 
in 2010, whereas Bangladesh had 72 (95% UI, 40–104) such 
deaths. Among the 20 countries with highest SSB-related 
deaths, at least 8 of these countries were in Latin America and 
the Caribbean across all age and sex subgroups (Figure 3).
Of the 20 most populous countries in the world, the death 
rate related to SSB intake was highest in Mexico in all age-sex 
groups, followed by the United States, Indonesia, and Brazil 
(Figure I in the online-only Data Supplement). In these 20 
countries, most SSB-related deaths were attributable to diabe-
tes mellitus, except in Russia and Egypt in which most SSB-
related deaths were attributable to CVD. Overall, the United 
States ranked second in SSB-related deaths among the 20 
most populous countries, with an absolute death rate of 125 
(95% UI, 101–149) per million adults, or 25 000 total deaths 
(95% UI, 20 000–30 000) related to SSB consumption in 2010 
(Table II in the online-only Data Supplement).
Morbidity Related to SSB Consumption
Global DALYS Related to SSB Consumption
In 2010, a total of 8 526 456 (95% UI, 2 769 953–19 244 657) 
DALYs were attributable to SSBs, of which 49.5% were attrib-
utable to CVD, 41.4% were attributable to diabetes mellitus, 
4.5% were attributable to BMI-related cancers, and 4.9% were 
attributable to musculoskeletal disorders (Table 4 and Table III 
in the online-only Data Supplement.). Globally, 0.7% (95% 
UI, 0.3%–1.5%) of total DALYs were related to SSB consump-
tion; 1.6% (95% UI, 0.5%–4.5%) of CVD DALYs, 4.5% (95% 
UI, 1.7%–8.9%) of diabetes mellitus DALYs, 0.2% (95% UI, 
0.1%–0.7%) of obesity-related cancer DALYs, and 0.4% (95% 
UI, 0.1%–1.3%) of musculoskeletal DALYs were attributable 
to intake of SSBs. Lower- and middle-income countries had 
the largest absolute number of SSB-related DALYs, a total of 
4 243 602 (95% UI, 998 925–9 058 923) DALYs, or 2931 (95% 
UI, 690–6258) per million adults. Upper- and middle-income 
countries had the highest percentage of diabetes mellitus–
related DALYS that were related to SSB consumption (6.1%; 
95% UI, 2.5–11.7; Table 4).
As with SSB-related mortality, the absolute number of 
DALYs attributable to SSBs was highest in men >65 years of 
age, at 6230 (95% UI, 2300–16 095) DALYs per million. Men 
<45 years of age had the highest percentage of CVD-related 
DALYs caused by SSBs (2.9%; 95% UI, 1.0%–6.9%), and 
the highest percentage of diabetes mellitus–related DALYS 
caused by SSBs (6.1%; 95% UI, 2.3%–12.1%).
Regional DALYs Related to SSB Consumption
Among 9 world regions, the greatest absolute SSB-related 
burdens were in South Asia, with 3528 (95% UI, 686–7070) 
DALYs per million adults and United States/Canada (3265; 
95 % UI, 1934–4982), whereas Australia/New Zealand 
had the least (609; 95% UI, 364–1028). In Latin America/
Caribbean, almost 1 in 10 diabetes mellitus–related DALYs 
were related to SSB consumption (9.7%; 95% UI, 4%–
18.3%), which also accounted for ~1 in 12 diabetes melli-
tus–related DALYs in United States/Canada (8.5%; 95% 
UI, 3.9%–14.3%). The percentage of all diabetes mellitus–
related DALYs caused by SSB consumption was highest in 
men <45 years of age in United States/Canada (12.9%; 95% 
UI, 5.8%–21.8%) and Latin America/Caribbean (12.4%; 
95% UI, 5.0%–23.2%).
National DALYs Related to SSB Consumption
Of the world’s 20 most populous countries, Mexico had the 
greatest number of SSB-attributable DALYs per million adults 
(3960; 95% UI, 1516–13 990), whereas China had the low-
est (584; 95% UI, 42–2462). In Mexico, almost 1 of every 
6 diabetes mellitus–related DALYs was attributable to SSB 
intake (15.8%; 95% UI, 7.0%–27.5%). In the United States, a 
total of 32 997 (95% UI, 2279–73 697) DALYs were related to 
SSB consumption in 2010, or 2087 (95% UI, 2050–5180) per 
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million adults, and 1.1% (95% UI, 0.6%–1.6%) of all DALYs 
in the United States were attributable to SSBs.
Discussion
These findings, based on a model that incorporated individual-
level national surveys of SSB consumption, country-level food 
availability data, the adiposity-mediated and direct effects of 
SSBs on chronic diseases, and cause-specific deaths and dis-
ability by age, sex, and country, provide current estimates of the 
worldwide annual mortality and morbidity related to SSB con-
sumption. In total, our model attributed >180 000 global deaths 
in 2010 to SSB consumption, with 72.3% from diabetes mel-
litus, 24.2% from CVD, and 3.5% from cancers. In addition, 
>8.5 million DALYs were linked to SSB consumption globally. 
To our knowledge, this investigation represents the first com-
prehensive, systematic assessment of the worldwide burdens of 
diabetes mellitus, CVD, and cancers attributable to SSBs.
Our findings demonstrate remarkable geographic heteroge-
neity in SSB-related mortality and morbidity, with substantial 
absolute and proportional burdens in Latin America and the 
Caribbean, and nearly none in East Asia. In Caribbean and 
Latin American countries, such as Mexico, homemade sug-
ary beverages (eg, “frescas”) are often made and consumed in 
addition to commercially produced SSBs; these high intakes 
are compounded by some of the highest rates of both obesity 
and diabetes mellitus in the world.7,8,42 The low cost of SSBs, 
lax regulation of advertising, and poor access to clean drinking 
water in some Latin American and Caribbean countries could 
contribute to the high SSB intakes in these regions and are 
natural targets for policy-driven interventions.43,44 Although 
the global proportion of deaths related to SSB consumption 
may seem low at first glance at ~.2% of all diabetes mellitus, 
CVD, and cancer deaths, we found great variability in national 
and regional burdens, with SSB-attributable proportional mor-
tality in Mexican men aged 20 to 44 years as high as 33%. 
Importantly, our findings demonstrate that 75% of deaths and 
85% of DALYs related to sugary beverages occur in low- and 
middle-income countries, highlighting the need for effective 
Table 2. Sources and Magnitudes of the Effects of SSBs on Diabetes Mellitus, SSB on BMI, and BMI on Chronic Disease Outcomes
Risk Factor
Type of Effect 
Estimate Source of Effect Estimate Unit of Effect Estimate Sex
Effect Size by Age Group
25–34 35–44 45–54 55–64 65–74 75–84 85+
SSB-diabetes mellitus Relative risk Published meta-analysis of 8 prospective 
cohort studies*
Per SSB serving/d Both 1.41 (1.19–1.66) 1.39 (1.18–1.63) 1.32 (1.15–1.51) 1.26 (1.12–1.41) 1.21 (1.10–1.33) 1.16 (1.08–1.24) 1.08 (1.04–1.12)
SSB-BMI (for baseline BMI < 25) Linear effect Original meta-analysis of 3 prospective cohort 
studies29
kg/m2 increase in BMI per  
SSB serving/d
Both 0.10 (0.05–0.15) 0.10 (0.05–0.15) 0.10 (0.05–0.15) 0.10 (0.05–0.15) 0.10 (0.05–0.15) 0.10 (0.05–0.15) 0.10 (0.05–0.15)
SSB-BMI (for baseline BMI ≥ 25) Linear effect Original meta-analysis of 3 prospective cohort 
studies29
kg/m2 increase in BMI per  
8-oz SSB serving/d
Both 0.23 (0.14–0.32) 0.23 (0.14–0.32) 0.23 (0.14–0.32) 0.23 (0.14–0.32) 0.23 (0.14–0.32) 0.23 (0.14–0.32) 0.23 (0.14–0.32)
BMI-ischemic stroke Relative risk Pooled analysis of APCSC, PSC, and ERFC 
international pooling projects24
Per kg/m2 increase in BMI Both 2.09 (1.81–2.40) 1.86 (1.67–2.08) 1.67 (1.53–1.81) 1.50 (1.40–1.60) 1.35 (1.28–1.41) 1.21 (1.16–1.26) 1.04 (0.96–1.12)
BMI-ischemic heart disease Relative risk Pooled analysis of APCSC, PSC, and ERFC 
international pooling projects24
Per 5 kg/m2 increase in BMI Both 1.79 (1.56–2.06) 1.66 (1.51–1.84) 1.55 (1.46–1.64) 1.44 (1.40–1.48) 1.35 (1.32–1.38) 1.26 (1.20–1.32) 1.14 (1.04–1.26)
BMI-hypertensive heart disease Relative risk Pooled analysis of APCSC, PSC, and ERFC 
international pooling projects24
Per 5 kg/m2 increase in BMI Both 2.30 (0.66–7.95) 2.15 (0.80–5.78) 2.02 (0.97–4.21) 1.90 (1.17–3.07) 1.81 (1.45–2.26) 1.63 (1.53–1.74) 1.45 (1.05–2.01)
BMI-diabetes mellitus Relative risk Pooled analysis of APCSC, PSC, and ERFC 
international pooling projects24
Per 5 kg/m2 increase in BMI Both 3.55 (2.41–5.23) 3.07 (2.28–4.15) 2.66 (2.15–3.30) 2.32 (2.04–2.63) 2.03 (1.95–2.11) 1.70 (1.61–1.79) 1.38 (1.23–1.56)
BMI-breast cancer Relative risk Meta-analysis of 221 cohort studies25 Per 5 kg/m2 increase in BMI Female 1.12 (1.08–1.16) 1.12 (1.08–1.16) 1.12 (1.08–1.16) 1.12 (1.08–1.16) 1.12 (1.08–1.16) 1.12 (1.08–1.16) 1.12 (1.08–1.16)
BMI-colon cancer Relative risk Meta-analysis of 221 cohort studies25 Per 5 kg/m2 increase in BMI Female 1.07 (1.03–1.12) 1.07 (1.03–1.12) 1.07 (1.03–1.12) 1.07 (1.03–1.12) 1.07 (1.03–1.12) 1.07 (1.03–1.12) 1.07 (1.03–1.12)
Male 1.20 (1.17–1.24) 1.20 (1.17–1.24) 1.20 (1.17–1.24) 1.20 (1.17–1.24) 1.20 (1.17–1.24) 1.20 (1.17–1.24) 1.20 (1.17–1.24)
BMI-pancreatic cancer Relative risk Meta-analysis of 221 cohort studies25 Per 5 kg/m2 increase in BMI Female 1.12 (1.03–1.23) 1.12 (1.03–1.23) 1.12 (1.03–1.23) 1.12 (1.03–1.23) 1.12 (1.03–1.23) 1.12 (1.03–1.23) 1.12 (1.03–1.23)
Male 1.07 (0.93–1.23) 1.07 (0.93–1.23) 1.07 (0.93–1.23) 1.07 (0.93–1.23) 1.07 (0.93–1.23) 1.07 (0.93–1.23) 1.07 (0.93–1.23)
BMI-esophageal cancer Relative risk Meta-analysis of 221 cohort studies25 Per 5 kg/m2 increase in BMI Female 1.51 (1.31–1.74) 1.51 (1.31–1.74) 1.51 (1.31–1.74) 1.51 (1.31–1.74) 1.51 (1.31–1.74) 1.51 (1.31–1.74) 1.51 (1.31–1.74)
Male 1.52 (1.33–1.74) 1.52 (1.33–1.74) 1.52 (1.33–1.74) 1.52 (1.33–1.74) 1.52 (1.33–1.74) 1.52 (1.33–1.74) 1.52 (1.33–1.74)
BMI-uterine cancer Relative risk Meta-analysis of 221 cohort studies25 Per 5 kg/m2 increase in BMI Female 1.59 (1.5–1.68) 1.59 (1.5–1.68) 1.59 (1.5–1.68) 1.59 (1.5–1.68) 1.59 (1.5–1.68) 1.59 (1.5–1.68) 1.59 (1.5–1.68)
BMI-kidney cancer Relative risk Meta-analysis of 221 cohort studies25 Per 5 kg/m2 increase in BMI Female 1.34 (1.25–1.43) 1.34 (1.25–1.43) 1.34 (1.25–1.43) 1.34 (1.25–1.43) 1.34 (1.25–1.43) 1.34 (1.25–1.43) 1.34 (1.25–1.43)
Male 1.24 (1.15–1.34) 1.24 (1.15–1.34) 1.24 (1.15–1.34) 1.24 (1.15–1.34) 1.24 (1.15–1.34) 1.24 (1.15–1.34) 1.24 (1.15–1.34)
BMI-gall bladder cancer Relative risk Meta-analysis of 221 cohort studies25 Per 5 kg/m2 increase in BMI Female 1.59 (1.02–2.47) 1.59 (1.02–2.47) 1.59 (1.02–2.47) 1.59 (1.02–2.47) 1.59 (1.02–2.47) 1.59 (1.02–2.47) 1.59 (1.02–2.47)
Male 1.09 (0.98–1.2) 1.09 (0.98–1.2) 1.09 (0.98–1.2) 1.09 (0.98–1.2) 1.09 (0.98–1.2) 1.09 (0.98–1.2) 1.09 (0.98–1.2)
BMI indicates body mass index; CI, confidence interval; CVD, cardiovascular disease; and SSB, sugar-sweetened beverages.
*Malik et al (2010).5 A meta-analysis of 8 prospective cohorts (310 819 participants, 15 043 incident cases of diabetes mellitus), comparing the highest (1–2 
servings/d) vs lowest (<1 serving/mo) category of intake. Three cohorts included adjustment for BMI, most appropriate for our modeling of direct (nonobesity-
mediated) effects; but these also adjusted for total energy intake, which could result in underestimation of true effects. A more recent meta-analysis of 6 cohorts, 
published after finalization of our dietary RRs, reported a similar pooled dose-response association per daily SSB serving of 1.20 (95% CI, 1.121.29).22
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interventions to reduce SSB consumption in not only richer, 
but also lower-income countries. Furthermore, our model esti-
mates the effect of removing all SSBs independent of any col-
lateral effects that such a change might have. However, it is 
possible that reduction in SSB intake could additionally influ-
ence other dietary behaviors, such as switching to healthier 
beverages and otherwise improving diet quality. Therefore, 
the number of deaths and DALYs that could be prevented by 
reducing SSB consumption globally may be greater than what 
is estimated by our current model.
The absolute burdens of deaths attributable to SSB con-
sumption are lower than for some risk factors for chronic 
diseases, including metabolic risk factors, such as BMI,40 
and other dietary factors, such as excess dietary sodium41 and 
insufficient consumption of fruits and vegetables.45 In 2010, 
~2.4 million chronic disease deaths were attributable to ele-
vated BMI,40 with the BMI-mediated chronic disease mortal-
ity attributable to SSB consumption accounting for ~1 in 12 
of those deaths. However, SSBs are but 1 contributor to the 
obesity epidemic, which is also related to multiple additional 
factors such as consumption of refined carbohydrates, other 
dietary sugars, inadequate physical activity, genetics/epi-
genetics, and psychosocial/environmental factors. In light of 
this, the number of SSB-related deaths is considerable given 
that it is only a single component of diet. In 2010, ~2.7 million 
deaths were attributable to elevated intake of dietary sodium41 
and 4.7 million were attributable to inadequate fruit and veg-
etable consumption45; yet, in comparison with sodium, which 
is nearly ubiquitous across the food supply, or fruits and veg-
etables, which represent large and diverse classes of foods, 
SSBs represent only a single class of beverage. Although 
substantial increases in global consumption of fruits and veg-
etables would require major long-term changes to agricultural 
systems, policies, transport and storage infrastructures, food 
manufacturing, and sociocultural priorities and norms, SSBs 
could be decreased without any new investments or techno-
logical advances in agriculture, transport, storage, manufac-
turing, or marketing.
Table 2. Sources and Magnitudes of the Effects of SSBs on Diabetes Mellitus, SSB on BMI, and BMI on Chronic Disease Outcomes
Risk Factor
Type of Effect 
Estimate Source of Effect Estimate Unit of Effect Estimate Sex
Effect Size by Age Group
25–34 35–44 45–54 55–64 65–74 75–84 85+
SSB-diabetes mellitus Relative risk Published meta-analysis of 8 prospective 
cohort studies*
Per SSB serving/d Both 1.41 (1.19–1.66) 1.39 (1.18–1.63) 1.32 (1.15–1.51) 1.26 (1.12–1.41) 1.21 (1.10–1.33) 1.16 (1.08–1.24) 1.08 (1.04–1.12)
SSB-BMI (for baseline BMI < 25) Linear effect Original meta-analysis of 3 prospective cohort 
studies29
kg/m2 increase in BMI per  
SSB serving/d
Both 0.10 (0.05–0.15) 0.10 (0.05–0.15) 0.10 (0.05–0.15) 0.10 (0.05–0.15) 0.10 (0.05–0.15) 0.10 (0.05–0.15) 0.10 (0.05–0.15)
SSB-BMI (for baseline BMI ≥ 25) Linear effect Original meta-analysis of 3 prospective cohort 
studies29
kg/m2 increase in BMI per  
8-oz SSB serving/d
Both 0.23 (0.14–0.32) 0.23 (0.14–0.32) 0.23 (0.14–0.32) 0.23 (0.14–0.32) 0.23 (0.14–0.32) 0.23 (0.14–0.32) 0.23 (0.14–0.32)
BMI-ischemic stroke Relative risk Pooled analysis of APCSC, PSC, and ERFC 
international pooling projects24
Per kg/m2 increase in BMI Both 2.09 (1.81–2.40) 1.86 (1.67–2.08) 1.67 (1.53–1.81) 1.50 (1.40–1.60) 1.35 (1.28–1.41) 1.21 (1.16–1.26) 1.04 (0.96–1.12)
BMI-ischemic heart disease Relative risk Pooled analysis of APCSC, PSC, and ERFC 
international pooling projects24
Per 5 kg/m2 increase in BMI Both 1.79 (1.56–2.06) 1.66 (1.51–1.84) 1.55 (1.46–1.64) 1.44 (1.40–1.48) 1.35 (1.32–1.38) 1.26 (1.20–1.32) 1.14 (1.04–1.26)
BMI-hypertensive heart disease Relative risk Pooled analysis of APCSC, PSC, and ERFC 
international pooling projects24
Per 5 kg/m2 increase in BMI Both 2.30 (0.66–7.95) 2.15 (0.80–5.78) 2.02 (0.97–4.21) 1.90 (1.17–3.07) 1.81 (1.45–2.26) 1.63 (1.53–1.74) 1.45 (1.05–2.01)
BMI-diabetes mellitus Relative risk Pooled analysis of APCSC, PSC, and ERFC 
international pooling projects24
Per 5 kg/m2 increase in BMI Both 3.55 (2.41–5.23) 3.07 (2.28–4.15) 2.66 (2.15–3.30) 2.32 (2.04–2.63) 2.03 (1.95–2.11) 1.70 (1.61–1.79) 1.38 (1.23–1.56)
BMI-breast cancer Relative risk Meta-analysis of 221 cohort studies25 Per 5 kg/m2 increase in BMI Female 1.12 (1.08–1.16) 1.12 (1.08–1.16) 1.12 (1.08–1.16) 1.12 (1.08–1.16) 1.12 (1.08–1.16) 1.12 (1.08–1.16) 1.12 (1.08–1.16)
BMI-colon cancer Relative risk Meta-analysis of 221 cohort studies25 Per 5 kg/m2 increase in BMI Female 1.07 (1.03–1.12) 1.07 (1.03–1.12) 1.07 (1.03–1.12) 1.07 (1.03–1.12) 1.07 (1.03–1.12) 1.07 (1.03–1.12) 1.07 (1.03–1.12)
Male 1.20 (1.17–1.24) 1.20 (1.17–1.24) 1.20 (1.17–1.24) 1.20 (1.17–1.24) 1.20 (1.17–1.24) 1.20 (1.17–1.24) 1.20 (1.17–1.24)
BMI-pancreatic cancer Relative risk Meta-analysis of 221 cohort studies25 Per 5 kg/m2 increase in BMI Female 1.12 (1.03–1.23) 1.12 (1.03–1.23) 1.12 (1.03–1.23) 1.12 (1.03–1.23) 1.12 (1.03–1.23) 1.12 (1.03–1.23) 1.12 (1.03–1.23)
Male 1.07 (0.93–1.23) 1.07 (0.93–1.23) 1.07 (0.93–1.23) 1.07 (0.93–1.23) 1.07 (0.93–1.23) 1.07 (0.93–1.23) 1.07 (0.93–1.23)
BMI-esophageal cancer Relative risk Meta-analysis of 221 cohort studies25 Per 5 kg/m2 increase in BMI Female 1.51 (1.31–1.74) 1.51 (1.31–1.74) 1.51 (1.31–1.74) 1.51 (1.31–1.74) 1.51 (1.31–1.74) 1.51 (1.31–1.74) 1.51 (1.31–1.74)
Male 1.52 (1.33–1.74) 1.52 (1.33–1.74) 1.52 (1.33–1.74) 1.52 (1.33–1.74) 1.52 (1.33–1.74) 1.52 (1.33–1.74) 1.52 (1.33–1.74)
BMI-uterine cancer Relative risk Meta-analysis of 221 cohort studies25 Per 5 kg/m2 increase in BMI Female 1.59 (1.5–1.68) 1.59 (1.5–1.68) 1.59 (1.5–1.68) 1.59 (1.5–1.68) 1.59 (1.5–1.68) 1.59 (1.5–1.68) 1.59 (1.5–1.68)
BMI-kidney cancer Relative risk Meta-analysis of 221 cohort studies25 Per 5 kg/m2 increase in BMI Female 1.34 (1.25–1.43) 1.34 (1.25–1.43) 1.34 (1.25–1.43) 1.34 (1.25–1.43) 1.34 (1.25–1.43) 1.34 (1.25–1.43) 1.34 (1.25–1.43)
Male 1.24 (1.15–1.34) 1.24 (1.15–1.34) 1.24 (1.15–1.34) 1.24 (1.15–1.34) 1.24 (1.15–1.34) 1.24 (1.15–1.34) 1.24 (1.15–1.34)
BMI-gall bladder cancer Relative risk Meta-analysis of 221 cohort studies25 Per 5 kg/m2 increase in BMI Female 1.59 (1.02–2.47) 1.59 (1.02–2.47) 1.59 (1.02–2.47) 1.59 (1.02–2.47) 1.59 (1.02–2.47) 1.59 (1.02–2.47) 1.59 (1.02–2.47)
Male 1.09 (0.98–1.2) 1.09 (0.98–1.2) 1.09 (0.98–1.2) 1.09 (0.98–1.2) 1.09 (0.98–1.2) 1.09 (0.98–1.2) 1.09 (0.98–1.2)
BMI indicates body mass index; CI, confidence interval; CVD, cardiovascular disease; and SSB, sugar-sweetened beverages.
*Malik et al (2010).5 A meta-analysis of 8 prospective cohorts (310 819 participants, 15 043 incident cases of diabetes mellitus), comparing the highest (1–2 
servings/d) vs lowest (<1 serving/mo) category of intake. Three cohorts included adjustment for BMI, most appropriate for our modeling of direct (nonobesity-
mediated) effects; but these also adjusted for total energy intake, which could result in underestimation of true effects. A more recent meta-analysis of 6 cohorts, 
published after finalization of our dietary RRs, reported a similar pooled dose-response association per daily SSB serving of 1.20 (95% CI, 1.121.29).22
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Table 3. Global And Regional Deaths Related to SSB Consumption in 2010
 
Population Characteristics
Number of Deaths Attributable to SSBs 
(95% UI) Deaths per Million Adults Attributable to SSBs (95% UI) Proportion of Deaths Attributable To SSBs (95% UI)
Population 
(millions)
Mean SSB Intake  
(Servings/d)
Mean BMI  
(kg/m2) CVD* Diabetes Mellitus† Cancers‡ Total§ CVD* Diabetes Mellitus† Cancers‡ Total§ CVD* Diabetes Mellitus† Cancers‡ Total§
Globe
  Women                
   Ages 20–44 987 0.8 (0.3–1.3) 25 (23–26) 1299 (891–1725) 7760 (7152–8337) 268 (186–351) 9327 (8392–10 254) 1 (0–2) 8 (7–8) 0 (0–0) 9 (9–10) 1.3 (0.9–1.7) 14.2 (13.1–15.3) 0.3 (0.2–0.4) 4.0 (3.6–4.4)
   Ages 45–64 654 0.4 (0.2–0.6) 27 (25–29) 4764 (3229–6342) 27 473 (25 067–29 900) 1154 (778–1555) 33 391 (29 786–37 045) 7 (5–10) 42 (38–46) 2 (1–3) 51 (46–57) 0.8 (0.5–1.0) 8.5 (7.7–9.2) 0.3 (0.2–0.4) 2.6 (2.3–2.9)
   Ages ≥65 293 0.3 (0.1–0.5) 26 (23–29) 13 739 (8905–19 263) 33 385 (30 527–36 169) 1854 (1204–2537) 48 978 (41 292–56 966) 47 (30–66) 114 (104–124) 6 (4–9) 167 (141–195) 0.3 (0.2–0.4) 3.4 (3.1–3.7) 0.2 (0.2–0.3) 0.8 (0.6–0.9)
   Women overall 1930 0.5 (0.2–0.8) 26 (24–28) 19 802 (13 133–27 332) 68 618 (64 410–72 881) 3276 (2160–4427) 91 695 (80 923–103 015) 10 (7–14) 35 (33–38) 2 (1–3) 47 (42–53) 0.4 (0.2–0.5) 5.1 (4.7–5.4) 0.3 (0.2–0.4) 1.2 (1.0–1.3)
  Men                
   Ages 20–44 1020 0.9 (0.4–1.4) 24 (23–26) 3045 (2071–4043) 10 291 (9426–11 115) 189 (131–251) 13 525 (11 887–15 214) 3 (2–4) 10 (9–11) 0 (0–0) 13 (12–15) 1.3 (0.9–1.7) 13.5 (12.4–14.6) 0.3 (0.2–0.4) 3.8 (3.4–4.3)
   Ages 45–64 645 0.4 (0.2–0.7) 26 (24–27) 9846 (6499–13 274) 28 713 (26 343–31 181) 1221 (839–1626) 39 780 (34 247–45 183) 15 (10–21) 45 (41–48) 2 (1–3) 62 (53–70) 0.7 (0.5–1.0) 7.9 (7.2–8.6) 0.3 (0.2–0.4) 2.0 (1.7–2.2)
   Ages ≥65 231 0.3 (0.1–0.5) 25 (23–27) 12 027 (7851–16 371) 25 159 (23 081–27 343) 1749 (1191–2318) 389 35 (32 988–45 331) 52 (34–71) 109 (100–118) 8 (5–10) 168 (143–196) 0.3 (0.2–0.4) 3.5 (3.2–3.8) 0.2 (0.1–0.3) 0.8 (0.6–0.9)
   Men overall 1890 0.6 (0.2–0.9) 25 (23–27) 24 918 (16 357–33 582) 64 163 (60 411–67 903) 3159 (2170–4198) 92 240 (80 161–105 248) 13 (9–18) 34 (32–36) 2 (1–3) 49 (42–56) 0.5 (0.3–0.6) 5.5 (5.2–5.8) 0.2 (0.2–0.3) 1.2 (1.1–1.4)
  Both sexes overall 3830 0.5 (0.2–0.9) 25 (23–27) 44 680 (29 087–60 715) 132 652 (125 924–139 384) 6449 (4333–8637) 183 781 (160 625–208 002) 12 (8–16) 35 (33–36) 2 (1–3) 48 (42–54) 0.4 (0.3–0.6) 5.3 (5.0–5.5) 0.3 (0.2–0.3) 1.2 (1.0–1.3)
Country income level
  High income 763 0.5 (0.3–0.6) 27 (25–28) 14 034 (8571–20 249) 27 812 (24 197–31 548) 3056 (1897–4279) 44 901 (34 663–56 077) 18 (11–27) 36 (32–41) 4 (2–6) 59 (45–73) 0.5 (0.3–0.8) 5.8 (5.3–6.3) 0.3 (0.2–0.4) 1.1 (0.9–1.3)
  Upper-middle income 1530 0.7 (0.3–1.1) 26 (24–28) 20 727 (13 597–28 337) 60 118 (54 138–66 061) 2606 (1734–3516) 83 451 (69 469–97 914) 14 (9–19) 39 (35–43) 2 (1–3) 55 (45–65) 0.5 (0.3–0.6) 7.2 (6.6–7.7) 0.3 (0.2–0.3) 1.3 (1.2–1.5)
  Lower-middle income 1210 0.6 (0.2–1.0) 25 (23–27) 8939 (576–1490) 36 886 (33 412–40 536) 650 (424–896) 46 475 (34 412–42 921) 1 (0–2) 30 (28–34) 1 (0–2) 38 (28–35) 0.3 (0.2–0.4) 3.8 (3.5–4.1) 0.2 (0.1–0.2) 1.1 (1.0–1.2)
  Low income 323 0.3 (0.1–0.5) 22 (20–24) 1021 (576–1490) 7965 (7395–8532) 124 (67–183) 9109 (8039–10 205) 3 (2–5) 25 (23–26) 0 (0–0) 28 (25–32) 0.2 (0.1–0.3) 3.5 (3.3–3.7) 0.1 (0.1–0.2) 1.2 (1.1–1.3)
Australia and New Zealand
  Women                
   Ages 20–44 3.6 0.4 (0.2–0.6) 26 (25–27) 1 (1–2) 6 (5–8) 1 (1–2) 9 (7–11) 0 (0–1) 2 (1–2) 0 (0–0) 2 (1–3) 1.5 (0.9–2.1) 12.1 (9.0–15.2) 0.3 (0.2–0.4) 1.6 (1.2–2.0)
   Ages 45–64 3.35 0.2 (0.1–0.3) 29 (28–30) 7 (4–10) 26 (19–34) 7 (4–10) 40 (30–51) 2 (1–3) 8 (6–10) 2 (1–3) 12 (9–15) 0.8 (0.5–1.2) 6.7 (4.9–8.8) 0.2 (0.1–0.4) 1.0 (0.7–1.2)
   Ages ≥65 1.94 0.1 (0.1–0.2) 28 (27–29) 70 (38–110) 107 (81–132 18 (11–25) 195 (146–253) 36 (19–57) 55 (42–68) 9 (5–13) 100 (75–130) 0.3 (0.1–0.4) 2.6 (2.0–3.3) 0.2 (0.1–0.3) 0.5 (0.4–0.7)
   Overall 8.89 0.2 (0.1–0.4) 27 (26–28) 79 (45–122) 139 (111–168) 26 (15–36) 244 (189–310) 9 (5–14) 16 (13–19) 3 (2–4) 27 (21–35) 0.3 (0.2–0.5) 3.1 (2.5–3.8) 0.2 (0.1–0.3) 0.6 (0.4–0.7)
  Men                
   Ages 20–44 3.57 0.4 (0.2–0.6) 27 (26–28) 5 (3–7) 10 (7–13) 1 (0–1) 16 (12–20) 1 (0–2) 3 (2–4) 0 (0–0) 5 (3–6) 1.5 (0.9–2.1) 12.1 (8.5–15.6) 0.3 (0.2–0.4) 2.7 (2.0–3.4)
   Ages 45–64 3.28 0.2 (0.1–0.3) 29 (28–30) 26 (16–37) 52 (38–66) 8 (5–11) 86 (65–107) 8 (5–11) 16 (12–20) 2 (1–3) 26 (20–33) 0.9 (0.5–1.2) 6.9 (5.1–8.7) 0.2 (0.1–0.3) 1.4 (1.1–1.8)
   Ages ≥65 1.64 0.1 (0.1–0.2) 28 (27–29) 70 (39–103) 126 (98–155) 20 (12–28) 215 (163–272) 43 (24–63) 77 (60–95) 12 (7–17) 132 (100–166) 0.3 (0.2–0.5) 3.1 (2.4–3.8) 0.2 (0.1–0.3) 0.7 (0.5–0.9)
   Overall 8.48 0.2 (0.1–0.4) 28 (27–28) 101 (61–146) 188 (155–222) 29 (17–40) 317 (249–389) 12 (7–17) 22 (18–26) 3 (2–5) 37 (29–46) 0.4 (0.2–0.6) 3.8 (3.2–4.5) 0.2 (0.1–0.3) 0.8 (0.7–1.0)
  Both sexes overall 17.4 0.2 (0.1–0.4) 28 (27–28) 180 (107–263) 327 (280–371) 54 (33–75) 561 (444–694) 10 (6–15) 19 (16–21) 3 (2–4) 32 (26–40) 0.3 (0.2–0.5) 3.5 (3.0–4.0) 0.2 (0.1–0.3) 0.7 (0.5–0.9)
Canada and United States
  Women                
   Ages 20–44 45 1.6 (1.2–2.0) 26 (26–27) 133 (77–199) 690 (500–850) 40 (23–58) 863 (660–1057) 3 (2–4) 15 (11–19) 1 (0–2) 19 (15–23) 4.6 (2.7–6.9) 30.8 (22.4–38.0) 0.9 (0.5–1.3) 9.2 (7.1–11.3)
   Ages 45–64 46.1 0.8 (0.6–1.0) 29 (28–30) 645 (388–936) 2621 (1921–3363) 222 (132–321) 3488 (2605–4342) 14 (8–20) 57 (42–73) 5 (3–7) 76 (57–94) 2.1 (1.3–3.1) 15.6 (11.4–20.0) 0.6 (0.4–0.9) 4.2 (3.2–5.3)
   Ages ≥65 25.6 0.6 (0.4–0.7) 28 (27–29) 2531 (1365–4106) 4729 (3583–5888) 437 (261–630) 7698 (5816–9888) 99 (53–160) 184 (140–230) 17 (10–25) 300 (227–386) 0.6 (0.3–1.0) 6.0 (4.5–7.4) 0.5 (0.3–0.7) 1.3 (1.0–1.7)
   Overall 117 1.0 (0.8–1.2) 28 (27–28) 3310 (1903–5176) 8040 (6670–9441) 699 (421–992) 12 049 (9467–14 760) 28 (16–44) 69 (57–81) 6 (4–8) 103 (81–126) 0.8 (0.4–1.2) 8.2 (6.8–9.6) 0.5 (0.3–0.7) 1.8 (1.4–2.2)
  Men                
   Ages 20–44 46.3 1.8 (1.3–2.2) 27 (27–28) 378 (216–558) 1116 (850–1368) 33 (20–48) 1527 (1170–1853) 8 (5–12) 24 (18–30) 1 (0–2) 33 (25–40) 5.0 (2.9–7.4) 33.1 (25.2–40.5) 0.9 (0.5–1.3) 12.3 (9.4–14.9)
   Ages 45–64 44.2 0.9 (0.7–1.1) 29 (29–30) 1714 (1035–2445) 4040 (2899–5119) 277 (167–399) 6031 (4617–7501) 39 (23–55) 91 (66–116) 6 (4–9) 136 (105–170) 2.3 (1.4–3.3) 16.9 (12.1–21.4) 0.7 (0.4–1.1) 4.9 (3.7–6.1)
   Ages ≥65 19.4 0.6 (0.5–0.8) 28 (27–28) 2365 (1334–3569) 4541 (3380–5693) 433 (257–618) 7339 (5521–9245) 122 (69–184) 235 (175–294) 22 (13–32) 379 (285–478) 0.8 (0.5–1.2) 7.1 (5.3–8.9) 0.5 (0.3–0.7) 1.7 (1.3–2.2)
   Overall 110 1.1 (0.8–1.4) 28 (27–29) 4457 (2613–6373) 9697 (8072–11 325) 743 (447–1041) 14 897 (11 858–18 080) 41 (24–58) 88 (74–103) 7 (4–9) 136 (108–165) 1.2 (0.7–1.7) 10.6 (8.8–12.4) 0.6 (0.3–0.8) 2.7 (2.1–3.2)
  Both sexes overall 226 1.1 (0.8–1.3) 28 (27–28) 7767 (4667–11 383) 17 736 (15 540–20 035) 1443 (870–2035) 26 946 (21 785–32 008) 34 (21–50) 78 (69–88) 6 (4–9) 119 (96–141) 1.0 (0.6–1.4) 9.4 (8.2–10.6) 0.5 (0.3–0.8) 2.2 (1.8–2.6)
East/Central Eurasia
  Women                
   Ages 20 to 44 60.4 0.4 (0.2–0.6) 24 (22–26) 109 (68–152) 212 (184–240) 17 (11–24) 338 (279–405) 2 (1–3) 4 (3–4) 0 (0–0) 6 (5–7) 1.3 (0.8–1.8) 11.0 (9.6–12.4) 0.3 (0.2–0.4) 2.0 (1.7–2.4)
   Ages 45 to 64 55.5 0.2 (0.1–0.3) 28 (26–30) 858 (524–1204) 749 (639–855) 136 (81–193) 1743 (1304–2192) 15 (9–22) 14 (12–15) 2 (1–3) 31 (24–40) 0.9 (0.5–1.2) 6.3 (5.3–7.2) 0.3 (0.2–0.4) 1.0 (0.7–1.3)
   Ages 65 and older 32.5 0.1 (0.1–0.2) 28 (24–31) 4093 (2397–5798) 1301 (1154–1451 252 (152–358) 5647 (3802–7521) 126 (74–178) 40 (36–45) 8 (5–11) 174 (117–231) 0.3 (0.2–0.5) 3.4 (3.0–3.7) 0.2 (0.1–0.3) 0.4 (0.3–0.5)
   Overall 148 0.2 (0.1–0.4) 26 (24–29) 5061 (2994–7115) 2262 (2066–2472) 405 (244–574) 7728 (5397–10 114) 34 (20–48) 15 (14–17) 3 (2–4) 52 (36–68) 0.4 (0.2–0.5) 4.3 (3.9–4.7) 0.2 (0.1–0.3) 0.5 (0.3–0.6)
  Men                
   Ages 20 to 44 59.7 0.4 (0.2–0.6) 25 (24–27) 496 (305–697) 340 (299–381) 15 (9–20) 850 (642–1081) 8 (5–12) 6 (5–6) 0 (0–0) 14 (11–18) 1.5 (0.9–2.1) 11.5 (10.1–12.9) 0.3 (0.2–0.4) 2.0 (1.5–2.6)
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Table 3. Global And Regional Deaths Related to SSB Consumption in 2010
 
Population Characteristics
Number of Deaths Attributable to SSBs 
(95% UI) Deaths per Million Adults Attributable to SSBs (95% UI) Proportion of Deaths Attributable To SSBs (95% UI)
Population 
(millions)
Mean SSB Intake  
(Servings/d)
Mean BMI  
(kg/m2) CVD* Diabetes Mellitus† Cancers‡ Total§ CVD* Diabetes Mellitus† Cancers‡ Total§ CVD* Diabetes Mellitus† Cancers‡ Total§
Globe
  Women                
   Ages 20–44 987 0.8 (0.3–1.3) 25 (23–26) 1299 (891–1725) 7760 (7152–8337) 268 (186–351) 9327 (8392–10 254) 1 (0–2) 8 (7–8) 0 (0–0) 9 (9–10) 1.3 (0.9–1.7) 14.2 (13.1–15.3) 0.3 (0.2–0.4) 4.0 (3.6–4.4)
   Ages 45–64 654 0.4 (0.2–0.6) 27 (25–29) 4764 (3229–6342) 27 473 (25 067–29 900) 1154 (778–1555) 33 391 (29 786–37 045) 7 (5–10) 42 (38–46) 2 (1–3) 51 (46–57) 0.8 (0.5–1.0) 8.5 (7.7–9.2) 0.3 (0.2–0.4) 2.6 (2.3–2.9)
   Ages ≥65 293 0.3 (0.1–0.5) 26 (23–29) 13 739 (8905–19 263) 33 385 (30 527–36 169) 1854 (1204–2537) 48 978 (41 292–56 966) 47 (30–66) 114 (104–124) 6 (4–9) 167 (141–195) 0.3 (0.2–0.4) 3.4 (3.1–3.7) 0.2 (0.2–0.3) 0.8 (0.6–0.9)
   Women overall 1930 0.5 (0.2–0.8) 26 (24–28) 19 802 (13 133–27 332) 68 618 (64 410–72 881) 3276 (2160–4427) 91 695 (80 923–103 015) 10 (7–14) 35 (33–38) 2 (1–3) 47 (42–53) 0.4 (0.2–0.5) 5.1 (4.7–5.4) 0.3 (0.2–0.4) 1.2 (1.0–1.3)
  Men                
   Ages 20–44 1020 0.9 (0.4–1.4) 24 (23–26) 3045 (2071–4043) 10 291 (9426–11 115) 189 (131–251) 13 525 (11 887–15 214) 3 (2–4) 10 (9–11) 0 (0–0) 13 (12–15) 1.3 (0.9–1.7) 13.5 (12.4–14.6) 0.3 (0.2–0.4) 3.8 (3.4–4.3)
   Ages 45–64 645 0.4 (0.2–0.7) 26 (24–27) 9846 (6499–13 274) 28 713 (26 343–31 181) 1221 (839–1626) 39 780 (34 247–45 183) 15 (10–21) 45 (41–48) 2 (1–3) 62 (53–70) 0.7 (0.5–1.0) 7.9 (7.2–8.6) 0.3 (0.2–0.4) 2.0 (1.7–2.2)
   Ages ≥65 231 0.3 (0.1–0.5) 25 (23–27) 12 027 (7851–16 371) 25 159 (23 081–27 343) 1749 (1191–2318) 389 35 (32 988–45 331) 52 (34–71) 109 (100–118) 8 (5–10) 168 (143–196) 0.3 (0.2–0.4) 3.5 (3.2–3.8) 0.2 (0.1–0.3) 0.8 (0.6–0.9)
   Men overall 1890 0.6 (0.2–0.9) 25 (23–27) 24 918 (16 357–33 582) 64 163 (60 411–67 903) 3159 (2170–4198) 92 240 (80 161–105 248) 13 (9–18) 34 (32–36) 2 (1–3) 49 (42–56) 0.5 (0.3–0.6) 5.5 (5.2–5.8) 0.2 (0.2–0.3) 1.2 (1.1–1.4)
  Both sexes overall 3830 0.5 (0.2–0.9) 25 (23–27) 44 680 (29 087–60 715) 132 652 (125 924–139 384) 6449 (4333–8637) 183 781 (160 625–208 002) 12 (8–16) 35 (33–36) 2 (1–3) 48 (42–54) 0.4 (0.3–0.6) 5.3 (5.0–5.5) 0.3 (0.2–0.3) 1.2 (1.0–1.3)
Country income level
  High income 763 0.5 (0.3–0.6) 27 (25–28) 14 034 (8571–20 249) 27 812 (24 197–31 548) 3056 (1897–4279) 44 901 (34 663–56 077) 18 (11–27) 36 (32–41) 4 (2–6) 59 (45–73) 0.5 (0.3–0.8) 5.8 (5.3–6.3) 0.3 (0.2–0.4) 1.1 (0.9–1.3)
  Upper-middle income 1530 0.7 (0.3–1.1) 26 (24–28) 20 727 (13 597–28 337) 60 118 (54 138–66 061) 2606 (1734–3516) 83 451 (69 469–97 914) 14 (9–19) 39 (35–43) 2 (1–3) 55 (45–65) 0.5 (0.3–0.6) 7.2 (6.6–7.7) 0.3 (0.2–0.3) 1.3 (1.2–1.5)
  Lower-middle income 1210 0.6 (0.2–1.0) 25 (23–27) 8939 (576–1490) 36 886 (33 412–40 536) 650 (424–896) 46 475 (34 412–42 921) 1 (0–2) 30 (28–34) 1 (0–2) 38 (28–35) 0.3 (0.2–0.4) 3.8 (3.5–4.1) 0.2 (0.1–0.2) 1.1 (1.0–1.2)
  Low income 323 0.3 (0.1–0.5) 22 (20–24) 1021 (576–1490) 7965 (7395–8532) 124 (67–183) 9109 (8039–10 205) 3 (2–5) 25 (23–26) 0 (0–0) 28 (25–32) 0.2 (0.1–0.3) 3.5 (3.3–3.7) 0.1 (0.1–0.2) 1.2 (1.1–1.3)
Australia and New Zealand
  Women                
   Ages 20–44 3.6 0.4 (0.2–0.6) 26 (25–27) 1 (1–2) 6 (5–8) 1 (1–2) 9 (7–11) 0 (0–1) 2 (1–2) 0 (0–0) 2 (1–3) 1.5 (0.9–2.1) 12.1 (9.0–15.2) 0.3 (0.2–0.4) 1.6 (1.2–2.0)
   Ages 45–64 3.35 0.2 (0.1–0.3) 29 (28–30) 7 (4–10) 26 (19–34) 7 (4–10) 40 (30–51) 2 (1–3) 8 (6–10) 2 (1–3) 12 (9–15) 0.8 (0.5–1.2) 6.7 (4.9–8.8) 0.2 (0.1–0.4) 1.0 (0.7–1.2)
   Ages ≥65 1.94 0.1 (0.1–0.2) 28 (27–29) 70 (38–110) 107 (81–132 18 (11–25) 195 (146–253) 36 (19–57) 55 (42–68) 9 (5–13) 100 (75–130) 0.3 (0.1–0.4) 2.6 (2.0–3.3) 0.2 (0.1–0.3) 0.5 (0.4–0.7)
   Overall 8.89 0.2 (0.1–0.4) 27 (26–28) 79 (45–122) 139 (111–168) 26 (15–36) 244 (189–310) 9 (5–14) 16 (13–19) 3 (2–4) 27 (21–35) 0.3 (0.2–0.5) 3.1 (2.5–3.8) 0.2 (0.1–0.3) 0.6 (0.4–0.7)
  Men                
   Ages 20–44 3.57 0.4 (0.2–0.6) 27 (26–28) 5 (3–7) 10 (7–13) 1 (0–1) 16 (12–20) 1 (0–2) 3 (2–4) 0 (0–0) 5 (3–6) 1.5 (0.9–2.1) 12.1 (8.5–15.6) 0.3 (0.2–0.4) 2.7 (2.0–3.4)
   Ages 45–64 3.28 0.2 (0.1–0.3) 29 (28–30) 26 (16–37) 52 (38–66) 8 (5–11) 86 (65–107) 8 (5–11) 16 (12–20) 2 (1–3) 26 (20–33) 0.9 (0.5–1.2) 6.9 (5.1–8.7) 0.2 (0.1–0.3) 1.4 (1.1–1.8)
   Ages ≥65 1.64 0.1 (0.1–0.2) 28 (27–29) 70 (39–103) 126 (98–155) 20 (12–28) 215 (163–272) 43 (24–63) 77 (60–95) 12 (7–17) 132 (100–166) 0.3 (0.2–0.5) 3.1 (2.4–3.8) 0.2 (0.1–0.3) 0.7 (0.5–0.9)
   Overall 8.48 0.2 (0.1–0.4) 28 (27–28) 101 (61–146) 188 (155–222) 29 (17–40) 317 (249–389) 12 (7–17) 22 (18–26) 3 (2–5) 37 (29–46) 0.4 (0.2–0.6) 3.8 (3.2–4.5) 0.2 (0.1–0.3) 0.8 (0.7–1.0)
  Both sexes overall 17.4 0.2 (0.1–0.4) 28 (27–28) 180 (107–263) 327 (280–371) 54 (33–75) 561 (444–694) 10 (6–15) 19 (16–21) 3 (2–4) 32 (26–40) 0.3 (0.2–0.5) 3.5 (3.0–4.0) 0.2 (0.1–0.3) 0.7 (0.5–0.9)
Canada and United States
  Women                
   Ages 20–44 45 1.6 (1.2–2.0) 26 (26–27) 133 (77–199) 690 (500–850) 40 (23–58) 863 (660–1057) 3 (2–4) 15 (11–19) 1 (0–2) 19 (15–23) 4.6 (2.7–6.9) 30.8 (22.4–38.0) 0.9 (0.5–1.3) 9.2 (7.1–11.3)
   Ages 45–64 46.1 0.8 (0.6–1.0) 29 (28–30) 645 (388–936) 2621 (1921–3363) 222 (132–321) 3488 (2605–4342) 14 (8–20) 57 (42–73) 5 (3–7) 76 (57–94) 2.1 (1.3–3.1) 15.6 (11.4–20.0) 0.6 (0.4–0.9) 4.2 (3.2–5.3)
   Ages ≥65 25.6 0.6 (0.4–0.7) 28 (27–29) 2531 (1365–4106) 4729 (3583–5888) 437 (261–630) 7698 (5816–9888) 99 (53–160) 184 (140–230) 17 (10–25) 300 (227–386) 0.6 (0.3–1.0) 6.0 (4.5–7.4) 0.5 (0.3–0.7) 1.3 (1.0–1.7)
   Overall 117 1.0 (0.8–1.2) 28 (27–28) 3310 (1903–5176) 8040 (6670–9441) 699 (421–992) 12 049 (9467–14 760) 28 (16–44) 69 (57–81) 6 (4–8) 103 (81–126) 0.8 (0.4–1.2) 8.2 (6.8–9.6) 0.5 (0.3–0.7) 1.8 (1.4–2.2)
  Men                
   Ages 20–44 46.3 1.8 (1.3–2.2) 27 (27–28) 378 (216–558) 1116 (850–1368) 33 (20–48) 1527 (1170–1853) 8 (5–12) 24 (18–30) 1 (0–2) 33 (25–40) 5.0 (2.9–7.4) 33.1 (25.2–40.5) 0.9 (0.5–1.3) 12.3 (9.4–14.9)
   Ages 45–64 44.2 0.9 (0.7–1.1) 29 (29–30) 1714 (1035–2445) 4040 (2899–5119) 277 (167–399) 6031 (4617–7501) 39 (23–55) 91 (66–116) 6 (4–9) 136 (105–170) 2.3 (1.4–3.3) 16.9 (12.1–21.4) 0.7 (0.4–1.1) 4.9 (3.7–6.1)
   Ages ≥65 19.4 0.6 (0.5–0.8) 28 (27–28) 2365 (1334–3569) 4541 (3380–5693) 433 (257–618) 7339 (5521–9245) 122 (69–184) 235 (175–294) 22 (13–32) 379 (285–478) 0.8 (0.5–1.2) 7.1 (5.3–8.9) 0.5 (0.3–0.7) 1.7 (1.3–2.2)
   Overall 110 1.1 (0.8–1.4) 28 (27–29) 4457 (2613–6373) 9697 (8072–11 325) 743 (447–1041) 14 897 (11 858–18 080) 41 (24–58) 88 (74–103) 7 (4–9) 136 (108–165) 1.2 (0.7–1.7) 10.6 (8.8–12.4) 0.6 (0.3–0.8) 2.7 (2.1–3.2)
  Both sexes overall 226 1.1 (0.8–1.3) 28 (27–28) 7767 (4667–11 383) 17 736 (15 540–20 035) 1443 (870–2035) 26 946 (21 785–32 008) 34 (21–50) 78 (69–88) 6 (4–9) 119 (96–141) 1.0 (0.6–1.4) 9.4 (8.2–10.6) 0.5 (0.3–0.8) 2.2 (1.8–2.6)
East/Central Eurasia
  Women                
   Ages 20 to 44 60.4 0.4 (0.2–0.6) 24 (22–26) 109 (68–152) 212 (184–240) 17 (11–24) 338 (279–405) 2 (1–3) 4 (3–4) 0 (0–0) 6 (5–7) 1.3 (0.8–1.8) 11.0 (9.6–12.4) 0.3 (0.2–0.4) 2.0 (1.7–2.4)
   Ages 45 to 64 55.5 0.2 (0.1–0.3) 28 (26–30) 858 (524–1204) 749 (639–855) 136 (81–193) 1743 (1304–2192) 15 (9–22) 14 (12–15) 2 (1–3) 31 (24–40) 0.9 (0.5–1.2) 6.3 (5.3–7.2) 0.3 (0.2–0.4) 1.0 (0.7–1.3)
   Ages 65 and older 32.5 0.1 (0.1–0.2) 28 (24–31) 4093 (2397–5798) 1301 (1154–1451 252 (152–358) 5647 (3802–7521) 126 (74–178) 40 (36–45) 8 (5–11) 174 (117–231) 0.3 (0.2–0.5) 3.4 (3.0–3.7) 0.2 (0.1–0.3) 0.4 (0.3–0.5)
   Overall 148 0.2 (0.1–0.4) 26 (24–29) 5061 (2994–7115) 2262 (2066–2472) 405 (244–574) 7728 (5397–10 114) 34 (20–48) 15 (14–17) 3 (2–4) 52 (36–68) 0.4 (0.2–0.5) 4.3 (3.9–4.7) 0.2 (0.1–0.3) 0.5 (0.3–0.6)
  Men                
   Ages 20 to 44 59.7 0.4 (0.2–0.6) 25 (24–27) 496 (305–697) 340 (299–381) 15 (9–20) 850 (642–1081) 8 (5–12) 6 (5–6) 0 (0–0) 14 (11–18) 1.5 (0.9–2.1) 11.5 (10.1–12.9) 0.3 (0.2–0.4) 2.0 (1.5–2.6)
  
D
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   Ages 45 to 64 47.3 0.2 (0.1–0.3) 27 (25–29) 2410 (1459–3389) 846 (752–942) 161 (98–228) 3417 (2352–4535) 51 (31–72) 18 (16–20) 3 (2–5) 72 (50–96) 0.9 (0.5–1.2) 6.4 (5.7–7.1) 0.3 (0.2–0.4) 1.0 (0.7–1.3)
   Ages 65 and older 17.6 0.1 (0.1–0.2) 26 (24–29) 3009 (1842–4216) 759 (686–834) 200 (122–278) 3969 (2676–5319) 171 (105–240) 43 (39–47) 11 (7–16) 226 (152–302) 0.4 (0.2–0.6) 3.6 (3.3–4.0) 0.2 (0.1–0.2) 0.5 (0.3–0.6)
   Overall 125 0.3 (0.1–0.4) 26 (24–28) 5915 (3625–8342) 1945 (1798–2093) 376 (231–527) 8236 (5675–10 849) 47 (29–67) 16 (14–17) 3 (2–4) 66 (46–87) 0.6 (0.3–0.8) 5.2 (4.8–5.6) 0.2 (0.1–0.3) 0.6 (0.4–0.9)
  Both sexes overall 273 0.2 (0.1–0.4) 26 (24–29) 10 976 (6591–15 346) 4206 (3913–4508) 781 (475–1098) 15 964 (11 097–20 903) 40 (24–56) 15 (14–17) 3 (2–4) 58 (41–77) 0.5 (0.3–0.6) 4.7 (4.4–5.0) 0.2 (0.1–0.3) 0.5 (0.4–0.7)
East and Southeast Asia
  Women                
   Ages 20–44 341 0.9 (0.4–1.3) 25 (23–26) 162 (96–234) 1849 (1549–2151) 44 (27–62) 2055 (1735–2378) 0 (0–0) 5 (4–6) 0 (0–0) 6 (5–7) 0.8 (0.5–1.1) 11.8 (9.8–13.7) 0.2 (0.1–0.2) 3.2 (2.7–3.7)
   Ages 45–64 238 0.4 (0.2–0.7) 27 (25–28) 679 (436–931) 7484 (6267–8654) 194 (116–278) 8356 (7044–9610) 3 (2–4) 31 (26–36) 1 (0–2) 35 (30–40) 0.5 (0.3–0.6) 6.7 (5.6–7.8) 0.1 (0.1–0.2) 2.3 (1.9–2.6)
   Ages ≥65 101 0.3 (0.1–0.5) 25 (22–27) 1565 (833–2348) 8651 (7223–10 117) 275 (143–414) 10 491 (8745–12 412) 16 (8–23) 86 (72–100) 3 (1–4) 104 (87–123) 0.1 (0.1–0.2) 2.9 (2.4–3.4) 0.1 (0.1–0.2) 0.6 (0.5–0.7)
   Overall 680 0.5 (0.2–0.9) 25 (23–27) 2406 (1380–3492) 17 983 (16 005–19 920) 513 (285–752) 20 902 (18 392–23 602) 4 (2–5) 26 (24–29) 1 (0–2) 31 (27–35) 0.2 (0.1–0.3) 4.2 (3.7–4.7) 0.1 (0.1–0.2) 1.0 (0.9–1.1)
  Men
   Ages 20–44 352 0.9 (0.4–1.4) 24 (23–25) 424 (244–613) 2337 (1966–2717) 38 (20–56) 2799 (2344–3253) 1 (0–2) 7 (6–8) 0 (0–0) 8 (7–9) 0.7 (0.4–1.1) 11.1 (9.4–13.0) 0.1 (0.1–0.2) 2.9 (2.4–3.4)
   Ages 45–64 243 0.5 (0.2–0.7) 25 (24–27) 1448 (890–2028) 7275 (6250–8331) 296 (161–449) 9019 (7723–10 305) 6 (4–8) 30 (26–34) 1 (0–2) 37 (32–42) 0.4 (0.3–0.6) 6.8 (5.9–7.8) 0.2 (0.1–0.3) 1.6 (1.3–1.8)
   Ages ≥65 84.6 0.3 (0.2–0.5) 24 (22–26) 1528 (793–2315) 4982 (4132–5857) 385 (194–579) 6895 (5496–8280) 18 (9–27) 59 (49–69) 5 (2–7) 82 (65–98) 0.1 (0.1–0.2) 2.5 (2.0–2.9) 0.1 (0.1–0.2) 0.4 (0.4–0.5)
   Overall 680 0.6 (0.3–0.9) 24 (23–26) 3400 (1920–4949) 14 594 (13 237–15 992) 719 (384–1073) 18 713 (16 178–21 266) 5 (3–7) 21 (19–24) 1 (0–2) 28 (24–31) 0.2 (0.1–0.3) 4.4 (4.0–4.9) 0.1 (0.1–0.2) 0.8 (0.7–0.9)
  Both sexes overall 1360 0.6 (0.3–0.9) 25 (23–27) 5807 (3314–8421) 32 577 (30 041–35 102) 1232 (670–1807) 39 615 (35 154–44 109) 4 (2–6) 24 (22–26) 1 (0–2) 29 (26–32) 0.2 (0.1–0.3) 4.3 (4.0–4.6) 0.1 (0.1–0.2) 0.9 (0.8–1.0)
Latin America and Caribbean
  Women
   Ages 20–44 88.1 1.7 (0.7–2.7) 26 (25–28) 290 (182–402) 1760 (1513–1958) 71 (43–100) 2121 (1810–2419) 3 (2–5) 20 (17–22) 1 (0–2) 24 (21–27) 3.9 (2.4–5.4) 30.4 (26.2–33.9) 1.0 (0.6–1.4) 10.9 (9.3–12.4)
   Ages 45–64 54.2 0.8 (0.3–1.4) 29 (27–31) 947 (572–1313) 7409 (6092–8614) 249 (147–354) 8605 (7111–10 031) 17 (11–24) 137 (112–159) 5 (3–7) 159 (131–185) 2.0 (1.2–2.8) 17.1 (14.1–19.9) 0.8 (0.5–1.1) 7.7 (6.4–9.0)
   Ages ≥65 22.7 0.6 (0.3–1.0) 27 (24–30) 2214 (1379–3141) 9992 (8510–11 441) 336 (205–468) 12 541 (10 455–14 98 (61–138) 440 (375–504) 15 (9–21) 552 (460–644) 0.8 (0.5–1.1) 7.3 (6.2–8.4) 0.6 (0.4–0.8) 2.7 (2.3–3.2)
628)
   Overall 165 1.1 (0.4–1.7) 27 (25–30) 3452 (2120–4845) 19 161 (16 982–21 159) 655 (403–919) 23 268 (19 980–26 370) 21 (13–29) 116 (103–128) 4 (2–6) 141 (121–160) 1.0 (0.6–1.4) 10.3 (9.2–11.4) 0.7 (0.4–1.0) 3.9 (3.4–4.5)
  Men
   Ages 20–44 85.6 1.8 (0.7–2.9) 25 (24–27) 648 (408–905) 2650 (2255–2957) 42 (25–59) 3340 (2813–3868) 8 (5–11) 31 (26–35) 0 (0–2) 39 (33–45) 4.4 (2.8–6.1) 33.4 (28.4–37.2) 0.7 (0.4–1.0) 13.9 (11.7–16.1)
   Ages 45–64 50.3 0.9 (0.3–1.5) 27 (25–28) 1798 (1088–2552) 8569 (6955–9929) 181 (111–254) 10 549 (8476–12 410) 36 (22–51) 170 (138–197) 4 (2–5) 210 (169–247) 2.1 (1.3–3.0) 18.5 (15.0–21.4) 0.7 (0.4–1.0) 7.5 (6.0–8.8)
   Ages ≥65 17.9 0.7 (0.3–1.1) 25 (23–27) 2116 (1349–2919) 8092 (6758–9376) 221 (145–305) 10 429 (8687–12 186) 118 (75–163) 452 (377–524) 12 (8–17) 582 (485–681) 0.8 (0.5–1.1) 8.5 (7.1–9.9) 0.4 (0.3–0.6) 2.7 (2.3–3.2)
   Overall 154 1.2 (0.4–1.9) 26 (24–27) 4562 (2872–6297) 19 311 (17 115–21 458) 445 (279–613) 24 318 (20 736–27 976) 30 (19–41) 126 (111–140) 3 (2–4) 158 (135–182) 1.2 (0.8–1.7) 12.9 (11.5–14.4) 0.5 (0.3–0.7) 4.4 (3.8–5.1)
  Both sexes overall 319 1.1 (0.4–1.8) 26 (24–29) 8013 (4992–11 191) 38 472 (35 106–41 892) 1100 (682–1524) 47 585 (41 061–53 845) 25 (16–35) 121 (110–131) 3 (2–5) 149 (129–169) 1.1 (0.7–1.6) 11.5 (10.5–12.5) 0.6 (0.4–0.9) 4.2 (3.6–4.7)
North Africa and Middle East
  Women
   Ages 20–44 66.1 0.6 (0.2–1.1) 27 (26–28) 234 (142–330) 515 (456–570) 27 (16–38) 776 (651–926) 4 (2–5) 8 (7–9) 0 (0–1) 12 (10–14) 2.0 (1.2–2.8) 14.4 (12.8–16.0) 0.4 (0.3–0.6) 3.5 (2.9–4.1)
   Ages 45–64 32.8 0.3 (0.1–0.6) 30 (29–32) 563 (341–801) 1363 (1202–1528) 52 (32–74) 1979 (1627–2321) 17 (10–24) 42 (37–47) 2 (1–3) 60 (50–71) 1.1 (0.7–1.6) 7.9 (7.0–8.9) 0.4 (0.2–0.5) 2.4 (2.0–2.8)
   Ages ≥65 11.2 0.3 (0.1–0.4) 28 (26–31) 995 (600–1400) 2067 (1811–2317) 43 (26–61) 3106 (2518–3694) 89 (54–125) 185 (162–208) 4 (2–6) 278 (226–331) 0.5 (0.3–0.7) 4.0 (3.5–4.5) 0.3 (0.2–0.5) 1.2 (1.0–1.4)
   Overall 110 0.4 (0.1–0.7) 28 (27–30) 1793 (1087–2564) 3945 (3585–4285) 123 (75–172) 5861 (4840–6860) 16 (10–23) 36 (33–39) 1 (0–2) 53 (44–62) 0.7 (0.4–1.0) 5.4 (4.9–5.9) 0.4 (0.2–0.5) 1.6 (1.3–1.9)
  Men
   Ages 20–44 71.6 0.7 (0.2–1.1) 26 (25–27) 496 (308–693) 636 (567–701) 14 (9–19) 1146 (920–1377) 7 (4–10) 9 (8–10) 0 (0–0) 16 (13–19) 1.9 (1.2–2.7) 15.0 (13.4–16.6) 0.3 (0.2–0.4) 3.4 (2.8–4.1)
   Ages 45–64 33.5 0.3 (0.1–0.6) 28 (26–29) 1006 (606–1409) 1485 (1292–1672) 32 (19–45) 2523 (1984–3053) 30 (18–42) 44 (39–50) 1 (1–1) 75 (59–91) 1.1 (0.6–1.5) 8.2 (7.1–9.2) 0.3 (0.2–0.4) 2.1 (1.6–2.5)
   Ages ≥65 9.67 0.3 (0.1–0.4) 26 (25–28) 1005 (626–1400) 1668 (1476–1854) 34 (22–46) 2707 (2204–3249) 104 (65–145) 172 (153–192) 3 (2–5) 280 (228–336) 0.5 (0.3–0.7) 4.2 (3.7–4.7) 0.2 (0.1–0.3) 1.0 (0.8–1.2)
   Overall 115 0.4 (0.2–0.7) 27 (25–28) 2507 (1551–3490) 3789 (3482–4110) 79 (50–110) 6376 (5165–7616) 22 (14–30) 33 (30–36) 1 (0–2) 56 (45–66) 0.8 (0.5–1.0) 6.1 (5.6–6.6) 0.2 (0.1–0.3) 1.5 (1.2–1.8)
  Both sexes overall 225 0.4 (0.2–0.7) 28 (26–29) 4300 (2640–5986) 7734 (7190–8293) 202 (125–283) 12 236 (10 059–14 421) 19 (12–27) 34 (32–37) 1 (0–2) 54 (45–64) 0.7 (0.4–1.0) 5.7 (5.3–6.2) 0.3 (0.2–0.4) 1.6 (1.3–1.8)
South Asia
  Women
   Ages 20–44 224 0.3 (0.1–0.5) 22 (20–23) 216 (112–333) 1260 (942–1574) 36 (18–55) 1512 (1145–1851) 1 (0–2) 6 (4–7) 0 (0–0) 7 (5–8) 0.6 (0.3–0.9) 9.0 (6.7–11.2) 0.2 (0.1–0.3) 2.2 (1.7–2.7)
   Ages 45–64 122 0.2 (0.0–0.3) 22 (20–24) 621 (317–945) 4639 (3378–5965) 118 (61–184) 5378 (4016–6767) 5 (3–8) 38 (28–49) 1 (0–2) 44 (33–56) 0.4 (0.2–0.6) 5.8 (4.2–7.5) 0.2 (0.1–0.3) 1.8 (1.3–2.3)
   Ages ≥65 40.1 0.1 (0.0–0.2) 21 (18–23) 126 (64–193) 887 (634–1160) 12 (6–19) 1026 (763–1319) 3 (2–5) 22 (16–29) 0 (0–0) 26 (19–33) 0.0 (0.0–0.0) 0.5 (0.4–0.6) 0.0 (0.0–0.0) 0.1 (0.1–0.2)
   Overall 385 0.2 (0.1–0.3) 21 (19–23) 963 (498–1467) 6787 (5461–8192) 167 (85–253) 7916 (6458–9589) 2 (1–4) 18 (14–21) 0 (0–1) 21 (17–25) 0.1 (0.1–0.2) 2.5 (2.0–3.0) 0.1 (0.1–0.2) 0.7 (0.6–0.9)
  Men
   Ages 20–44 238 0.4 (0.1–0.6) 21 (20–23) 355 (177–554) 1570 (1033–2111) 20 (10–31) 1945 (1361–2541) 1 (1–3) 7 (4–9) 0 (0–0) 8 (6–11) 0.5 (0.2–0.7) 6.7 (4.4–9.0) 0.2 (0.1–0.3) 1.8 (1.3–2.4)
   Ages 45–64 126 0.2 (0.0–0.3) 22 (20–23) 608 (308–921) 2858 (1791–3897) 56 (28–91) 3522 (2410–4585) 5 (2–7) 23 (14–31) 0 (0–1) 28 (19–36) 0.2 (0.1–0.3) 2.7 (1.7–3.7) 0.1 (0.1–0.2) 0.7 (0.5–0.9)
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(95% UI) Deaths per Million Adults Attributable to SSBs (95% UI) Proportion of Deaths Attributable To SSBs (95% UI)
Population 
(millions)
Mean SSB Intake  
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   Ages 45 to 64 47.3 0.2 (0.1–0.3) 27 (25–29) 2410 (1459–3389) 846 (752–942) 161 (98–228) 3417 (2352–4535) 51 (31–72) 18 (16–20) 3 (2–5) 72 (50–96) 0.9 (0.5–1.2) 6.4 (5.7–7.1) 0.3 (0.2–0.4) 1.0 (0.7–1.3)
   Ages 65 and older 17.6 0.1 (0.1–0.2) 26 (24–29) 3009 (1842–4216) 759 (686–834) 200 (122–278) 3969 (2676–5319) 171 (105–240) 43 (39–47) 11 (7–16) 226 (152–302) 0.4 (0.2–0.6) 3.6 (3.3–4.0) 0.2 (0.1–0.2) 0.5 (0.3–0.6)
   Overall 125 0.3 (0.1–0.4) 26 (24–28) 5915 (3625–8342) 1945 (1798–2093) 376 (231–527) 8236 (5675–10 849) 47 (29–67) 16 (14–17) 3 (2–4) 66 (46–87) 0.6 (0.3–0.8) 5.2 (4.8–5.6) 0.2 (0.1–0.3) 0.6 (0.4–0.9)
  Both sexes overall 273 0.2 (0.1–0.4) 26 (24–29) 10 976 (6591–15 346) 4206 (3913–4508) 781 (475–1098) 15 964 (11 097–20 903) 40 (24–56) 15 (14–17) 3 (2–4) 58 (41–77) 0.5 (0.3–0.6) 4.7 (4.4–5.0) 0.2 (0.1–0.3) 0.5 (0.4–0.7)
East and Southeast Asia
  Women                
   Ages 20–44 341 0.9 (0.4–1.3) 25 (23–26) 162 (96–234) 1849 (1549–2151) 44 (27–62) 2055 (1735–2378) 0 (0–0) 5 (4–6) 0 (0–0) 6 (5–7) 0.8 (0.5–1.1) 11.8 (9.8–13.7) 0.2 (0.1–0.2) 3.2 (2.7–3.7)
   Ages 45–64 238 0.4 (0.2–0.7) 27 (25–28) 679 (436–931) 7484 (6267–8654) 194 (116–278) 8356 (7044–9610) 3 (2–4) 31 (26–36) 1 (0–2) 35 (30–40) 0.5 (0.3–0.6) 6.7 (5.6–7.8) 0.1 (0.1–0.2) 2.3 (1.9–2.6)
   Ages ≥65 101 0.3 (0.1–0.5) 25 (22–27) 1565 (833–2348) 8651 (7223–10 117) 275 (143–414) 10 491 (8745–12 412) 16 (8–23) 86 (72–100) 3 (1–4) 104 (87–123) 0.1 (0.1–0.2) 2.9 (2.4–3.4) 0.1 (0.1–0.2) 0.6 (0.5–0.7)
   Overall 680 0.5 (0.2–0.9) 25 (23–27) 2406 (1380–3492) 17 983 (16 005–19 920) 513 (285–752) 20 902 (18 392–23 602) 4 (2–5) 26 (24–29) 1 (0–2) 31 (27–35) 0.2 (0.1–0.3) 4.2 (3.7–4.7) 0.1 (0.1–0.2) 1.0 (0.9–1.1)
  Men
   Ages 20–44 352 0.9 (0.4–1.4) 24 (23–25) 424 (244–613) 2337 (1966–2717) 38 (20–56) 2799 (2344–3253) 1 (0–2) 7 (6–8) 0 (0–0) 8 (7–9) 0.7 (0.4–1.1) 11.1 (9.4–13.0) 0.1 (0.1–0.2) 2.9 (2.4–3.4)
   Ages 45–64 243 0.5 (0.2–0.7) 25 (24–27) 1448 (890–2028) 7275 (6250–8331) 296 (161–449) 9019 (7723–10 305) 6 (4–8) 30 (26–34) 1 (0–2) 37 (32–42) 0.4 (0.3–0.6) 6.8 (5.9–7.8) 0.2 (0.1–0.3) 1.6 (1.3–1.8)
   Ages ≥65 84.6 0.3 (0.2–0.5) 24 (22–26) 1528 (793–2315) 4982 (4132–5857) 385 (194–579) 6895 (5496–8280) 18 (9–27) 59 (49–69) 5 (2–7) 82 (65–98) 0.1 (0.1–0.2) 2.5 (2.0–2.9) 0.1 (0.1–0.2) 0.4 (0.4–0.5)
   Overall 680 0.6 (0.3–0.9) 24 (23–26) 3400 (1920–4949) 14 594 (13 237–15 992) 719 (384–1073) 18 713 (16 178–21 266) 5 (3–7) 21 (19–24) 1 (0–2) 28 (24–31) 0.2 (0.1–0.3) 4.4 (4.0–4.9) 0.1 (0.1–0.2) 0.8 (0.7–0.9)
  Both sexes overall 1360 0.6 (0.3–0.9) 25 (23–27) 5807 (3314–8421) 32 577 (30 041–35 102) 1232 (670–1807) 39 615 (35 154–44 109) 4 (2–6) 24 (22–26) 1 (0–2) 29 (26–32) 0.2 (0.1–0.3) 4.3 (4.0–4.6) 0.1 (0.1–0.2) 0.9 (0.8–1.0)
Latin America and Caribbean
  Women
   Ages 20–44 88.1 1.7 (0.7–2.7) 26 (25–28) 290 (182–402) 1760 (1513–1958) 71 (43–100) 2121 (1810–2419) 3 (2–5) 20 (17–22) 1 (0–2) 24 (21–27) 3.9 (2.4–5.4) 30.4 (26.2–33.9) 1.0 (0.6–1.4) 10.9 (9.3–12.4)
   Ages 45–64 54.2 0.8 (0.3–1.4) 29 (27–31) 947 (572–1313) 7409 (6092–8614) 249 (147–354) 8605 (7111–10 031) 17 (11–24) 137 (112–159) 5 (3–7) 159 (131–185) 2.0 (1.2–2.8) 17.1 (14.1–19.9) 0.8 (0.5–1.1) 7.7 (6.4–9.0)
   Ages ≥65 22.7 0.6 (0.3–1.0) 27 (24–30) 2214 (1379–3141) 9992 (8510–11 441) 336 (205–468) 12 541 (10 455–14 98 (61–138) 440 (375–504) 15 (9–21) 552 (460–644) 0.8 (0.5–1.1) 7.3 (6.2–8.4) 0.6 (0.4–0.8) 2.7 (2.3–3.2)
628)
   Overall 165 1.1 (0.4–1.7) 27 (25–30) 3452 (2120–4845) 19 161 (16 982–21 159) 655 (403–919) 23 268 (19 980–26 370) 21 (13–29) 116 (103–128) 4 (2–6) 141 (121–160) 1.0 (0.6–1.4) 10.3 (9.2–11.4) 0.7 (0.4–1.0) 3.9 (3.4–4.5)
  Men
   Ages 20–44 85.6 1.8 (0.7–2.9) 25 (24–27) 648 (408–905) 2650 (2255–2957) 42 (25–59) 3340 (2813–3868) 8 (5–11) 31 (26–35) 0 (0–2) 39 (33–45) 4.4 (2.8–6.1) 33.4 (28.4–37.2) 0.7 (0.4–1.0) 13.9 (11.7–16.1)
   Ages 45–64 50.3 0.9 (0.3–1.5) 27 (25–28) 1798 (1088–2552) 8569 (6955–9929) 181 (111–254) 10 549 (8476–12 410) 36 (22–51) 170 (138–197) 4 (2–5) 210 (169–247) 2.1 (1.3–3.0) 18.5 (15.0–21.4) 0.7 (0.4–1.0) 7.5 (6.0–8.8)
   Ages ≥65 17.9 0.7 (0.3–1.1) 25 (23–27) 2116 (1349–2919) 8092 (6758–9376) 221 (145–305) 10 429 (8687–12 186) 118 (75–163) 452 (377–524) 12 (8–17) 582 (485–681) 0.8 (0.5–1.1) 8.5 (7.1–9.9) 0.4 (0.3–0.6) 2.7 (2.3–3.2)
   Overall 154 1.2 (0.4–1.9) 26 (24–27) 4562 (2872–6297) 19 311 (17 115–21 458) 445 (279–613) 24 318 (20 736–27 976) 30 (19–41) 126 (111–140) 3 (2–4) 158 (135–182) 1.2 (0.8–1.7) 12.9 (11.5–14.4) 0.5 (0.3–0.7) 4.4 (3.8–5.1)
  Both sexes overall 319 1.1 (0.4–1.8) 26 (24–29) 8013 (4992–11 191) 38 472 (35 106–41 892) 1100 (682–1524) 47 585 (41 061–53 845) 25 (16–35) 121 (110–131) 3 (2–5) 149 (129–169) 1.1 (0.7–1.6) 11.5 (10.5–12.5) 0.6 (0.4–0.9) 4.2 (3.6–4.7)
North Africa and Middle East
  Women
   Ages 20–44 66.1 0.6 (0.2–1.1) 27 (26–28) 234 (142–330) 515 (456–570) 27 (16–38) 776 (651–926) 4 (2–5) 8 (7–9) 0 (0–1) 12 (10–14) 2.0 (1.2–2.8) 14.4 (12.8–16.0) 0.4 (0.3–0.6) 3.5 (2.9–4.1)
   Ages 45–64 32.8 0.3 (0.1–0.6) 30 (29–32) 563 (341–801) 1363 (1202–1528) 52 (32–74) 1979 (1627–2321) 17 (10–24) 42 (37–47) 2 (1–3) 60 (50–71) 1.1 (0.7–1.6) 7.9 (7.0–8.9) 0.4 (0.2–0.5) 2.4 (2.0–2.8)
   Ages ≥65 11.2 0.3 (0.1–0.4) 28 (26–31) 995 (600–1400) 2067 (1811–2317) 43 (26–61) 3106 (2518–3694) 89 (54–125) 185 (162–208) 4 (2–6) 278 (226–331) 0.5 (0.3–0.7) 4.0 (3.5–4.5) 0.3 (0.2–0.5) 1.2 (1.0–1.4)
   Overall 110 0.4 (0.1–0.7) 28 (27–30) 1793 (1087–2564) 3945 (3585–4285) 123 (75–172) 5861 (4840–6860) 16 (10–23) 36 (33–39) 1 (0–2) 53 (44–62) 0.7 (0.4–1.0) 5.4 (4.9–5.9) 0.4 (0.2–0.5) 1.6 (1.3–1.9)
  Men
   Ages 20–44 71.6 0.7 (0.2–1.1) 26 (25–27) 496 (308–693) 636 (567–701) 14 (9–19) 1146 (920–1377) 7 (4–10) 9 (8–10) 0 (0–0) 16 (13–19) 1.9 (1.2–2.7) 15.0 (13.4–16.6) 0.3 (0.2–0.4) 3.4 (2.8–4.1)
   Ages 45–64 33.5 0.3 (0.1–0.6) 28 (26–29) 1006 (606–1409) 1485 (1292–1672) 32 (19–45) 2523 (1984–3053) 30 (18–42) 44 (39–50) 1 (1–1) 75 (59–91) 1.1 (0.6–1.5) 8.2 (7.1–9.2) 0.3 (0.2–0.4) 2.1 (1.6–2.5)
   Ages ≥65 9.67 0.3 (0.1–0.4) 26 (25–28) 1005 (626–1400) 1668 (1476–1854) 34 (22–46) 2707 (2204–3249) 104 (65–145) 172 (153–192) 3 (2–5) 280 (228–336) 0.5 (0.3–0.7) 4.2 (3.7–4.7) 0.2 (0.1–0.3) 1.0 (0.8–1.2)
   Overall 115 0.4 (0.2–0.7) 27 (25–28) 2507 (1551–3490) 3789 (3482–4110) 79 (50–110) 6376 (5165–7616) 22 (14–30) 33 (30–36) 1 (0–2) 56 (45–66) 0.8 (0.5–1.0) 6.1 (5.6–6.6) 0.2 (0.1–0.3) 1.5 (1.2–1.8)
  Both sexes overall 225 0.4 (0.2–0.7) 28 (26–29) 4300 (2640–5986) 7734 (7190–8293) 202 (125–283) 12 236 (10 059–14 421) 19 (12–27) 34 (32–37) 1 (0–2) 54 (45–64) 0.7 (0.4–1.0) 5.7 (5.3–6.2) 0.3 (0.2–0.4) 1.6 (1.3–1.8)
South Asia
  Women
   Ages 20–44 224 0.3 (0.1–0.5) 22 (20–23) 216 (112–333) 1260 (942–1574) 36 (18–55) 1512 (1145–1851) 1 (0–2) 6 (4–7) 0 (0–0) 7 (5–8) 0.6 (0.3–0.9) 9.0 (6.7–11.2) 0.2 (0.1–0.3) 2.2 (1.7–2.7)
   Ages 45–64 122 0.2 (0.0–0.3) 22 (20–24) 621 (317–945) 4639 (3378–5965) 118 (61–184) 5378 (4016–6767) 5 (3–8) 38 (28–49) 1 (0–2) 44 (33–56) 0.4 (0.2–0.6) 5.8 (4.2–7.5) 0.2 (0.1–0.3) 1.8 (1.3–2.3)
   Ages ≥65 40.1 0.1 (0.0–0.2) 21 (18–23) 126 (64–193) 887 (634–1160) 12 (6–19) 1026 (763–1319) 3 (2–5) 22 (16–29) 0 (0–0) 26 (19–33) 0.0 (0.0–0.0) 0.5 (0.4–0.6) 0.0 (0.0–0.0) 0.1 (0.1–0.2)
   Overall 385 0.2 (0.1–0.3) 21 (19–23) 963 (498–1467) 6787 (5461–8192) 167 (85–253) 7916 (6458–9589) 2 (1–4) 18 (14–21) 0 (0–1) 21 (17–25) 0.1 (0.1–0.2) 2.5 (2.0–3.0) 0.1 (0.1–0.2) 0.7 (0.6–0.9)
  Men
   Ages 20–44 238 0.4 (0.1–0.6) 21 (20–23) 355 (177–554) 1570 (1033–2111) 20 (10–31) 1945 (1361–2541) 1 (1–3) 7 (4–9) 0 (0–0) 8 (6–11) 0.5 (0.2–0.7) 6.7 (4.4–9.0) 0.2 (0.1–0.3) 1.8 (1.3–2.4)
   Ages 45–64 126 0.2 (0.0–0.3) 22 (20–23) 608 (308–921) 2858 (1791–3897) 56 (28–91) 3522 (2410–4585) 5 (2–7) 23 (14–31) 0 (0–1) 28 (19–36) 0.2 (0.1–0.3) 2.7 (1.7–3.7) 0.1 (0.1–0.2) 0.7 (0.5–0.9)
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The burdens attributable to SSB are also relatively unique 
because of their predominant proportional impact on the young. 
Throughout much of the world, intakes at younger ages are far 
higher than later in life. Consequently, the proportional mor-
tality attributable to SSBs is remarkably high among younger 
adults, exceeding 1 in 10 of all diabetes mellitus– and obesity-
related deaths in nearly every region of the world. Younger 
adults also constitute the largest proportion of the workforce in 
most countries, producing tremendous economic losses related 
to SSB intakes in these age groups.47 Our findings suggest that 
~1 in 20 diabetes mellitus–related DALYs in adults <44 years 
of age are attributable to SSB intake, highlighting the consider-
able social and financial impacts of SSB consumption from not 
only healthcare costs of managing diabetes mellitus, but also 
losses of wages and productivity.
Although we demonstrated an inverse age effect in pro-
portional disease burdens attributable to SSBs, it remains to 
be seen whether this pattern represents an effect of aging (ie, 
owing to people decreasing their intakes as they get older) or 
a birth cohort or generational effect (ie, owing to more recent 
   Ages ≥65 36.5 0.1 (0.0–0.2) 21 (19–23) 89 (47–136) 590 (379–806) 6 (3–10) 685 (463–914) 2 (1–4) 16 (10–22) 0 (0–0) 19 (13–25) 0.0 (0.0–0.0) 0.3 (0.2–0.5) 0.0 (0.0–0.0) 0.1 (0.1–0.1)
   Overall 401 0.2 (0.1–0.4) 21 (19–23) 1053 (543–1601) 5017 (3900–6227) 83 (43–128) 6152 (4806–7478) 3 (1–4) 13 (10–16) 0 (0–0) 15 (12–19) 0.1 (0.1–0.2) 1.7 (1.3–2.1) 0.1 (0.0–0.1) 0.4 (0.3–0.5)
  Both sexes overall 786 0.2 (0.1–0.4) 21 (19–23) 2015 (1042–3051) 11 803 (10 025–13 663) 250 (130–376) 14 068 (11 790–16 456) 3 (1–4) 15 (13–17) 0 (0–0) 18 (15–21) 0.1 (0.1–0.2) 2.0 (1.7–2.4) 0.1 (0.1–0.2) 0.6 (0.5–0.6)
Sub-Saharan Africa
  Women
   Ages 20–44 102 0.7 (0.2–1.2) 23 (22–25) 133 (89–181) 1399 (1277–1516) 17 (12–23) 1549 (1399–1700) 1 (1–2) 14 (13–15) 0 (0–0) 15 (14–17) 1.2 (0.8–1.6) 13.2 (12.1–14.3) 0.3 (0.2–0.4) 6.1 (5.5–6.6)
   Ages 45–64 46 0.3 (0.1–0.6) 25 (23–26) 294 (200–396) 2818 (2516–3113) 51 (34–68) 3163 (2814–3509) 6 (4–9) 61 (55–68) 1 (0–2) 69 (61–76) 0.6 (0.4–0.8) 7.3 (6.5–8.1) 0.3 (0.2–0.3) 3.3 (2.9–3.6)
   Ages ≥65 15.1 0.2 (0.1–0.4) 23 (20–26) 420 (285–565) 3060 (2697–3398) 42 (29–56) 3522 (3085–3938) 28 (19–37) 203 (179–225) 3 (2–4) 233 (204–261) 0.3 (0.2–0.4) 3.8 (3.3–4.2) 0.2 (0.2–0.3) 1.5 (1.3–1.7)
   Overall 163 0.4 (0.1–0.8) 24 (21–26) 847 (573–1136) 7277 (6761–7739) 110 (74–148) 8234 (7514–8915) 5 (4–7) 45 (42–48) 1 (0–2) 51 (46–55) 0.4 (0.3–0.5) 5.6 (5.2–5.9) 0.2 (0.2–0.3) 2.3 (2.1–2.5)
  Men
   Ages 20–44 103 0.8 (0.2–1.3) 22 (20–24) 148 (90–211) 1453 (1335–1574) 13 (8–18) 1613 (1463–1777) 1 (0–2) 14 (13–15) 0 (0–0) 16 (14–17) 1.0 (0.6–1.4) 12.6 (11.6–13.7) 0.3 (0.2–0.5) 6.1 (5.5–6.7)
   Ages 45– 64 42.5 0.4 (0.1–0.6) 23 (21–25) 288 (187–393) 2765 (2486–3059) 48 (32–65) 3101 (2767–3452) 7 (4–9) 65 (59–72) 1 (1–2) 73 (65–81) 0.5 (0.3–0.7) 7.1 (6.3–7.8) 0.4 (0.2–0.5) 3.2 (2.8–3.5)
   Ages ≥65 12.3 0.3 (0.1–0.5) 22 (20–25) 266 (170–366) 2215 (2001–2433) 39 (26–52) 2519 (2252–2790) 22 (14–30) 180 (163–198) 3 (2–4) 205 (183–227) 0.2 (0.2–0.3) 4.0 (3.6–4.4) 0.3 (0.2–0.4) 1.5 (1.4–1.7)
   Overall 158 0.5 (0.1–0.8) 22 (20–24) 702 (455–970) 6432 (6035–6837) 100 (67–135) 7234 (6625–7840) 4 (3–6) 41 (38–43) 1 (0–1) 46 (42–50) 0.4 (0.2–0.5) 6.0 (5.7–6.4) 0.3 (0.2–0.4) 2.5 (2.3–2.7)
  Both sexes overall 320 0.5 (0.1–0.8) 23 (21–25) 1549 (1043–2096) 13 709 (12 984–14 396) 210 (141–281) 15 468 (14 295–16 610) 5 (3–7) 43 (41–45) 1 (0–2) 48 (45–52) 0.4 (0.3–0.5) 5.8 (5.5–6.1) 0.3 (0.2–0.4) 2.4 (2.2–2.6)
Western Europe
  Women                
   Ages 20–44 57.2 0.6 (0.4–0.7) 24 (23–26) 19 (13–26) 71 (63–78) 15 (9–20) 104 (88–120) 0 (0–0) 1 (0–2) 0 (0–0) 2 (1–3) 1.2 (0.8–1.6) 12.2 (10.8–13.5) 0.3 (0.2–0.3) 1.2 (1.0–1.4)
   Ages 45–64 55.9 0.2 (0.2–0.3) 28 (26–30) 149 (90–209) 363 (317–408) 125 (76–176) 638 (502–778) 3 (2–4) 6 (6–7) 2 (1–3) 11 (9–14) 0.9 (0.5–1.2) 6.6 (5.8–7.4) 0.3 (0.2–0.4) 0.9 (0.7–1.1)
   Ages ≥65 42.9 0.2 (0.1–0.2) 28 (25–30) 1724 (1014–2488) 2591 (2325–2877) 438 (260–623) 4752 (3769–5788) 40 (24–58) 60 (54–67) 10 (6–15) 111 (88–135) 0.3 (0.2–0.4) 2.5 (2.2–2.8) 0.2 (0.1–0.3) 0.5 (0.4–0.7)
   Overall 156 0.4 (0.3–0.5) 26 (24–28) 1892 (1115–2722) 3025 (2753–3317) 578 (348–823) 5494 (4364–6646) 12 (7–17) 19 (18–21) 4 (2–5) 35 (28–43) 0.3 (0.2–0.5) 2.7 (2.5–3.0) 0.2 (0.1–0.3) 0.6 (0.5–0.7)
  Men
   Ages 20–44 58.4 0.7 (0.5–0.9) 26 (25–27) 96 (59–134) 180 (156–202) 14 (8–19) 289 (232–345) 2 (1–2) 3 (3–3) 0 (0–0) 5 (4–6) 1.6 (1.0–2.2) 13.5 (11.8–15.2) 0.3 (0.2–0.5) 2.8 (2.3–3.4)
   Ages 45–64 54.8 0.3 (0.2–0.3) 28 (27–30) 547 (332–768) 824 (721–934) 161 (97–226) 1532 (1191–1881) 10 (6–14) 15 (13–17) 3 (2–4) 28 (22–34) 0.9 (0.5–1.3) 6.9 (6.1–7.8) 0.3 (0.2–0.4) 1.3 (1.0–1.6)
   Ages ≥65 31.9 0.2 (0.1–0.3) 28 (26–29) 1579 (941–2204) 2187 (1939–2429) 411 (249–579) 4177 (3222–5139) 49 (29–69) 68 (61–76) 13 (8–18) 131 (101–161) 0.4 (0.2–0.5) 3.1 (2.7–3.4) 0.2 (0.1–0.3) 0.7 (0.5–0.8)
   Overall 145 0.4 (0.3–0.5) 27 (26–28) 2222 (1337–3116) 3191 (2871–3483) 586 (354–823) 5998 (4645–7365) 15 (9–21) 22 (20–24) 4 (2–6) 41 (32–51) 0.4 (0.3–0.6) 3.8 (3.4–4.1) 0.2 (0.1–0.3) 0.8 (0.6–1.0)
  Both sexes overall 301 0.4 (0.3–0.5) 27 (25–28) 4114 (2460–5750) 6215 (5768–6701) 1163 (703–1643) 11 493 (9044–13 926) 14 (8–19) 21 (19–22) 4 (2–5) 38 (30–46) 0.4 (0.2–0.5) 3.2 (3.0–3.4) 0.2 (0.1–0.3) 0.7 (0.5–0.8)
Table 3. Continued
 
Population Characteristics
Number of Deaths Attributable to SSBs 
(95% UI) Deaths per Million Adults Attributable to SSBs (95% UI) Proportion of Deaths Attributable To SSBs (95% UI)
Population 
(millions)
Mean SSB Intake  
(Servings/d)
Mean BMI  
(kg/m2) CVD* Diabetes Mellitus† Cancers‡ Total§ CVD* Diabetes Mellitus† Cancers‡ Total§ CVD* Diabetes Mellitus† Cancers‡ Total§
Countries are grouped into regions as follows: Australia/New Zealand – Australia, New Zealand; East/Central Eurasia – Albania, Armenia, Azerbaijan, Bulgaria, Bosnia and 
Herzegovina, Belarus, Czech Republic, Estonia, Georgia, Croatia, Hungary, Kazakhstan, Kyrgyzstan, Lithuania, Latvia, Moldova, Macedonia, Montenegro, Mongolia, Poland, 
Romania, Russian Federation, Serbia, Slovakia, Slovenia, Tajikistan, Turkmenistan, Ukraine, Uzbekistan; East/Southeast Asia – Brunei Darussalam, China, Fiji, Micronesia, 
Indonesia, Japan, Cambodia, Kiribati, Republic of Korea, Lao People’s Democratic Republic, Sri Lanka, Maldives, Marshall Islands, Myanmar, Malaysia, Philippines, Papua New 
Guinea, Democratic People’s Republic of Korea, Singapore, Solomon Islands, Thailand, Timor-Leste, Tonga, Taiwan, Viet Nam, Vanuatu, Samoa; Latin America/Caribbean – 
Argentina, Antigua and Barbuda, Bahamas, Belize, Bolivia, Brazil, Barbados, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, Grenada, Guatemala, 
Guyana, Honduras, Haiti, Jamaica, Saint Lucia, Mexico, Nicaragua, Panama, Peru, Paraguay, El Salvador, Suriname, Trinidad and Tobago, Uruguay, Saint Vincent and the 
Grenadines, Venezuela; North Africa/Middle East – United Arab Emirates, Bahrain, Algeria, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libyan Arab Jamahiriya, Morocco, Oman, 
Occupied Palestinian Territory, Qatar, Saudi Arabia, Syrian Arab Republic, Tunisia, Turkey, Yemen; South Asia – Afghanistan, Bangladesh, Bhutan, India, Nepal, Pakistan; Sub-
Saharan Africa – Angola, Burundi, Benin, Burkina Faso, Botswana, Central African Republic, Côte d’Ivoire, Cameroon, Democratic Republic of the Congo, Congo, Comoros, 
Cape Verde, Djibouti, Eritrea, Ethiopia, Gabon, Ghana, Guinea, Gambia, Guinea-Bissau, Equatorial Guinea, Kenya, Liberia, Lesotho, Madagascar, Mali, Mozambique, Mauritania, 
Mauritius, Malawi, Namibia, Niger, Nigeria, Rwanda, Sudan, Senegal, Sierra Leone, Somalia, São Tomé and Príncipe, Swaziland, Seychelles, Chad, Togo, United Republic of 
Tanzania, Uganda, South Africa, Zambia, Zimbabwe; Western Europe – Andorra, Austria, Belgium, Switzerland, Cyprus, Germany, Denmark, Spain, Finland, France, United 
Kingdom, Greece, Ireland, Iceland, Israel, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Sweden. BMI indicates body mass index; CVD, cardiovascular disease; SSB, 
sugar-sweetened beverages; and UI, uncertainty intervals.
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generations consuming higher intakes than older generations). 
If the latter is even partly contributing, then global mortality 
and morbidity attributable to SSBs may steeply rise as current 
generations age into higher risk of chronic diseases while con-
tinuing their higher intakes of SSBs.
This investigation had several strengths. We used global 
dietary data based on individual-level, largely nationally rep-
resentative surveys, and assessed and adjusted for compara-
bility, consistency, bias, and missing data across surveys. We 
evaluated and incorporated the best available evidence for 
effects of SSBs on BMI and diabetes mellitus and of BMI on 
adiposity-related diseases. We performed sensitivity analyses 
to assess the potential for overestimation of effects of individ-
ual diet components on chronic disease through comparison 
with dietary pattern studies based on both observational data 
and randomized trials. These sensitivity analyses indicated 
that the effects of dietary patterns on CHD predicted from the 
effects of individual dietary components on CHD were very 
similar to those observed both in prospective cohort studies 
evaluating associations of overall dietary patterns on CHD 
   Ages ≥65 36.5 0.1 (0.0–0.2) 21 (19–23) 89 (47–136) 590 (379–806) 6 (3–10) 685 (463–914) 2 (1–4) 16 (10–22) 0 (0–0) 19 (13–25) 0.0 (0.0–0.0) 0.3 (0.2–0.5) 0.0 (0.0–0.0) 0.1 (0.1–0.1)
   Overall 401 0.2 (0.1–0.4) 21 (19–23) 1053 (543–1601) 5017 (3900–6227) 83 (43–128) 6152 (4806–7478) 3 (1–4) 13 (10–16) 0 (0–0) 15 (12–19) 0.1 (0.1–0.2) 1.7 (1.3–2.1) 0.1 (0.0–0.1) 0.4 (0.3–0.5)
  Both sexes overall 786 0.2 (0.1–0.4) 21 (19–23) 2015 (1042–3051) 11 803 (10 025–13 663) 250 (130–376) 14 068 (11 790–16 456) 3 (1–4) 15 (13–17) 0 (0–0) 18 (15–21) 0.1 (0.1–0.2) 2.0 (1.7–2.4) 0.1 (0.1–0.2) 0.6 (0.5–0.6)
Sub-Saharan Africa
  Women
   Ages 20–44 102 0.7 (0.2–1.2) 23 (22–25) 133 (89–181) 1399 (1277–1516) 17 (12–23) 1549 (1399–1700) 1 (1–2) 14 (13–15) 0 (0–0) 15 (14–17) 1.2 (0.8–1.6) 13.2 (12.1–14.3) 0.3 (0.2–0.4) 6.1 (5.5–6.6)
   Ages 45–64 46 0.3 (0.1–0.6) 25 (23–26) 294 (200–396) 2818 (2516–3113) 51 (34–68) 3163 (2814–3509) 6 (4–9) 61 (55–68) 1 (0–2) 69 (61–76) 0.6 (0.4–0.8) 7.3 (6.5–8.1) 0.3 (0.2–0.3) 3.3 (2.9–3.6)
   Ages ≥65 15.1 0.2 (0.1–0.4) 23 (20–26) 420 (285–565) 3060 (2697–3398) 42 (29–56) 3522 (3085–3938) 28 (19–37) 203 (179–225) 3 (2–4) 233 (204–261) 0.3 (0.2–0.4) 3.8 (3.3–4.2) 0.2 (0.2–0.3) 1.5 (1.3–1.7)
   Overall 163 0.4 (0.1–0.8) 24 (21–26) 847 (573–1136) 7277 (6761–7739) 110 (74–148) 8234 (7514–8915) 5 (4–7) 45 (42–48) 1 (0–2) 51 (46–55) 0.4 (0.3–0.5) 5.6 (5.2–5.9) 0.2 (0.2–0.3) 2.3 (2.1–2.5)
  Men
   Ages 20–44 103 0.8 (0.2–1.3) 22 (20–24) 148 (90–211) 1453 (1335–1574) 13 (8–18) 1613 (1463–1777) 1 (0–2) 14 (13–15) 0 (0–0) 16 (14–17) 1.0 (0.6–1.4) 12.6 (11.6–13.7) 0.3 (0.2–0.5) 6.1 (5.5–6.7)
   Ages 45– 64 42.5 0.4 (0.1–0.6) 23 (21–25) 288 (187–393) 2765 (2486–3059) 48 (32–65) 3101 (2767–3452) 7 (4–9) 65 (59–72) 1 (1–2) 73 (65–81) 0.5 (0.3–0.7) 7.1 (6.3–7.8) 0.4 (0.2–0.5) 3.2 (2.8–3.5)
   Ages ≥65 12.3 0.3 (0.1–0.5) 22 (20–25) 266 (170–366) 2215 (2001–2433) 39 (26–52) 2519 (2252–2790) 22 (14–30) 180 (163–198) 3 (2–4) 205 (183–227) 0.2 (0.2–0.3) 4.0 (3.6–4.4) 0.3 (0.2–0.4) 1.5 (1.4–1.7)
   Overall 158 0.5 (0.1–0.8) 22 (20–24) 702 (455–970) 6432 (6035–6837) 100 (67–135) 7234 (6625–7840) 4 (3–6) 41 (38–43) 1 (0–1) 46 (42–50) 0.4 (0.2–0.5) 6.0 (5.7–6.4) 0.3 (0.2–0.4) 2.5 (2.3–2.7)
  Both sexes overall 320 0.5 (0.1–0.8) 23 (21–25) 1549 (1043–2096) 13 709 (12 984–14 396) 210 (141–281) 15 468 (14 295–16 610) 5 (3–7) 43 (41–45) 1 (0–2) 48 (45–52) 0.4 (0.3–0.5) 5.8 (5.5–6.1) 0.3 (0.2–0.4) 2.4 (2.2–2.6)
Western Europe
  Women                
   Ages 20–44 57.2 0.6 (0.4–0.7) 24 (23–26) 19 (13–26) 71 (63–78) 15 (9–20) 104 (88–120) 0 (0–0) 1 (0–2) 0 (0–0) 2 (1–3) 1.2 (0.8–1.6) 12.2 (10.8–13.5) 0.3 (0.2–0.3) 1.2 (1.0–1.4)
   Ages 45–64 55.9 0.2 (0.2–0.3) 28 (26–30) 149 (90–209) 363 (317–408) 125 (76–176) 638 (502–778) 3 (2–4) 6 (6–7) 2 (1–3) 11 (9–14) 0.9 (0.5–1.2) 6.6 (5.8–7.4) 0.3 (0.2–0.4) 0.9 (0.7–1.1)
   Ages ≥65 42.9 0.2 (0.1–0.2) 28 (25–30) 1724 (1014–2488) 2591 (2325–2877) 438 (260–623) 4752 (3769–5788) 40 (24–58) 60 (54–67) 10 (6–15) 111 (88–135) 0.3 (0.2–0.4) 2.5 (2.2–2.8) 0.2 (0.1–0.3) 0.5 (0.4–0.7)
   Overall 156 0.4 (0.3–0.5) 26 (24–28) 1892 (1115–2722) 3025 (2753–3317) 578 (348–823) 5494 (4364–6646) 12 (7–17) 19 (18–21) 4 (2–5) 35 (28–43) 0.3 (0.2–0.5) 2.7 (2.5–3.0) 0.2 (0.1–0.3) 0.6 (0.5–0.7)
  Men
   Ages 20–44 58.4 0.7 (0.5–0.9) 26 (25–27) 96 (59–134) 180 (156–202) 14 (8–19) 289 (232–345) 2 (1–2) 3 (3–3) 0 (0–0) 5 (4–6) 1.6 (1.0–2.2) 13.5 (11.8–15.2) 0.3 (0.2–0.5) 2.8 (2.3–3.4)
   Ages 45–64 54.8 0.3 (0.2–0.3) 28 (27–30) 547 (332–768) 824 (721–934) 161 (97–226) 1532 (1191–1881) 10 (6–14) 15 (13–17) 3 (2–4) 28 (22–34) 0.9 (0.5–1.3) 6.9 (6.1–7.8) 0.3 (0.2–0.4) 1.3 (1.0–1.6)
   Ages ≥65 31.9 0.2 (0.1–0.3) 28 (26–29) 1579 (941–2204) 2187 (1939–2429) 411 (249–579) 4177 (3222–5139) 49 (29–69) 68 (61–76) 13 (8–18) 131 (101–161) 0.4 (0.2–0.5) 3.1 (2.7–3.4) 0.2 (0.1–0.3) 0.7 (0.5–0.8)
   Overall 145 0.4 (0.3–0.5) 27 (26–28) 2222 (1337–3116) 3191 (2871–3483) 586 (354–823) 5998 (4645–7365) 15 (9–21) 22 (20–24) 4 (2–6) 41 (32–51) 0.4 (0.3–0.6) 3.8 (3.4–4.1) 0.2 (0.1–0.3) 0.8 (0.6–1.0)
  Both sexes overall 301 0.4 (0.3–0.5) 27 (25–28) 4114 (2460–5750) 6215 (5768–6701) 1163 (703–1643) 11 493 (9044–13 926) 14 (8–19) 21 (19–22) 4 (2–5) 38 (30–46) 0.4 (0.2–0.5) 3.2 (3.0–3.4) 0.2 (0.1–0.3) 0.7 (0.5–0.8)
Table 3. Continued
 
Population Characteristics
Number of Deaths Attributable to SSBs 
(95% UI) Deaths per Million Adults Attributable to SSBs (95% UI) Proportion of Deaths Attributable To SSBs (95% UI)
Population 
(millions)
Mean SSB Intake  
(Servings/d)
Mean BMI  
(kg/m2) CVD* Diabetes Mellitus† Cancers‡ Total§ CVD* Diabetes Mellitus† Cancers‡ Total§ CVD* Diabetes Mellitus† Cancers‡ Total§
(Continued)
*CVD deaths include those from ischemic heart disease, ischemic stroke, and hypertensive heart disease.
†Diabetes mellitus deaths include deaths from the direct effects of SSBs on diabetes mellitus and the effects of SSBs on diabetes mellitus that are mediated 
through BMI.
‡Cancer deaths include those from breast cancer, uterine cancer, esophageal cancer, colon and rectum cancers, pancreatic cancers, kidney cancers, and gall 
bladder cancer.
§Total deaths include those from CVD, diabetes mellitus, and cancers as described above.
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and randomized controlled studies of the impact of dietary 
patterns on CVD risk factors and CHD. Therefore, in com-
bination, these sensitivity analyses confirm that the effects of 
single dietary factors on chronic diseases, such as those used 
in this study, are unlikely to overestimate the effects of diet on 
noncommunicable diseases attributable to residual confound-
ing from other dietary components. Our analytic framework 
incorporated variation by age, sex, and country in SSB intakes, 
etiologic effects of SSBs on disease, and cause-specific mortal-
ity and morbidity, and also propagated uncertainty from each 
of these inputs into the final mortality estimates. Notably, our 
analyses did not simply involve comparisons of SSB intakes 
and disease rates, which would be limited by substantial con-
founding and ecological fallacy, but quantitatively assessed 
and incorporated age- and sex-specific data on SSB consump-
tion and external evidence on the causal effects of SSBs on 
disease risk, and validated data on country, age, sex, and cause-
specific mortality.
Limitations should be considered. We did not identify 
national surveys on SSB consumption in some countries, 
especially those in South Asia and Sub-Saharan Africa, 
which limits the statistical certainty of estimates in these 
regions. Yet, no previous global data on individual-level SSB 
intakes have been compiled,19 and the dietary survey data we 
collected covered 62% of the world’s population. We imple-
mented hierarchical modeling methods with multiple infor-
mative time-varying covariates to account for missing data 
and to quantify its effects on uncertainty. Given our focus on 
chronic disease mortality, we did not collect SSB intakes in 
children and adolescents, among whom SSB consumption is 
likely higher than in young adults. Conversely, although cur-
rent morbidity and future mortality attributable to SSBs may 
be appreciable even in youth, current mortality levels would 
be very low, producing little impact on our estimated burdens 
of deaths. Whereas effects of SSB intake on weight gain have 
been confirmed by randomized controlled trials and gene-diet 
interactions,2–4 the impact of BMI on chronic diseases was 
based on prospective observational studies, which might be 
overestimated because of residual confounding or underes-
timated owing to measurement error. Yet, these data repre-
sent the best available evidence for the effects of adiposity 
on chronic diseases, and the magnitude and causality of these 
Figure 2. Proportion* of combined mortality from diabetes mellitus, CVD, and cancers that is attributable to SSBs in 2010 in 3 age strata 
for women (A) and men (B). The color scale of each map indicates the proportional mortality for the given age-sex stratum in each 
country of the world, highlighting the inverse age gradient. *Proportional mortality was determined by summing SSB-attributable mortality 
across the outcomes of interest (diabetes mellitus, CVD, and cancers), and then dividing by the total number of deaths caused by these 
outcomes within the population of interest. CVD indicates cardiovascular disease; and SSB, sugar-sweetened beverages.
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effects are supported by extensive experimental and shorter-
term clinical interventions.24 In this analysis, we included 
only the BMI-mediated effects of SSB intake on CVD and 
cancers, because these effects have been well-established.24,30 
However, SSB intake has been associated, independent of 
weight gain, with increases in inflammatory biomarkers 
and triglycerides, and the development of hypertension and 
hyperuricemia, as well, which may indicate direct effects 
on outcomes related to these pathways, such as CVD and 
cancers.33,47–50 Therefore, the death and DALY burdens pre-
sented here could be an underestimate of the true burden of 
SSB-related disease. Our analyses included diabetes melli-
tus mortality, but because diabetes mellitus is not often listed 
as the proximal cause of death, the total number of diabetes 
mellitus deaths reported here could be an underestimate. 
However, because many who have diabetes mellitus in life 
ultimately die of CVD causes, we include CVD mortality in 
our analyses, thereby mitigating possible underestimation of 
total SSB-related mortality.
Using a comparative risk assessment model, we found that 
in 2010, 184 000 deaths and 8.5 million DALYs worldwide 
were attributable to consumption of sugary beverages, with 
three-quarters of these burdens occurring in low- and middle-
income countries and the highest proportional burdens among 
adults 20 to 44 years of age. These results indicate the need for 
population-based efforts to reduce SSB consumption through-
out the world through effective health policies and targeted 
interventions directed at stemming obesity-related disease.
Figure 3. The 20 countries* with highest absolute SSB-attributable mortality in 2010. Mortality is standardized per million adults.** The 
20 countries selected in each age–sex group are those with highest SSB-attributable mortality AND with populations of at least 1 million. 
Note that y axis scales differ in each panel. *The 47 smaller countries that were excluded because their populations were <1 million 
were Andorra, Antigua and Barbuda, Bahamas, Bahrain, Barbados, Belize, Bhutan, Brunei Darussalam, Cape Verde, China (Macao 
SAR), Comoros, Cyprus, Djibouti, Dominica, Equatorial Guinea, Fiji, French Polynesia, Gabon, Gambia, Grenada, Guadeloupe, Guinea-
Bissau, Guyana, Iceland, Kiribati, Luxembourg, Maldives, Malta, Marshall Islands, Martinique, Mauritius, Micronesia, Montenegro, 
Netherlands Antilles, Réunion, Saint Lucia, Saint Vincent and the Grenadines, Samoa, São Tomé and Príncipe, Seychelles, Solomon 
Islands, Suriname, Swaziland, Timor-Leste, Tonga, Trinidad and Tobago, and Vanuatu. **Population-standardized absolute mortality was 
calculated by dividing attributable deaths by the adult population of the entity of interest (ie, country, region, or age–sex groups within a 
country or region) and then multiplying by 1 million. CVD indicates cardiovascular disease; D.R., Dominican Republic; P.N. Guinea, Papua 
New Guinea: SSB, sugar-sweetened beverages; and U.A.E., United Arab Emirates.
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Table 4. Global and Regional DALYs Related to SSB Consumption in 2010
Population Characteristics Number of DALYs Attributable to SSBs (95% UI) DALYs per Million Adults Attributable to SSBs (95% UI) Percentage of DALYs Attributable to SSBs (95% UI)
Population
Mean  
SSB Intake 
(Servings/d)
Mean  
BMI (kg/m2) CVD‡ Diabetes Mellitus§ Cancersβ Musculoskeletal¶ Total† CVD‡ Diabetes Mellitus§ Cancersβ Musculoskeletal¶ Total† CVD‡
Diabetes 
Mellitus§ Cancersβ Musculoskeletal¶ Total†
Globe
  Women
   Ages 20–44 987 0.8 (0.3–1.3) 24.7 (23.1–26.3) 294 808 (53 872–894 390) 372 240 (140 880–769 120) 34 343 (6024–132 271) 33 489 (5007–143 503) 734 880 (260 247–1 760 532) 230 (42–698) 290 (110–600) 27 (5–103) 26 (4–112) 573 (203–1373) 2.5 (0.9–6.6) 3.5 (1.3–7.1) 0.2 (0.1–0.7) 0.2 (0.0–0.5) 0.4 (0.2–0.9)
   Ages 45–64 654 0.4 (0.2–0.6) 27.2 (25.2–29.1) 519 525 (77 623–1 416 485) 712 098 (280 473–1 406 840) 87 985 (15 112–264 554) 132 295 (18 392–411 280) 1 451 903 (472 003–3 185 858) 795 (119–2167) 1089 (429–2152) 135 (23–405) 202 (28–629) 2221 (722–4874) 1.2 (0.4–3.1) 4.7 (1.8–9.1) 0.2 (0.1–0.6) 0.4 (0.1–1.4) 0.8 (0.3–1.7)
   Ages ≥65 293 0.3 (0.1–0.5) 25.8 (22.8–28.7) 742 527 (121 255–2 136 253) 595 440 (239 959–1 174 648) 68 755 (11 181–236 558) 88 073 (10 524–327 831) 1 494 795 (461 518–3 634 885) 2537 (414–7300) 2035 (820–4014) 235 (38–808) 301 (36–1120) 5108 (1577–12 420) 0.9 (0.2–3.0) 4.2 (1.6–8.2) 0.3 (0.0–1.0) 0.5 (0.1–2.0) 0.8 (0.3–2.1)
   Women overall 1930 0.5 (0.2–0.8) 25.7 (23.5–27.9) 1 556 860 (252 750–4 447 127) 1 679 778 (661 311–3 350 608) 191 083 (32 317–633 384) 253 857 (33 923–882 614) 3 681 578 (1 193 768–8 581 275) 699 (113–1996) 754 (297–1504) 86 (15–284) 114 (15–396) 1652 (536–3851) 1.5 (0.5–4.2) 4.1 (1.6–8.1) 0.2 (0.1–0.7) 0.4 (0.1–1.3) 0.7 (0.3–1.5)
  Men
   Ages 20–44 1020 0.9 (0.4–1.4) 24.3 (22.9–25.8) 619 039 (118 456–1 602 534) 465 992 (179 272–941 049) 24 712 (4043–76 731) 21 364 (3397–62 462) 1 131 107 (387 637–2 420 754) 466 (89–1207) 351 (135–709) 19 (3–58) 16 (3–47) 852 (292–1823) 2.9 (1.0–6.9) 6.1 (2.3–12.1) 0.2 (0.0–0.6) 0.1 (0.0–0.5) 0.5 (0.2–0.9)
   Ages 45–64 645 0.4 (0.2–0.7) 25.8 (24.1–27.5) 1 230 704 (180 660–2 779 689) 843 033 (335 415–1 635 657) 103 247 (14 853–250 627) 94 963 (12 361–267 311) 2 271 946 (656 182–4 517 436) 1907 (280–4308) 1307 (520–2535) 160 (23–388) 147 (19–414) 3521 (1017–7002) 1.4 (0.4–4.1) 4.9 (1.9–9.5) 0.2 (0.0–0.8) 0.5 (0.1–1.6) 0.8 (0.3–1.7)
   Ages ≥65 231 0.3 (0.1–0.5) 24.7 (22.7–26.8) 812 458 (226 030–2 424 935) 517 800 (209 314–994 182) 67 653 (15 239–304 601) 43 914 (7232–176 926) 1 441 825 (532 366–3 725 193) 3510 (977–10477) 2237 (904–4295) 292 (66–1316) 190 (31–764) 6230 (2300–16 095) 1.1 (0.2–3.2) 3.7 (1.4–7.2) 0.2 (0.0–0.8) 0.5 (0.1–1.8) 0.8 (0.3–1.8)
   Men overall 1890 0.6 (0.2–0.9) 24.8 (23.1–26.6) 2 662 201 (525 146–6 807 159) 1 826 824 (724 002–3 570 888) 195 612 (34 136–631 960) 160 241 (22 989–506 700) 4 844 878 
(1 576 185–10 663 382)
1208 (238–3088) 829 (328–1620) 89 (15–287) 73 (10–230) 2198 (715–4837) 1.8 (0.6–4.7) 4.9 (1.9–9.6) 0.2 (0.0–0.7) 0.4 (0.1–1.3) 0.7 (0.3–1.5)
  Both sexes overall 3830 0.5 (0.2–0.9) 25.3 (23.3–27.3) 4 219 061 (777 896–11 254 286) 3 506 602 (138 5313–6 921 496) 386 695 (66 453–1 265 343) 414 097 (56 912–1 389 314) 8 526 456 
(2 769 953–19 244 657)
952 (175–2539) 791 (313–1561) 87 (15–285) 93 (13–313) 1924 (625–4342) 1.6 (0.5–4.5) 4.5 (1.7–8.9) 0.2 (0.1–0.7) 0.4 (0.1–1.3) 0.7 (0.3–1.5)
Country income level
  High income 763 0.5 (0.3–0.6) 26.7 (25.0–28.5) 280 243 (167 025–583 031) 881 425 (394 880–1 562 988) 50 087 (25 564–133 452) 44 740 (15 407–155 255) 1 256 495 (699 247–2 292 130) 336 (200–699) 1057 (473–1874) 60 (31–160) 54 (18–186) 1507 (838–2748) 1.0 (0.6–2.4) 4.4 (1.8–8.2) 0.1 (0.1–0.3) 0.1 (0.0–0.4) 0.5 (0.3–1.1)
  Upper middle income 1530 0.7 (0.3–1.1) 26.3 (24.4–28.2) 619 316 (203 775–2 447 285) 1 376 986 (568 380–2 649 568) 69 435 (17 044–365 715) 79 980 (19 886–345 074) 2 145 716 (948 946–5 564 122) 353 (116–1397) 786 (324–1512) 40 (10–209) 46 (11–197) 1225 (542–3175) 1.5 (0.7–3.4) 6.1 (2.5–11.7) 0.2 (0.1–0.5) 0.3 (0.1–0.9) 0.8 (0.4–1.6)
  Lower middle 
income
1210 0.6 (0.2–1.0) 25.2 (23.2–27.2) 2 753 266 (375 163–6 534 363) 1 074 097 (370 326–2 298 304) 211 883 (21 492–572 887) 204 356 (18 242–608 452) 4 243 602 (998 925–9 058 923) 1902 (259–4514) 742 (256–1588) 146 (15–396) 141 (13–420) 2931 (690–6258) 1.6 (0.5–4.8) 4.6 (1.6–9.6) 0.2 (0.0–0.8) 0.4 (0.1–1.4) 0.8 (0.3–1.8)
  Low income 323 0.3 (0.1–0.5) 22.1 (19.8–24.4) 566 236 (31 933–1 689 606) 174 095 (51 727–410 636) 55 290 (2353–193 290) 85 021 (3377–280 533) 880 643 (122 835–2 329 483) 1420 (80–4238) 437 (130–1030) 139 (6–485) 213 (8–704) 2209 (308–5843) 2.6 (0.3–8.4) 2.1 (0.7–4.6) 0.4 (0.0–1.5) 0.7 (0.0–2.9) 0.5 (0.1–1.5)
Australia and New Zealand
  Women
   Ages 20–44 3.6 0.4 (0.2–0.6) 26.0 (25.2–26.9) 173 (106–259) 554 (206–1191) 53 (33–80) 39 (18–74) 818 (456–1479) 39 (24–58) 124 (46–267) 12 (7–18) 9 (4–17) 183 (102–331) 1.1 (0.7–1.5) 1.2 (0.4–2.6) 0.1 (0.1–0.2) 0.0 (0.0–0.1) 0.1 (0.1–0.2)
   Ages 45–64 3.35 0.2 (0.1–0.3) 28.8 (27.7–29.9) 319 (219–457) 1148 (432–2503) 180 (122–256) 182 (83–344) 1829 (1060–3196) 95 (65–136) 343 (129–747) 54 (36–76) 54 (25–103) 546 (316–954) 0.4 (0.3–0.6) 1.9 (0.7–3.7) 0.1 (0.1–0.1) 0.1 (0.0–0.2) 0.2 (0.1–0.3)
   Ages ≥65 1.94 0.1 (0.1–0.2) 27.8 (26.9–28.8) 644 (474–853) 1396 (544–2927) 150 (100–213) 96 (46–177) 2286 (1383–3792) 331 (244–439) 718 (280–1505) 77 (51–109) 50 (24–91) 1176 (711–1950) 0.2 (0.2–0.3) 1.6 (0.6–3.2) 0.1 (0.0–0.1) 0.1 (0.0–0.1) 0.2 (0.1–0.3)
   Women overall 8.89 0.2 (0.1–0.4) 27.4 (26.4–28.4) 1136 (800–1569) 3097 (1183–6621) 383 (254–548) 317 (147–595) 4933 (2898–8467) 116 (82–161) 317 (121–678) 39 (26–56) 32 (15–61) 505 (297–868) 0.6 (0.4–0.8) 1.6 (0.6–3.2) 0.1 (0.1–0.1) 0.1 (0.0–0.1) 0.2 (0.1–0.3)
  Men
   Ages 20–44 3.57 0.4 (0.2–0.6) 26.9 (26.2–27.6) 410 (267–601) 713 (257–1529) 36 (20–59) 25 (12–48) 1184 (682–2025) 92 (60–134) 159 (57–342) 8 (4–13) 6 (3–11) 264 (152–452) 1.3 (0.9–1.7) 2.7 (1.0–5.6) 0.1 (0.0–0.1) 0.0 (0.0–0.0) 0.2 (0.1–0.3)
   Ages 45–64 3.28 0.2 (0.1–0.3) 28.9 (28.2–29.7) 872 (626–1176) 1628 (611–3414) 194 (123–281) 117 (55–224) 2811 (1711–4663) 266 (191–359) 496 (186–1041) 59 (37–86) 36 (17–68) 857 (522–1422) 0.5 (0.4–0.7) 1.8 (0.7–3.6) 0.1 (0.0–0.1) 0.1 (0.0–0.1) 0.2 (0.2–0.4)
   Ages ≥65 1.64 0.1 (0.1–0.2) 27.9 (27.1–28.6) 830 (615–1091) 1672 (633–3439) 177 (114–255) 53 (25–102) 2732 (1670–4525) 507 (376–667) 1022 (387–2103) 108 (70–156) 33 (15–63) 1670 (1021–2766) 0.2 (0.2–0.3) 1.3 (0.5–2.6) 0.1 (0.0–0.1) 0.0 (0.0–0.1) 0.2 (0.1–0.3)
   Men overall 8.48 0.2 (0.1–0.4) 27.8 (27.0–28.5) 2112 (1509–2868) 4012 (1501–8382) 407 (256–595) 196 (92–374) 6727 (4063–11 213) 225 (161–305) 427 (160–893) 43 (27–63) 21 (10–40) 716 (433–1194) 0.7 (0.5–0.9) 1.9 (0.7–3.9) 0.1 (0.0–0.1) 0.0 (0.0–0.1) 0.2 (0.1–0.3)
  Both sexes overall 17.4 0.2 (0.1–0.4) 27.6 (26.7–28.4) 3248 (2308–4437) 7109 (2683–15 003) 790 (511–1144) 513 (239–969) 11 660 (6962–19 680) 170 (121–232) 371 (140–783) 41 (27–60) 27 (12–51) 609 (364–1028) 0.6 (0.4–0.8) 1.7 (0.7–3.5) 0.1 (0.0–0.1) 0.0 (0.0–0.1) 0.2 (0.1–0.3)
Canada and United States
  Women
   Ages 20–44 45 1.6 (1.2–2.0) 26.4 (25.7–27.0) 10 059 (6559–13 985) 46 638 (22 427–79 711) 1608 (1022–2448) 1297 (632–2466) 59 603 (34 939–93 195) 178 (116–248) 827 (398–1413) 29 (18–43) 23 (11–44) 1057 (619–1652) 2.5 (1.8–3.4) 6.5 (2.9–11.5) 0.2 (0.1–0.4) 0.1 (0.0–0.1) 0.6 (0.3–1.0)
   Ages 45–64 46.1 0.8 (0.6–1.0) 29.2 (28.4–30.1) 21 516 (15 138–28 549) 117 050 (55 317–198 511) 5942 (4009–8354) 6632 (3309–12 439) 151 139 (88 769–236 152) 467 (329–620) 2541 (1201–4309) 129 (87–181) 144 (72–270) 3281 (1927–5126) 1.1 (0.8–1.3) 9.0 (4.2–15.0) 0.2 (0.1–0.2) 0.2 (0.1–0.4) 0.9 (0.5–1.4)
   Ages ≥65 25.6 0.6 (0.4–0.7) 28.0 (27.2–28.8) 24 760 (18 351–32 226) 114 732 (53 922–194 331) 4240 (2850–6161) 3283 (1648–6002) 147 015 (86 073–227 384) 966 (716–1257) 4475 (2103–7579) 165 (111–240) 128 (64–234) 5734 (3357–8868) 0.5 (0.4–0.6) 7.4 (3.4–12.2) 0.1 (0.1–0.2) 0.1 (0.1–0.3) 0.8 (0.4–1.3)
   Women overall 117 1.0 (0.8–1.2) 27.7 (26.9–28.5) 56 335 (40 048–74 759) 278 420 (131 666–472 553) 11 790 (7881–16 963) 11 211 (5589–20 906) 357 756 (209 781–556 731) 440 (313–584) 2173 (1028–3689) 92 (62–132) 88 (44–163) 2793 (1638–4346) 1.4 (1.0–1.8) 7.6 (3.5–12.9) 0.2 (0.1–0.3) 0.1 (0.1–0.3) 0.7 (0.4–1.2)
  Men
   Ages 20–44 46.3 1.8 (1.3–2.2) 27.2 (26.6–27.7) 21 980 (14 596–31 212) 64 555 (30 299–108 124) 1283 (733–2170) 948 (450–1731) 88 767 (52 997–134 444) 377 (250–535) 1107 (520–1855) 22 (13–37) 16 (8–30) 1523 (909–2306) 3.1 (2.2–4.2) 12.9 (5.8–21.8) 0.2 (0.1–0.4) 0.1 (0.0–0.1) 0.8 (0.4–1.3)
   Ages 45–64 44.2 0.9 (0.7–1.1) 29.1 (28.5–29.8) 50 846 (36 756–66 835) 160 750 (74 845–268 450) 6624 (4074–10 105) 4690 (2251–8367) 222 910 (135 121–330 714) 1151 (832–1513) 3638 (1694–6076) 150 (92–229) 106 (51–189) 5045 (3058–7485) 1.3 (1.0–1.7) 9.1 (4.0–15.0) 0.2 (0.1–0.3) 0.2 (0.1–0.4) 1.1 (0.6–1.7)
   Ages ≥65 19.4 0.6 (0.5–0.8) 27.9 (27.3–28.5) 28 821 (21 554–36 844) 111 961 (50 940–188 457) 4076 (2550–6098) 1766 (862–3175) 146 625 (85 561–223 353) 1489 (1114–1904) 5785 (2632–9737) 211 (132–315) 91 (45–164) 7576 (4421–11540) 0.6 (0.4–0.7) 6.2 (2.8–10.5) 0.1 (0.1–0.1) 0.1 (0.1–0.3) 0.8 (0.5–1.3)
   Men overall 110 1.1 (0.8–1.4) 27.9 (27.3–28.5) 101 648 (72 907–134 891) 337 267 (156 083–565 031) 11 983 (7357–18 373) 7404 (3563–13 273) 458 302 (273 679–688 510) 834 (598–1107) 2768 (1281–4638) 98 (60–151) 61 (29–109) 3762 (2246–5651) 1.7 (1.2–2.2) 9.4 (4.2–15.8) 0.2 (0.1–0.3) 0.1 (0.1–0.3) 0.9 (0.5–1.4)
  Both sexes overall 226 1.1 (0.8–1.3) 27.8 (27.1–28.5) 157 983 (112 955–209 650) 615 686 (287 750–1 037 584) 23 773 (15 238–35 336) 18 616 (9151–34 179) 816 058 (483 460–1 245 241) 632 (452–839) 2463 (1151–4151) 95 (61–141) 74 (37–137) 3265 (1934–4982) 1.5 (1.1–2.0) 8.5 (3.9–14.3) 0.2 (0.1–0.3) 0.1 (0.1–0.3) 0.8 (0.5–1.3)
East and Southeast Asia
  Women
   Ages 20–44 341 0.9 (0.4–1.3) 24.9 (23.4–26.4) 43 502 (5336–261 258) 66 098 (24 272–144 241) 7540 (706–50 420) 8651 (679–74 288) 125 791 (37 694–501 434) 100 (12–603) 153 (56–333) 17 (2–116) 20 (2–172) 290 (87–1158) 2.5 (0.6–7.2) 4.4 (1.6–8.8) 0.2 (0.0–0.7) 0.2 (0.0–0.7) 0.6 (0.2–1.5)
   Ages 45–64 238 0.4 (0.2–0.7) 26.6 (24.7–28.5) 52 701 (7184–220 062) 135 713 (50 776–273 544) 11 095 (1499–48 858) 23 984 (2383–100 452) 223 492 (73 317–596 369) 221 (30–923) 569 (213–1148) 47 (6–205) 101 (10–421) 938 (308–2502) 1.1 (0.2–3.7) 5.4 (2.1–10.6) 0.2 (0.0–0.7) 0.5 (0.1–1.9) 1.1 (0.4–2.7)
   Ages ≥65 101 0.3 (0.1–0.5) 24.5 (21.6–27.5) 241 385 (11 010–970 152) 110 547 (38 953–245 152) 25 084 (1042–129 905) 36 381 (1480–187 636) 413 397 (67 327–1 465 240) 2398 (109–9638) 1098 (387–2435) 249 (10–1291) 361 (15–1864) 4107 (669–14 556) 1.0 (0.1–3.7) 4.5 (1.7–9.0) 0.3 (0.0–1.1) 0.7 (0.1–2.7) 1.1 (0.3–2.7)
   Women overall 680 0.5 (0.2–0.9) 25.2 (23.1–27.3) 337 588 (23 529–1 451 472) 312 357 (114 002–662 937) 43 719 (3248–229183) 69 015 (4542–362 376) 762 680 (178 337–2 563 042) 437 (30–1880) 405 (148–859) 57 (4–297) 89 (6–469) 988 (231–3320) 1.5 (0.3–4.9) 4.8 (1.8–9.5) 0.2 (0.0–0.8) 0.4 (0.1–1.8) 1.0 (0.3–2.3)
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Table 4. Global and Regional DALYs Related to SSB Consumption in 2010
Population Characteristics Number of DALYs Attributable to SSBs (95% UI) DALYs per Million Adults Attributable to SSBs (95% UI) Percentage of DALYs Attributable to SSBs (95% UI)
Population
Mean  
SSB Intake 
(Servings/d)
Mean  
BMI (kg/m2) CVD‡ Diabetes Mellitus§ Cancersβ Musculoskeletal¶ Total† CVD‡ Diabetes Mellitus§ Cancersβ Musculoskeletal¶ Total† CVD‡
Diabetes 
Mellitus§ Cancersβ Musculoskeletal¶ Total†
Globe
  Women
   Ages 20–44 987 0.8 (0.3–1.3) 24.7 (23.1–26.3) 294 808 (53 872–894 390) 372 240 (140 880–769 120) 34 343 (6024–132 271) 33 489 (5007–143 503) 734 880 (260 247–1 760 532) 230 (42–698) 290 (110–600) 27 (5–103) 26 (4–112) 573 (203–1373) 2.5 (0.9–6.6) 3.5 (1.3–7.1) 0.2 (0.1–0.7) 0.2 (0.0–0.5) 0.4 (0.2–0.9)
   Ages 45–64 654 0.4 (0.2–0.6) 27.2 (25.2–29.1) 519 525 (77 623–1 416 485) 712 098 (280 473–1 406 840) 87 985 (15 112–264 554) 132 295 (18 392–411 280) 1 451 903 (472 003–3 185 858) 795 (119–2167) 1089 (429–2152) 135 (23–405) 202 (28–629) 2221 (722–4874) 1.2 (0.4–3.1) 4.7 (1.8–9.1) 0.2 (0.1–0.6) 0.4 (0.1–1.4) 0.8 (0.3–1.7)
   Ages ≥65 293 0.3 (0.1–0.5) 25.8 (22.8–28.7) 742 527 (121 255–2 136 253) 595 440 (239 959–1 174 648) 68 755 (11 181–236 558) 88 073 (10 524–327 831) 1 494 795 (461 518–3 634 885) 2537 (414–7300) 2035 (820–4014) 235 (38–808) 301 (36–1120) 5108 (1577–12 420) 0.9 (0.2–3.0) 4.2 (1.6–8.2) 0.3 (0.0–1.0) 0.5 (0.1–2.0) 0.8 (0.3–2.1)
   Women overall 1930 0.5 (0.2–0.8) 25.7 (23.5–27.9) 1 556 860 (252 750–4 447 127) 1 679 778 (661 311–3 350 608) 191 083 (32 317–633 384) 253 857 (33 923–882 614) 3 681 578 (1 193 768–8 581 275) 699 (113–1996) 754 (297–1504) 86 (15–284) 114 (15–396) 1652 (536–3851) 1.5 (0.5–4.2) 4.1 (1.6–8.1) 0.2 (0.1–0.7) 0.4 (0.1–1.3) 0.7 (0.3–1.5)
  Men
   Ages 20–44 1020 0.9 (0.4–1.4) 24.3 (22.9–25.8) 619 039 (118 456–1 602 534) 465 992 (179 272–941 049) 24 712 (4043–76 731) 21 364 (3397–62 462) 1 131 107 (387 637–2 420 754) 466 (89–1207) 351 (135–709) 19 (3–58) 16 (3–47) 852 (292–1823) 2.9 (1.0–6.9) 6.1 (2.3–12.1) 0.2 (0.0–0.6) 0.1 (0.0–0.5) 0.5 (0.2–0.9)
   Ages 45–64 645 0.4 (0.2–0.7) 25.8 (24.1–27.5) 1 230 704 (180 660–2 779 689) 843 033 (335 415–1 635 657) 103 247 (14 853–250 627) 94 963 (12 361–267 311) 2 271 946 (656 182–4 517 436) 1907 (280–4308) 1307 (520–2535) 160 (23–388) 147 (19–414) 3521 (1017–7002) 1.4 (0.4–4.1) 4.9 (1.9–9.5) 0.2 (0.0–0.8) 0.5 (0.1–1.6) 0.8 (0.3–1.7)
   Ages ≥65 231 0.3 (0.1–0.5) 24.7 (22.7–26.8) 812 458 (226 030–2 424 935) 517 800 (209 314–994 182) 67 653 (15 239–304 601) 43 914 (7232–176 926) 1 441 825 (532 366–3 725 193) 3510 (977–10477) 2237 (904–4295) 292 (66–1316) 190 (31–764) 6230 (2300–16 095) 1.1 (0.2–3.2) 3.7 (1.4–7.2) 0.2 (0.0–0.8) 0.5 (0.1–1.8) 0.8 (0.3–1.8)
   Men overall 1890 0.6 (0.2–0.9) 24.8 (23.1–26.6) 2 662 201 (525 146–6 807 159) 1 826 824 (724 002–3 570 888) 195 612 (34 136–631 960) 160 241 (22 989–506 700) 4 844 878 
(1 576 185–10 663 382)
1208 (238–3088) 829 (328–1620) 89 (15–287) 73 (10–230) 2198 (715–4837) 1.8 (0.6–4.7) 4.9 (1.9–9.6) 0.2 (0.0–0.7) 0.4 (0.1–1.3) 0.7 (0.3–1.5)
  Both sexes overall 3830 0.5 (0.2–0.9) 25.3 (23.3–27.3) 4 219 061 (777 896–11 254 286) 3 506 602 (138 5313–6 921 496) 386 695 (66 453–1 265 343) 414 097 (56 912–1 389 314) 8 526 456 
(2 769 953–19 244 657)
952 (175–2539) 791 (313–1561) 87 (15–285) 93 (13–313) 1924 (625–4342) 1.6 (0.5–4.5) 4.5 (1.7–8.9) 0.2 (0.1–0.7) 0.4 (0.1–1.3) 0.7 (0.3–1.5)
Country income level
  High income 763 0.5 (0.3–0.6) 26.7 (25.0–28.5) 280 243 (167 025–583 031) 881 425 (394 880–1 562 988) 50 087 (25 564–133 452) 44 740 (15 407–155 255) 1 256 495 (699 247–2 292 130) 336 (200–699) 1057 (473–1874) 60 (31–160) 54 (18–186) 1507 (838–2748) 1.0 (0.6–2.4) 4.4 (1.8–8.2) 0.1 (0.1–0.3) 0.1 (0.0–0.4) 0.5 (0.3–1.1)
  Upper middle income 1530 0.7 (0.3–1.1) 26.3 (24.4–28.2) 619 316 (203 775–2 447 285) 1 376 986 (568 380–2 649 568) 69 435 (17 044–365 715) 79 980 (19 886–345 074) 2 145 716 (948 946–5 564 122) 353 (116–1397) 786 (324–1512) 40 (10–209) 46 (11–197) 1225 (542–3175) 1.5 (0.7–3.4) 6.1 (2.5–11.7) 0.2 (0.1–0.5) 0.3 (0.1–0.9) 0.8 (0.4–1.6)
  Lower middle 
income
1210 0.6 (0.2–1.0) 25.2 (23.2–27.2) 2 753 266 (375 163–6 534 363) 1 074 097 (370 326–2 298 304) 211 883 (21 492–572 887) 204 356 (18 242–608 452) 4 243 602 (998 925–9 058 923) 1902 (259–4514) 742 (256–1588) 146 (15–396) 141 (13–420) 2931 (690–6258) 1.6 (0.5–4.8) 4.6 (1.6–9.6) 0.2 (0.0–0.8) 0.4 (0.1–1.4) 0.8 (0.3–1.8)
  Low income 323 0.3 (0.1–0.5) 22.1 (19.8–24.4) 566 236 (31 933–1 689 606) 174 095 (51 727–410 636) 55 290 (2353–193 290) 85 021 (3377–280 533) 880 643 (122 835–2 329 483) 1420 (80–4238) 437 (130–1030) 139 (6–485) 213 (8–704) 2209 (308–5843) 2.6 (0.3–8.4) 2.1 (0.7–4.6) 0.4 (0.0–1.5) 0.7 (0.0–2.9) 0.5 (0.1–1.5)
Australia and New Zealand
  Women
   Ages 20–44 3.6 0.4 (0.2–0.6) 26.0 (25.2–26.9) 173 (106–259) 554 (206–1191) 53 (33–80) 39 (18–74) 818 (456–1479) 39 (24–58) 124 (46–267) 12 (7–18) 9 (4–17) 183 (102–331) 1.1 (0.7–1.5) 1.2 (0.4–2.6) 0.1 (0.1–0.2) 0.0 (0.0–0.1) 0.1 (0.1–0.2)
   Ages 45–64 3.35 0.2 (0.1–0.3) 28.8 (27.7–29.9) 319 (219–457) 1148 (432–2503) 180 (122–256) 182 (83–344) 1829 (1060–3196) 95 (65–136) 343 (129–747) 54 (36–76) 54 (25–103) 546 (316–954) 0.4 (0.3–0.6) 1.9 (0.7–3.7) 0.1 (0.1–0.1) 0.1 (0.0–0.2) 0.2 (0.1–0.3)
   Ages ≥65 1.94 0.1 (0.1–0.2) 27.8 (26.9–28.8) 644 (474–853) 1396 (544–2927) 150 (100–213) 96 (46–177) 2286 (1383–3792) 331 (244–439) 718 (280–1505) 77 (51–109) 50 (24–91) 1176 (711–1950) 0.2 (0.2–0.3) 1.6 (0.6–3.2) 0.1 (0.0–0.1) 0.1 (0.0–0.1) 0.2 (0.1–0.3)
   Women overall 8.89 0.2 (0.1–0.4) 27.4 (26.4–28.4) 1136 (800–1569) 3097 (1183–6621) 383 (254–548) 317 (147–595) 4933 (2898–8467) 116 (82–161) 317 (121–678) 39 (26–56) 32 (15–61) 505 (297–868) 0.6 (0.4–0.8) 1.6 (0.6–3.2) 0.1 (0.1–0.1) 0.1 (0.0–0.1) 0.2 (0.1–0.3)
  Men
   Ages 20–44 3.57 0.4 (0.2–0.6) 26.9 (26.2–27.6) 410 (267–601) 713 (257–1529) 36 (20–59) 25 (12–48) 1184 (682–2025) 92 (60–134) 159 (57–342) 8 (4–13) 6 (3–11) 264 (152–452) 1.3 (0.9–1.7) 2.7 (1.0–5.6) 0.1 (0.0–0.1) 0.0 (0.0–0.0) 0.2 (0.1–0.3)
   Ages 45–64 3.28 0.2 (0.1–0.3) 28.9 (28.2–29.7) 872 (626–1176) 1628 (611–3414) 194 (123–281) 117 (55–224) 2811 (1711–4663) 266 (191–359) 496 (186–1041) 59 (37–86) 36 (17–68) 857 (522–1422) 0.5 (0.4–0.7) 1.8 (0.7–3.6) 0.1 (0.0–0.1) 0.1 (0.0–0.1) 0.2 (0.2–0.4)
   Ages ≥65 1.64 0.1 (0.1–0.2) 27.9 (27.1–28.6) 830 (615–1091) 1672 (633–3439) 177 (114–255) 53 (25–102) 2732 (1670–4525) 507 (376–667) 1022 (387–2103) 108 (70–156) 33 (15–63) 1670 (1021–2766) 0.2 (0.2–0.3) 1.3 (0.5–2.6) 0.1 (0.0–0.1) 0.0 (0.0–0.1) 0.2 (0.1–0.3)
   Men overall 8.48 0.2 (0.1–0.4) 27.8 (27.0–28.5) 2112 (1509–2868) 4012 (1501–8382) 407 (256–595) 196 (92–374) 6727 (4063–11 213) 225 (161–305) 427 (160–893) 43 (27–63) 21 (10–40) 716 (433–1194) 0.7 (0.5–0.9) 1.9 (0.7–3.9) 0.1 (0.0–0.1) 0.0 (0.0–0.1) 0.2 (0.1–0.3)
  Both sexes overall 17.4 0.2 (0.1–0.4) 27.6 (26.7–28.4) 3248 (2308–4437) 7109 (2683–15 003) 790 (511–1144) 513 (239–969) 11 660 (6962–19 680) 170 (121–232) 371 (140–783) 41 (27–60) 27 (12–51) 609 (364–1028) 0.6 (0.4–0.8) 1.7 (0.7–3.5) 0.1 (0.0–0.1) 0.0 (0.0–0.1) 0.2 (0.1–0.3)
Canada and United States
  Women
   Ages 20–44 45 1.6 (1.2–2.0) 26.4 (25.7–27.0) 10 059 (6559–13 985) 46 638 (22 427–79 711) 1608 (1022–2448) 1297 (632–2466) 59 603 (34 939–93 195) 178 (116–248) 827 (398–1413) 29 (18–43) 23 (11–44) 1057 (619–1652) 2.5 (1.8–3.4) 6.5 (2.9–11.5) 0.2 (0.1–0.4) 0.1 (0.0–0.1) 0.6 (0.3–1.0)
   Ages 45–64 46.1 0.8 (0.6–1.0) 29.2 (28.4–30.1) 21 516 (15 138–28 549) 117 050 (55 317–198 511) 5942 (4009–8354) 6632 (3309–12 439) 151 139 (88 769–236 152) 467 (329–620) 2541 (1201–4309) 129 (87–181) 144 (72–270) 3281 (1927–5126) 1.1 (0.8–1.3) 9.0 (4.2–15.0) 0.2 (0.1–0.2) 0.2 (0.1–0.4) 0.9 (0.5–1.4)
   Ages ≥65 25.6 0.6 (0.4–0.7) 28.0 (27.2–28.8) 24 760 (18 351–32 226) 114 732 (53 922–194 331) 4240 (2850–6161) 3283 (1648–6002) 147 015 (86 073–227 384) 966 (716–1257) 4475 (2103–7579) 165 (111–240) 128 (64–234) 5734 (3357–8868) 0.5 (0.4–0.6) 7.4 (3.4–12.2) 0.1 (0.1–0.2) 0.1 (0.1–0.3) 0.8 (0.4–1.3)
   Women overall 117 1.0 (0.8–1.2) 27.7 (26.9–28.5) 56 335 (40 048–74 759) 278 420 (131 666–472 553) 11 790 (7881–16 963) 11 211 (5589–20 906) 357 756 (209 781–556 731) 440 (313–584) 2173 (1028–3689) 92 (62–132) 88 (44–163) 2793 (1638–4346) 1.4 (1.0–1.8) 7.6 (3.5–12.9) 0.2 (0.1–0.3) 0.1 (0.1–0.3) 0.7 (0.4–1.2)
  Men
   Ages 20–44 46.3 1.8 (1.3–2.2) 27.2 (26.6–27.7) 21 980 (14 596–31 212) 64 555 (30 299–108 124) 1283 (733–2170) 948 (450–1731) 88 767 (52 997–134 444) 377 (250–535) 1107 (520–1855) 22 (13–37) 16 (8–30) 1523 (909–2306) 3.1 (2.2–4.2) 12.9 (5.8–21.8) 0.2 (0.1–0.4) 0.1 (0.0–0.1) 0.8 (0.4–1.3)
   Ages 45–64 44.2 0.9 (0.7–1.1) 29.1 (28.5–29.8) 50 846 (36 756–66 835) 160 750 (74 845–268 450) 6624 (4074–10 105) 4690 (2251–8367) 222 910 (135 121–330 714) 1151 (832–1513) 3638 (1694–6076) 150 (92–229) 106 (51–189) 5045 (3058–7485) 1.3 (1.0–1.7) 9.1 (4.0–15.0) 0.2 (0.1–0.3) 0.2 (0.1–0.4) 1.1 (0.6–1.7)
   Ages ≥65 19.4 0.6 (0.5–0.8) 27.9 (27.3–28.5) 28 821 (21 554–36 844) 111 961 (50 940–188 457) 4076 (2550–6098) 1766 (862–3175) 146 625 (85 561–223 353) 1489 (1114–1904) 5785 (2632–9737) 211 (132–315) 91 (45–164) 7576 (4421–11540) 0.6 (0.4–0.7) 6.2 (2.8–10.5) 0.1 (0.1–0.1) 0.1 (0.1–0.3) 0.8 (0.5–1.3)
   Men overall 110 1.1 (0.8–1.4) 27.9 (27.3–28.5) 101 648 (72 907–134 891) 337 267 (156 083–565 031) 11 983 (7357–18 373) 7404 (3563–13 273) 458 302 (273 679–688 510) 834 (598–1107) 2768 (1281–4638) 98 (60–151) 61 (29–109) 3762 (2246–5651) 1.7 (1.2–2.2) 9.4 (4.2–15.8) 0.2 (0.1–0.3) 0.1 (0.1–0.3) 0.9 (0.5–1.4)
  Both sexes overall 226 1.1 (0.8–1.3) 27.8 (27.1–28.5) 157 983 (112 955–209 650) 615 686 (287 750–1 037 584) 23 773 (15 238–35 336) 18 616 (9151–34 179) 816 058 (483 460–1 245 241) 632 (452–839) 2463 (1151–4151) 95 (61–141) 74 (37–137) 3265 (1934–4982) 1.5 (1.1–2.0) 8.5 (3.9–14.3) 0.2 (0.1–0.3) 0.1 (0.1–0.3) 0.8 (0.5–1.3)
East and Southeast Asia
  Women
   Ages 20–44 341 0.9 (0.4–1.3) 24.9 (23.4–26.4) 43 502 (5336–261 258) 66 098 (24 272–144 241) 7540 (706–50 420) 8651 (679–74 288) 125 791 (37 694–501 434) 100 (12–603) 153 (56–333) 17 (2–116) 20 (2–172) 290 (87–1158) 2.5 (0.6–7.2) 4.4 (1.6–8.8) 0.2 (0.0–0.7) 0.2 (0.0–0.7) 0.6 (0.2–1.5)
   Ages 45–64 238 0.4 (0.2–0.7) 26.6 (24.7–28.5) 52 701 (7184–220 062) 135 713 (50 776–273 544) 11 095 (1499–48 858) 23 984 (2383–100 452) 223 492 (73 317–596 369) 221 (30–923) 569 (213–1148) 47 (6–205) 101 (10–421) 938 (308–2502) 1.1 (0.2–3.7) 5.4 (2.1–10.6) 0.2 (0.0–0.7) 0.5 (0.1–1.9) 1.1 (0.4–2.7)
   Ages ≥65 101 0.3 (0.1–0.5) 24.5 (21.6–27.5) 241 385 (11 010–970 152) 110 547 (38 953–245 152) 25 084 (1042–129 905) 36 381 (1480–187 636) 413 397 (67 327–1 465 240) 2398 (109–9638) 1098 (387–2435) 249 (10–1291) 361 (15–1864) 4107 (669–14 556) 1.0 (0.1–3.7) 4.5 (1.7–9.0) 0.3 (0.0–1.1) 0.7 (0.1–2.7) 1.1 (0.3–2.7)
   Women overall 680 0.5 (0.2–0.9) 25.2 (23.1–27.3) 337 588 (23 529–1 451 472) 312 357 (114 002–662 937) 43 719 (3248–229183) 69 015 (4542–362 376) 762 680 (178 337–2 563 042) 437 (30–1880) 405 (148–859) 57 (4–297) 89 (6–469) 988 (231–3320) 1.5 (0.3–4.9) 4.8 (1.8–9.5) 0.2 (0.0–0.8) 0.4 (0.1–1.8) 1.0 (0.3–2.3)
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Table 4. Continued
Population Characteristics Number of DALYs Attributable to SSBs (95% UI) DALYs per Million Adults Attributable to SSBs (95% UI) Percentage of DALYs Attributable to SSBs (95% UI)
Population
Mean  
SSB Intake 
(Servings/d)
Mean  
BMI (kg/m2) CVD‡ Diabetes Mellitus§ Cancersβ Musculoskeletal¶ Total† CVD‡ Diabetes Mellitus§ Cancersβ Musculoskeletal¶ Total† CVD‡
Diabetes 
Mellitus§ Cancersβ Musculoskeletal¶ Total†
  Men
   Ages 20–44 352 0.9 (0.4–1.4) 24.1 (22.8–25.5) 88 199 (12 895–393 677) 76 211 (29 010–154 587) 4449 (494–19 905) 3536 (432–13 127) 172 396 (53 231–528 216) 196 (29–875) 169 (64–343) 10 (1–44) 8 (1–29) 383 (118–1173) 2.4 (0.6–6.7) 5.8 (2.0–11.8) 0.1 (0.0–0.4) 0.1 (0.0–0.5) 0.6 (0.2–1.4)
   Ages 45–64 243 0.5 (0.2–0.7) 25.2 (23.7–26.7) 153 823 (16 420–557 260) 145  043 (54 636–293 663) 13 398 (1697–40 947) 16 893 (1570–60 715) 329 156 (89 301–871 090) 632 (67–2290) 596 (225–1207) 55 (7–168) 69 (6–250) 1353 (367–3580) 1.4 (0.3–4.3) 5.6 (2.0–11.0) 0.2 (0.0–0.6) 0.5 (0.1–1.7) 1.1 (0.4–2.5)
   Ages ≥65 84.6 0.3 (0.2–0.5) 23.9 (22.0–25.8) 236 311 (16 201–1 229 854) 85 066 (32 508–176 977) 27 019 (1619–215 283) 16 121 (942–102 011) 364 516 (61 902–1 706 625) 2795 (192–14 544) 1006 (384–2093) 320 (19–2546) 191 (11–1206) 4311 (732–20 182) 1.2 (0.1–3.6) 4.1 (1.5–8.2) 0.2 (0.0–0.8) 0.6 (0.0–2.1) 1.0 (0.3–2.3)
   Men overall 680 0.6 (0.3–0.9) 24.3 (22.7–25.9) 478 333 (45 516–2 180 791) 306 319 (116 153–625 226) 44 866 (3810–276 135) 36 550 (2944–175 853) 866 068 (204 434–3 105 931) 615 (59–2803) 394 (149–804) 58 (5–355) 47 (4–226) 1113 (263–3992) 1.7 (0.3–4.9) 5.2 (1.8–10.3) 0.2 (0.0–0.6) 0.4 (0.0–1.4) 0.9 (0.3–2.1)
  Both sexes overall 1360 0.6 (0.3–0.9) 24.8 (22.9–26.6) 815 921 (69 045–3 632 262) 618 677 (230 155–1 288 163) 88 585 (7058–505 318) 105 565 (7486–538 229) 1 628 748 (382 771–5 668 974) 526 (45–2343) 399 (148–831) 57 (5–326) 68 (5–347) 1051 (247–3657) 1.6 (0.3–4.9) 5.0 (1.8–9.9) 0.2 (0.0–0.7) 0.4 (0.0–1.6) 0.9 (0.3–2.2)
East/Central Eurasia
  Women
   Ages 20–44 60.4 0.4 (0.2–0.6) 24.3 (22.3–26.3) 6687 (2880–17 236) 17 253 (5092–43 821) 751 (302–2019) 757 (263–1784) 25 448 (11 085–57 788) 86 (37–222) 223 (66–566) 10 (4–26) 10 (3–23) 328 (143–746) 1.1 (0.4–5.0) 1.9 (0.6–4.3) 0.1 (0.0–0.4) 0.1 (0.0–0.1) 0.2 (0.1–0.5)
   Ages 45–64 55.5 0.2 (0.1–0.3) 28.0 (25.6–30.4) 16 929 (8580–29 657) 33 426 (10 337–85 735) 2790 (1355–5077) 3815 (1350–8390) 56 960 (28 529–112 668) 305 (155–535) 603 (186–1546) 50 (24–92) 69 (24–151) 1027 (514–2032) 0.3 (0.2–0.6) 2.5 (0.9–5.1) 0.1 (0.0–0.1) 0.1 (0.0–0.3) 0.3 (0.1–0.5)
   Ages ≥65 32.5 0.1 (0.1–0.2) 27.6 (24.0–31.1) 39 042 (1 4017–166 425) 29 247 (9463–70 097) 2253 (856–7102) 2656 (679–11 622) 73 197 (32 657–237 016) 1201 (431–5119) 900 (291–2156) 69 (26–218) 82 (21–358) 2252 (1005–7291) 0.3 (0.1–1.6) 2.3 (0.9–4.6) 0.1 (0.0–0.7) 0.2 (0.0–1.1) 0.3 (0.1–1.2)
   Women overall 148 0.2 (0.1–0.4) 26.5 (23.8–29.2) 62 658 (25 477–213 318) 79 926 (24 893–199 653) 5793 (2513–14 197) 7228 (2292–21 797) 155 605 (72 271–407 471) 379 (154–1289) 483 (150–1207) 35 (15–86) 44 (14–132) 941 (437–2463) 0.6 (0.2–2.4) 2.2 (0.8–4.7) 0.1 (0.0–0.4) 0.1 (0.0–0.5) 0.3 (0.1–0.8)
  Men
   Ages 20–44 59.7 0.4 (0.2–0.6) 25.3 (23.5–27.0) 25 573 (12 021–50 703) 20 702 (6121–51 122) 566 (213–1371) 490 (169–1192) 47 331 (24 300–87 712) 331 (156–656) 268 (79–662) 7 (3–18) 6 (2–15) 613 (315–1136) 1.0 (0.5–2.6) 4.3 (1.5–8.8) 0.1 (0.0–0.2) 0.0 (0.0–0.1) 0.2 (0.1–0.5)
   Ages 45–64 47.3 0.2 (0.1–0.3) 27.2 (25.3–29.2) 51 698 (25 795–102 375) 32 181 (9826–78 698) 3025 (1308–6353) 2208 (756–5400) 89 113 (48 274–164 867) 1093 (545–2164) 680 (208–1663) 64 (28–134) 47 (16–114) 1884 (1020–3485) 0.4 (0.2–1.2) 2.7 (1.0–5.6) 0.1 (0.0–0.2) 0.1 (0.0–0.4) 0.3 (0.1–0.6)
   Ages ≥65 17.6 0.1 (0.1–0.2) 26.4 (24.0–28.8) 30 889 (12 279–110 774) 16 525 (5222–38 531) 1701 (673–4952) 847 (232–3141) 49 962 (23 995–144 178) 1755 (698–6295) 939 (297–2189) 97 (38–281) 48 (13–178) 2839 (1363–8193) 0.3 (0.1–1.3) 1.8 (0.7–3.7) 0.1 (0.0–0.4) 0.1 (0.0–0.6) 0.2 (0.1–1.0)
   Men overall 125 0.3 (0.1–0.4) 26.2 (24.2–28.2) 108 161 (50 095–263 852) 69 409 (21 169–168 352) 5293 (2194–12 675) 3545 (1158–9734) 186 407 (96 568–396 757) 761 (352–1856) 488 (149–1184) 37 (15–89) 25 (8–68) 1311 (679–2791) 0.6 (0.3–1.7) 2.9 (1.1–6.0) 0.1 (0.0–0.3) 0.1 (0.0–0.4) 0.2 (0.1–0.7)
  Both sexes overall 273 0.2 (0.1–0.4) 26.3 (24.0–28.7) 170  819 (75 572–477 170) 149 335 (46 062–368 005) 11 086 (4708–26 872) 10 773 (3449–31 530) 342 012 (168 839–804 228) 555 (246–1551) 485 (150–1196) 36 (15–87) 35 (11–103) 1112 (549–2615) 0.6 (0.2–2.0) 2.6 (0.9–5.4) 0.1 (0.0–0.3) 0.1 (0.0–0.4) 0.2 (0.1–0.7)
Latin America and Caribbean
  Women
   Ages 20–44 88.1 1.7 (0.7–2.7) 26.4 (24.5–28.3) 20 231 (11 217–34 984) 98 436 (41 292–182 108) 2985 (1449–6155) 3673 (1510–7479) 125 324 (65 460–212 885) 177 (98–307) 864 (362–1598) 26 (13–54) 32 (13–66) 1099 (574–1868) 4.5 (2.4–8.1) 7.3 (2.9–14.2) 0.5 (0.2–1.1) 0.3 (0.1–0.6) 0.9 (0.4–1.6)
   Ages 45–64 54.2 0.8 (0.3–1.4) 28.9 (26.7–31.1) 30 068 (17 678–51 607) 206 008 (87 896–382 255) 6269 (3230–11 478) 12 640 (5174–26 028) 254 985 (132 029–440 829) 554 (326–952) 3799 (1621–7049) 116 (60–212) 233 (95–480) 4702 (2435–8129) 2.0 (1.1–3.4) 10.3 (4.3–19.2) 0.4 (0.2–0.7) 0.7 (0.3–1.6) 1.8 (0.9–3.2)
   Ages ≥65 22.7 0.6 (0.3–1.0) 26.8 (23.8–29.9) 29 093 (15 669–59 087) 164 436 (69 037–306 255) 3771 (1731–8177) 4931 (1875–11 862) 202 232 (100 088–362 843) 1281 (690–2602) 7243 (3041–13489) 166 (76–360) 217 (83–522) 8907 (4408–15 981) 1.1 (0.5–2.7) 9.5 (3.9–17.7) 0.3 (0.1–0.9) 0.6 (0.2–1.9) 1.8 (0.9–3.5)
   Women overall 165 1.1 (0.4–1.7) 27.2 (24.8–29.6) 79 392 (44 564–145 678) 468 879 (198 225–870 618) 13 025 (6411–25 810) 21 244 (8559–45 369) 582 542 (297 578–1 016 557) 416 (233–763) 2456 (1038–4560) 68 (34–135) 111 (45–238) 3051 (1559–5324) 2.5 (1.3–4.7) 9.0 (3.7–17.0) 0.4 (0.2–0.9) 0.6 (0.2–1.4) 1.5 (0.7–2.8)
  Men
   Ages 20–44 85.6 1.8 (0.7–2.9) 25.2 (23.6–26.8) 35 314 (20 390–58 766) 121 160 (51 509–224 711) 1606 (755–3095) 2294 (926–4807) 160  374 (86 326–268 070) 316 (183–527) 1086 (462–2013) 14 (7–28) 21 (8–43) 1437 (773–2402) 5.2 (2.7–9.7) 12.4 (5.0–23.2) 0.3 (0.1–0.7) 0.2 (0.1–0.6) 0.8 (0.4–1.5)
   Ages 45–64 50.3 0.9 (0.3–1.5) 26.6 (24.8–28.4) 53 094 (32 118–89 724) 233 094 (98 549–432 220) 4061 (2139–7159) 7829 (3174–16 611) 298 078 (157 064–507 815) 1056 (639–1784) 4634 (1959–8593) 81 (43–142) 156 (63–330) 5926 (3123–10 096) 2.2 (1.2–4.0) 10.6 (4.5–19.8) 0.2 (0.1–0.5) 0.7 (0.2–1.6) 1.6 (0.8–2.8)
   Ages ≥65 17.9 0.7 (0.3–1.1) 25.2 (23.1–27.4) 33 828 (19 127–69 167) 142 331 (58 743–264 426) 2597 (1333–5295) 2691 (1008–6728) 181 446 (91 832–323 350) 1889 (1068–3863) 7950 (3281–14 770) 145 (74–296) 150 (56–376) 10 135 (5129–18 061) 1.2 (0.6–3.3) 8.2 (3.4–15.6) 0.2 (0.1–0.5) 0.6 (0.2–2.0) 1.5 (0.7–3.0)
   Men overall 154 1.2 (0.4–1.9) 25.6 (23.7–27.4) 122 237 (71 635–217 657) 496 584 (208 800–921 357) 8264 (4227–15 549) 12 814 (5108–28 146) 639 899 (335 222–1 099 235) 680 (398–1210) 2762 (1161–5124) 46 (24–86) 71 (28–157) 3559 (1864–6113) 2.9 (1.5–5.7) 10.4 (4.3–19.5) 0.2 (0.1–0.6) 0.5 (0.2–1.4) 1.3 (0.7–2.4)
  Both sexes overall 319 1.1 (0.4–1.8) 26.4 (24.2–28.5) 201 629 (116 199–363 336) 965 464 (407 026–1 791 975) 21 289 (10 638–41 358) 34 058 (13 667–73 516) 1 222 440 (632 800–2 115 792) 544 (313–980) 2604 (1098–4834) 57 (29–112) 92 (37–198) 3297 (1707–5707) 2.7 (1.4–5.2) 9.7 (4.0–18.3) 0.3 (0.1–0.7) 0.5 (0.2–1.4) 1.4 (0.7–2.6)
North Africa and Middle East
  Women
   Ages 20–44 66.1 0.6 (0.2–1.1) 27.0 (25.7–28.3) 12 731 (6052–25 713) 37 908 (13 277–83 700) 982 (461–1989) 1246 (498–2593) 52 867 (25 377–102 851) 145 (69–292) 431 (151–951) 11 (5–23) 14 (6–29) 601 (288–1169) 1.4 (0.7–2.7) 4.2 (1.6–8.4) 0.2 (0.1–0.3) 0.1 (0.0–0.2) 0.5 (0.2–1.0)
   Ages 45–64 32.8 0.3 (0.1–0.6) 30.5 (28.8–32.1) 12 492 (6428–21 695) 50 952 (18 414–110 019) 1110 (566–1990) 3770 (1480–7759) 68 325 (33 214–129 147) 381 (196–661) 1553 (561–3353) 34 (17–61) 115 (45–236) 2082 (1012–3936) 0.6 (0.3–1.0) 5.3 (2.0–10.5) 0.1 (0.1–0.2) 0.2 (0.1–0.5) 0.9 (0.4–1.6)
   Ages ≥65 11.2 0.3 (0.1–0.4) 28.3 (25.8–30.8) 9885 (4252–26 282) 34 536 (12 924–72 621) 416 (182–1059) 1249 (407–3710) 46 086 (21 681–96 060) 886 (381–2356) 3096 (1158–6509) 37 (16–95) 112 (36–333) 4131 (1943–8610) 0.3 (0.2–0.9) 4.3 (1.7–8.7) 0.1 (0.0–0.3) 0.2 (0.1–0.7) 0.8 (0.3–1.6)
   Women overall 110 0.4 (0.1–0.7) 28.4 (26.5–30.2) 35 108 (16 732–73 690) 123 397 (44 615–266 339) 2508 (1210–5039) 6265 (2385–14 062) 167 278 (80 272–328 058) 266 (127–558) 935 (338–2018) 19 (9–38) 47 (18–107) 1268 (608–2486) 0.8 (0.4–1.6) 4.6 (1.7–9.2) 0.1 (0.1–0.3) 0.2 (0.1–0.5) 0.7 (0.3–1.4)
  Men
   Ages 20–44 71.6 0.7 (0.2–1.1) 26.1 (24.9–27.2) 22 944 (11 640–43 242) 49 709 (17 626–106  374) 504 (214–1049) 891 (349–1901) 74 048 (36 978–137 613) 243 (123–457) 525 (186–1125) 5 (2–11) 9 (4–20) 783 (391–1455) 1.5 (0.8–2.8) 7.3 (2.8–14.6) 0.1 (0.0–0.2) 0.1 (0.0–0.2) 0.6 (0.3–1.2)
   Ages 45–64 33.5 0.3 (0.1–0.6) 27.8 (26.5–29.1) 21 313 (11 343–35 722) 53 721 (19 533–112 453) 594 (276–1075) 2525 (978–5327) 78 153 (39 911–140 341) 635 (338–1065) 1602 (582–3353) 18 (8–32) 75 (29–159) 2330 (1190–4184) 0.7 (0.4–1.1) 5.0 (1.9–10.0) 0.1 (0.0–0.1) 0.2 (0.1–0.4) 0.8 (0.4–1.5)
   Ages ≥65 9.67 0.3 (0.1–0.4) 26.4 (24.7–28.1) 10 576 (5113–28 404) 29 478 (10 930–60 885) 297 (133–788) 671 (228–2155) 41 022 (20 093–84 738) 1094 (529–2937) 3048 (1130–6296) 31 (14–82) 69 (24–223) 4242 (2078–8762) 0.4 (0.2–1.0) 3.8 (1.5–7.6) 0.0 (0.0–0.1) 0.2 (0.0–0.6) 0.7 (0.3–1.5)
   Men overall 115 0.4 (0.2–0.7) 26.6 (25.2–28.0) 54 833 (28 096–107 367) 132 907 (48 089–279 713) 1395 (623–2912) 4088 (1555–9383) 193 223 (96 982–362 692) 398 (204–779) 964 (349–2030) 10 (5–21) 30 (11–68) 1402 (704–2632) 0.8 (0.4–1.6) 5.4 (2.1–10.7) 0.1 (0.0–0.1) 0.1 (0.0–0.4) 0.7 (0.3–1.4)
  Both sexes overall 225 0.4 (0.2–0.7) 27.5 (25.9–29.1) 89 942 (44 828–181 058) 256 304 (92 704–546 052) 3903 (1833–7951) 10352 (3940–23 445) 360 500 (177 254–690 750) 333 (166–671) 950 (344–2024) 14 (7–29) 38 (15–87) 1336 (657–2561) 0.8 (0.4–1.6) 5.0 (1.9–10.0) 0.1 (0.0–0.2) 0.2 (0.1–0.4) 0.7 (0.3–1.4)
South Asia
  Women
   Ages 20–44 224 0.3 (0.1–0.5) 21.6 (20.1–23.2) 161 612 (13 397–421 698) 63 895 (19 728–142 776) 16 834 (1267–57 540) 13 509 (702–40 691) 255 850 (53 752–579 714) 543 (45–1418) 215 (66–480) 57 (4–193) 45 (2–137) 860 (181–1949) 4.5 (0.4–11.8) 1.7 (0.5–3.9) 0.5 (0.0–1.6) 0.3 (0.0–0.9) 0.4 (0.1–1.1)
   Ages 45–64 122 0.2 (0.0–0.3) 22.1 (20.3–24.0) 331 469 (14 304–891 167) 106 165 (34 086–226 102) 50 720 (2242–156 917) 63 622 (2267–191 320) 551 976 (69 830–1 304 908) 2727 (118–7333) 874 (280–1860) 417 (18–1291) 523 (19–1574) 4542 (575–10 737) 3.4 (0.2–9.6) 2.4 (0.8–5.1) 0.6 (0.0–2.2) 1.1 (0.0–3.7) 0.9 (0.1–2.5)
   Ages ≥65 40.1 0.1 (0.0–0.2) 20.6 (18.0–23.2) 332 328 (46 536–653 573) 74 360 (28 880–152 361) 25 555 (2584–58 894) 29 896 (3312–68 673) 462 139 (102 995–849 463) 8292 (1161–16 307) 1855 (721–3801) 638 (64–1469) 746 (83–1713) 11 531 (2570–21 194) 2.3 (0.2–6.3) 2.2 (0.8–4.5) 0.8 (0.1–2.6) 1.1 (0.1–3.6) 0.9 (0.2–2.4)
   Women overall 385 0.2 (0.1–0.3) 21.4 (19.3–23.4) 825 409 (74 237–1 966 438) 244 420 (82 694–521 238) 93 109 (6093–273 351) 107 028 (6282–300  684) 1 269 965 (226 577–2 734 084) 1798 (162–4284) 532 (180–1135) 203 (13–595) 233 (14–655) 2766 (494–5956) 3.4 (0.2–9.2) 2.1 (0.7–4.5) 0.6 (0.0–2.1) 0.8 (0.0–2.8) 0.8 (0.1–2.0)
  Men
   Ages 20–44 238 0.4 (0.1–0.6) 21.2 (19.6–22.7) 361 696 (33 983–832 009) 82 398 (26 816–183 165) 12 771 (1034–35 964) 9673 (552–26 553) 466 539 (92 219–972 543) 1141 (107–2624) 260 (85–578) 40 (3–113) 31 (2–84) 1471 (291–3067) 4.9 (0.5–12.9) 2.9 (0.9–6.3) 0.4 (0.0–1.2) 0.2 (0.0–0.7) 0.5 (0.1–1.1)
   Ages 45–64 126 0.2 (0.0–0.3) 21.6 (19.8–23.5) 807 618 (41 130–1 640 736) 140 143 (48 397–292 875) 63 770 (2954–145 853) 47 102 (1996–118 867) 1 058 632 (123 445–2 015 267) 6409 (326–13 021) 1112 (384–2324) 506 (23–1157) 374 (16–943) 8401 (980–15 993) 3.5 (0.2–10.0) 2.7 (0.9–5.5) 0.5 (0.0–1.7) 0.8 (0.0–2.8) 1.0 (0.1–2.5)
(Continued )
D
ow
nloaded from
 http://ahajournals.org by on September 15, 2020
Singh et al  Global SSB-Related Morbidity and Mortality  659
Table 4. Continued
Population Characteristics Number of DALYs Attributable to SSBs (95% UI) DALYs per Million Adults Attributable to SSBs (95% UI) Percentage of DALYs Attributable to SSBs (95% UI)
Population
Mean  
SSB Intake 
(Servings/d)
Mean  
BMI (kg/m2) CVD‡ Diabetes Mellitus§ Cancersβ Musculoskeletal¶ Total† CVD‡ Diabetes Mellitus§ Cancersβ Musculoskeletal¶ Total† CVD‡
Diabetes 
Mellitus§ Cancersβ Musculoskeletal¶ Total†
  Men
   Ages 20–44 352 0.9 (0.4–1.4) 24.1 (22.8–25.5) 88 199 (12 895–393 677) 76 211 (29 010–154 587) 4449 (494–19 905) 3536 (432–13 127) 172 396 (53 231–528 216) 196 (29–875) 169 (64–343) 10 (1–44) 8 (1–29) 383 (118–1173) 2.4 (0.6–6.7) 5.8 (2.0–11.8) 0.1 (0.0–0.4) 0.1 (0.0–0.5) 0.6 (0.2–1.4)
   Ages 45–64 243 0.5 (0.2–0.7) 25.2 (23.7–26.7) 153 823 (16 420–557 260) 145  043 (54 636–293 663) 13 398 (1697–40 947) 16 893 (1570–60 715) 329 156 (89 301–871 090) 632 (67–2290) 596 (225–1207) 55 (7–168) 69 (6–250) 1353 (367–3580) 1.4 (0.3–4.3) 5.6 (2.0–11.0) 0.2 (0.0–0.6) 0.5 (0.1–1.7) 1.1 (0.4–2.5)
   Ages ≥65 84.6 0.3 (0.2–0.5) 23.9 (22.0–25.8) 236 311 (16 201–1 229 854) 85 066 (32 508–176 977) 27 019 (1619–215 283) 16 121 (942–102 011) 364 516 (61 902–1 706 625) 2795 (192–14 544) 1006 (384–2093) 320 (19–2546) 191 (11–1206) 4311 (732–20 182) 1.2 (0.1–3.6) 4.1 (1.5–8.2) 0.2 (0.0–0.8) 0.6 (0.0–2.1) 1.0 (0.3–2.3)
   Men overall 680 0.6 (0.3–0.9) 24.3 (22.7–25.9) 478 333 (45 516–2 180 791) 306 319 (116 153–625 226) 44 866 (3810–276 135) 36 550 (2944–175 853) 866 068 (204 434–3 105 931) 615 (59–2803) 394 (149–804) 58 (5–355) 47 (4–226) 1113 (263–3992) 1.7 (0.3–4.9) 5.2 (1.8–10.3) 0.2 (0.0–0.6) 0.4 (0.0–1.4) 0.9 (0.3–2.1)
  Both sexes overall 1360 0.6 (0.3–0.9) 24.8 (22.9–26.6) 815 921 (69 045–3 632 262) 618 677 (230 155–1 288 163) 88 585 (7058–505 318) 105 565 (7486–538 229) 1 628 748 (382 771–5 668 974) 526 (45–2343) 399 (148–831) 57 (5–326) 68 (5–347) 1051 (247–3657) 1.6 (0.3–4.9) 5.0 (1.8–9.9) 0.2 (0.0–0.7) 0.4 (0.0–1.6) 0.9 (0.3–2.2)
East/Central Eurasia
  Women
   Ages 20–44 60.4 0.4 (0.2–0.6) 24.3 (22.3–26.3) 6687 (2880–17 236) 17 253 (5092–43 821) 751 (302–2019) 757 (263–1784) 25 448 (11 085–57 788) 86 (37–222) 223 (66–566) 10 (4–26) 10 (3–23) 328 (143–746) 1.1 (0.4–5.0) 1.9 (0.6–4.3) 0.1 (0.0–0.4) 0.1 (0.0–0.1) 0.2 (0.1–0.5)
   Ages 45–64 55.5 0.2 (0.1–0.3) 28.0 (25.6–30.4) 16 929 (8580–29 657) 33 426 (10 337–85 735) 2790 (1355–5077) 3815 (1350–8390) 56 960 (28 529–112 668) 305 (155–535) 603 (186–1546) 50 (24–92) 69 (24–151) 1027 (514–2032) 0.3 (0.2–0.6) 2.5 (0.9–5.1) 0.1 (0.0–0.1) 0.1 (0.0–0.3) 0.3 (0.1–0.5)
   Ages ≥65 32.5 0.1 (0.1–0.2) 27.6 (24.0–31.1) 39 042 (1 4017–166 425) 29 247 (9463–70 097) 2253 (856–7102) 2656 (679–11 622) 73 197 (32 657–237 016) 1201 (431–5119) 900 (291–2156) 69 (26–218) 82 (21–358) 2252 (1005–7291) 0.3 (0.1–1.6) 2.3 (0.9–4.6) 0.1 (0.0–0.7) 0.2 (0.0–1.1) 0.3 (0.1–1.2)
   Women overall 148 0.2 (0.1–0.4) 26.5 (23.8–29.2) 62 658 (25 477–213 318) 79 926 (24 893–199 653) 5793 (2513–14 197) 7228 (2292–21 797) 155 605 (72 271–407 471) 379 (154–1289) 483 (150–1207) 35 (15–86) 44 (14–132) 941 (437–2463) 0.6 (0.2–2.4) 2.2 (0.8–4.7) 0.1 (0.0–0.4) 0.1 (0.0–0.5) 0.3 (0.1–0.8)
  Men
   Ages 20–44 59.7 0.4 (0.2–0.6) 25.3 (23.5–27.0) 25 573 (12 021–50 703) 20 702 (6121–51 122) 566 (213–1371) 490 (169–1192) 47 331 (24 300–87 712) 331 (156–656) 268 (79–662) 7 (3–18) 6 (2–15) 613 (315–1136) 1.0 (0.5–2.6) 4.3 (1.5–8.8) 0.1 (0.0–0.2) 0.0 (0.0–0.1) 0.2 (0.1–0.5)
   Ages 45–64 47.3 0.2 (0.1–0.3) 27.2 (25.3–29.2) 51 698 (25 795–102 375) 32 181 (9826–78 698) 3025 (1308–6353) 2208 (756–5400) 89 113 (48 274–164 867) 1093 (545–2164) 680 (208–1663) 64 (28–134) 47 (16–114) 1884 (1020–3485) 0.4 (0.2–1.2) 2.7 (1.0–5.6) 0.1 (0.0–0.2) 0.1 (0.0–0.4) 0.3 (0.1–0.6)
   Ages ≥65 17.6 0.1 (0.1–0.2) 26.4 (24.0–28.8) 30 889 (12 279–110 774) 16 525 (5222–38 531) 1701 (673–4952) 847 (232–3141) 49 962 (23 995–144 178) 1755 (698–6295) 939 (297–2189) 97 (38–281) 48 (13–178) 2839 (1363–8193) 0.3 (0.1–1.3) 1.8 (0.7–3.7) 0.1 (0.0–0.4) 0.1 (0.0–0.6) 0.2 (0.1–1.0)
   Men overall 125 0.3 (0.1–0.4) 26.2 (24.2–28.2) 108 161 (50 095–263 852) 69 409 (21 169–168 352) 5293 (2194–12 675) 3545 (1158–9734) 186 407 (96 568–396 757) 761 (352–1856) 488 (149–1184) 37 (15–89) 25 (8–68) 1311 (679–2791) 0.6 (0.3–1.7) 2.9 (1.1–6.0) 0.1 (0.0–0.3) 0.1 (0.0–0.4) 0.2 (0.1–0.7)
  Both sexes overall 273 0.2 (0.1–0.4) 26.3 (24.0–28.7) 170  819 (75 572–477 170) 149 335 (46 062–368 005) 11 086 (4708–26 872) 10 773 (3449–31 530) 342 012 (168 839–804 228) 555 (246–1551) 485 (150–1196) 36 (15–87) 35 (11–103) 1112 (549–2615) 0.6 (0.2–2.0) 2.6 (0.9–5.4) 0.1 (0.0–0.3) 0.1 (0.0–0.4) 0.2 (0.1–0.7)
Latin America and Caribbean
  Women
   Ages 20–44 88.1 1.7 (0.7–2.7) 26.4 (24.5–28.3) 20 231 (11 217–34 984) 98 436 (41 292–182 108) 2985 (1449–6155) 3673 (1510–7479) 125 324 (65 460–212 885) 177 (98–307) 864 (362–1598) 26 (13–54) 32 (13–66) 1099 (574–1868) 4.5 (2.4–8.1) 7.3 (2.9–14.2) 0.5 (0.2–1.1) 0.3 (0.1–0.6) 0.9 (0.4–1.6)
   Ages 45–64 54.2 0.8 (0.3–1.4) 28.9 (26.7–31.1) 30 068 (17 678–51 607) 206 008 (87 896–382 255) 6269 (3230–11 478) 12 640 (5174–26 028) 254 985 (132 029–440 829) 554 (326–952) 3799 (1621–7049) 116 (60–212) 233 (95–480) 4702 (2435–8129) 2.0 (1.1–3.4) 10.3 (4.3–19.2) 0.4 (0.2–0.7) 0.7 (0.3–1.6) 1.8 (0.9–3.2)
   Ages ≥65 22.7 0.6 (0.3–1.0) 26.8 (23.8–29.9) 29 093 (15 669–59 087) 164 436 (69 037–306 255) 3771 (1731–8177) 4931 (1875–11 862) 202 232 (100 088–362 843) 1281 (690–2602) 7243 (3041–13489) 166 (76–360) 217 (83–522) 8907 (4408–15 981) 1.1 (0.5–2.7) 9.5 (3.9–17.7) 0.3 (0.1–0.9) 0.6 (0.2–1.9) 1.8 (0.9–3.5)
   Women overall 165 1.1 (0.4–1.7) 27.2 (24.8–29.6) 79 392 (44 564–145 678) 468 879 (198 225–870 618) 13 025 (6411–25 810) 21 244 (8559–45 369) 582 542 (297 578–1 016 557) 416 (233–763) 2456 (1038–4560) 68 (34–135) 111 (45–238) 3051 (1559–5324) 2.5 (1.3–4.7) 9.0 (3.7–17.0) 0.4 (0.2–0.9) 0.6 (0.2–1.4) 1.5 (0.7–2.8)
  Men
   Ages 20–44 85.6 1.8 (0.7–2.9) 25.2 (23.6–26.8) 35 314 (20 390–58 766) 121 160 (51 509–224 711) 1606 (755–3095) 2294 (926–4807) 160  374 (86 326–268 070) 316 (183–527) 1086 (462–2013) 14 (7–28) 21 (8–43) 1437 (773–2402) 5.2 (2.7–9.7) 12.4 (5.0–23.2) 0.3 (0.1–0.7) 0.2 (0.1–0.6) 0.8 (0.4–1.5)
   Ages 45–64 50.3 0.9 (0.3–1.5) 26.6 (24.8–28.4) 53 094 (32 118–89 724) 233 094 (98 549–432 220) 4061 (2139–7159) 7829 (3174–16 611) 298 078 (157 064–507 815) 1056 (639–1784) 4634 (1959–8593) 81 (43–142) 156 (63–330) 5926 (3123–10 096) 2.2 (1.2–4.0) 10.6 (4.5–19.8) 0.2 (0.1–0.5) 0.7 (0.2–1.6) 1.6 (0.8–2.8)
   Ages ≥65 17.9 0.7 (0.3–1.1) 25.2 (23.1–27.4) 33 828 (19 127–69 167) 142 331 (58 743–264 426) 2597 (1333–5295) 2691 (1008–6728) 181 446 (91 832–323 350) 1889 (1068–3863) 7950 (3281–14 770) 145 (74–296) 150 (56–376) 10 135 (5129–18 061) 1.2 (0.6–3.3) 8.2 (3.4–15.6) 0.2 (0.1–0.5) 0.6 (0.2–2.0) 1.5 (0.7–3.0)
   Men overall 154 1.2 (0.4–1.9) 25.6 (23.7–27.4) 122 237 (71 635–217 657) 496 584 (208 800–921 357) 8264 (4227–15 549) 12 814 (5108–28 146) 639 899 (335 222–1 099 235) 680 (398–1210) 2762 (1161–5124) 46 (24–86) 71 (28–157) 3559 (1864–6113) 2.9 (1.5–5.7) 10.4 (4.3–19.5) 0.2 (0.1–0.6) 0.5 (0.2–1.4) 1.3 (0.7–2.4)
  Both sexes overall 319 1.1 (0.4–1.8) 26.4 (24.2–28.5) 201 629 (116 199–363 336) 965 464 (407 026–1 791 975) 21 289 (10 638–41 358) 34 058 (13 667–73 516) 1 222 440 (632 800–2 115 792) 544 (313–980) 2604 (1098–4834) 57 (29–112) 92 (37–198) 3297 (1707–5707) 2.7 (1.4–5.2) 9.7 (4.0–18.3) 0.3 (0.1–0.7) 0.5 (0.2–1.4) 1.4 (0.7–2.6)
North Africa and Middle East
  Women
   Ages 20–44 66.1 0.6 (0.2–1.1) 27.0 (25.7–28.3) 12 731 (6052–25 713) 37 908 (13 277–83 700) 982 (461–1989) 1246 (498–2593) 52 867 (25 377–102 851) 145 (69–292) 431 (151–951) 11 (5–23) 14 (6–29) 601 (288–1169) 1.4 (0.7–2.7) 4.2 (1.6–8.4) 0.2 (0.1–0.3) 0.1 (0.0–0.2) 0.5 (0.2–1.0)
   Ages 45–64 32.8 0.3 (0.1–0.6) 30.5 (28.8–32.1) 12 492 (6428–21 695) 50 952 (18 414–110 019) 1110 (566–1990) 3770 (1480–7759) 68 325 (33 214–129 147) 381 (196–661) 1553 (561–3353) 34 (17–61) 115 (45–236) 2082 (1012–3936) 0.6 (0.3–1.0) 5.3 (2.0–10.5) 0.1 (0.1–0.2) 0.2 (0.1–0.5) 0.9 (0.4–1.6)
   Ages ≥65 11.2 0.3 (0.1–0.4) 28.3 (25.8–30.8) 9885 (4252–26 282) 34 536 (12 924–72 621) 416 (182–1059) 1249 (407–3710) 46 086 (21 681–96 060) 886 (381–2356) 3096 (1158–6509) 37 (16–95) 112 (36–333) 4131 (1943–8610) 0.3 (0.2–0.9) 4.3 (1.7–8.7) 0.1 (0.0–0.3) 0.2 (0.1–0.7) 0.8 (0.3–1.6)
   Women overall 110 0.4 (0.1–0.7) 28.4 (26.5–30.2) 35 108 (16 732–73 690) 123 397 (44 615–266 339) 2508 (1210–5039) 6265 (2385–14 062) 167 278 (80 272–328 058) 266 (127–558) 935 (338–2018) 19 (9–38) 47 (18–107) 1268 (608–2486) 0.8 (0.4–1.6) 4.6 (1.7–9.2) 0.1 (0.1–0.3) 0.2 (0.1–0.5) 0.7 (0.3–1.4)
  Men
   Ages 20–44 71.6 0.7 (0.2–1.1) 26.1 (24.9–27.2) 22 944 (11 640–43 242) 49 709 (17 626–106  374) 504 (214–1049) 891 (349–1901) 74 048 (36 978–137 613) 243 (123–457) 525 (186–1125) 5 (2–11) 9 (4–20) 783 (391–1455) 1.5 (0.8–2.8) 7.3 (2.8–14.6) 0.1 (0.0–0.2) 0.1 (0.0–0.2) 0.6 (0.3–1.2)
   Ages 45–64 33.5 0.3 (0.1–0.6) 27.8 (26.5–29.1) 21 313 (11 343–35 722) 53 721 (19 533–112 453) 594 (276–1075) 2525 (978–5327) 78 153 (39 911–140 341) 635 (338–1065) 1602 (582–3353) 18 (8–32) 75 (29–159) 2330 (1190–4184) 0.7 (0.4–1.1) 5.0 (1.9–10.0) 0.1 (0.0–0.1) 0.2 (0.1–0.4) 0.8 (0.4–1.5)
   Ages ≥65 9.67 0.3 (0.1–0.4) 26.4 (24.7–28.1) 10 576 (5113–28 404) 29 478 (10 930–60 885) 297 (133–788) 671 (228–2155) 41 022 (20 093–84 738) 1094 (529–2937) 3048 (1130–6296) 31 (14–82) 69 (24–223) 4242 (2078–8762) 0.4 (0.2–1.0) 3.8 (1.5–7.6) 0.0 (0.0–0.1) 0.2 (0.0–0.6) 0.7 (0.3–1.5)
   Men overall 115 0.4 (0.2–0.7) 26.6 (25.2–28.0) 54 833 (28 096–107 367) 132 907 (48 089–279 713) 1395 (623–2912) 4088 (1555–9383) 193 223 (96 982–362 692) 398 (204–779) 964 (349–2030) 10 (5–21) 30 (11–68) 1402 (704–2632) 0.8 (0.4–1.6) 5.4 (2.1–10.7) 0.1 (0.0–0.1) 0.1 (0.0–0.4) 0.7 (0.3–1.4)
  Both sexes overall 225 0.4 (0.2–0.7) 27.5 (25.9–29.1) 89 942 (44 828–181 058) 256 304 (92 704–546 052) 3903 (1833–7951) 10352 (3940–23 445) 360 500 (177 254–690 750) 333 (166–671) 950 (344–2024) 14 (7–29) 38 (15–87) 1336 (657–2561) 0.8 (0.4–1.6) 5.0 (1.9–10.0) 0.1 (0.0–0.2) 0.2 (0.1–0.4) 0.7 (0.3–1.4)
South Asia
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   Ages 20–44 224 0.3 (0.1–0.5) 21.6 (20.1–23.2) 161 612 (13 397–421 698) 63 895 (19 728–142 776) 16 834 (1267–57 540) 13 509 (702–40 691) 255 850 (53 752–579 714) 543 (45–1418) 215 (66–480) 57 (4–193) 45 (2–137) 860 (181–1949) 4.5 (0.4–11.8) 1.7 (0.5–3.9) 0.5 (0.0–1.6) 0.3 (0.0–0.9) 0.4 (0.1–1.1)
   Ages 45–64 122 0.2 (0.0–0.3) 22.1 (20.3–24.0) 331 469 (14 304–891 167) 106 165 (34 086–226 102) 50 720 (2242–156 917) 63 622 (2267–191 320) 551 976 (69 830–1 304 908) 2727 (118–7333) 874 (280–1860) 417 (18–1291) 523 (19–1574) 4542 (575–10 737) 3.4 (0.2–9.6) 2.4 (0.8–5.1) 0.6 (0.0–2.2) 1.1 (0.0–3.7) 0.9 (0.1–2.5)
   Ages ≥65 40.1 0.1 (0.0–0.2) 20.6 (18.0–23.2) 332 328 (46 536–653 573) 74 360 (28 880–152 361) 25 555 (2584–58 894) 29 896 (3312–68 673) 462 139 (102 995–849 463) 8292 (1161–16 307) 1855 (721–3801) 638 (64–1469) 746 (83–1713) 11 531 (2570–21 194) 2.3 (0.2–6.3) 2.2 (0.8–4.5) 0.8 (0.1–2.6) 1.1 (0.1–3.6) 0.9 (0.2–2.4)
   Women overall 385 0.2 (0.1–0.3) 21.4 (19.3–23.4) 825 409 (74 237–1 966 438) 244 420 (82 694–521 238) 93 109 (6093–273 351) 107 028 (6282–300  684) 1 269 965 (226 577–2 734 084) 1798 (162–4284) 532 (180–1135) 203 (13–595) 233 (14–655) 2766 (494–5956) 3.4 (0.2–9.2) 2.1 (0.7–4.5) 0.6 (0.0–2.1) 0.8 (0.0–2.8) 0.8 (0.1–2.0)
  Men
   Ages 20–44 238 0.4 (0.1–0.6) 21.2 (19.6–22.7) 361 696 (33 983–832 009) 82 398 (26 816–183 165) 12 771 (1034–35 964) 9673 (552–26 553) 466 539 (92 219–972 543) 1141 (107–2624) 260 (85–578) 40 (3–113) 31 (2–84) 1471 (291–3067) 4.9 (0.5–12.9) 2.9 (0.9–6.3) 0.4 (0.0–1.2) 0.2 (0.0–0.7) 0.5 (0.1–1.1)
   Ages 45–64 126 0.2 (0.0–0.3) 21.6 (19.8–23.5) 807 618 (41 130–1 640 736) 140 143 (48 397–292 875) 63 770 (2954–145 853) 47 102 (1996–118 867) 1 058 632 (123 445–2 015 267) 6409 (326–13 021) 1112 (384–2324) 506 (23–1157) 374 (16–943) 8401 (980–15 993) 3.5 (0.2–10.0) 2.7 (0.9–5.5) 0.5 (0.0–1.7) 0.8 (0.0–2.8) 1.0 (0.1–2.5)
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   Ages 45–64 54.8 0.3 (0.2–0.3) 28.2 (26.9–29.6) 12 886 (8760–17 955) 29 963 (12 733–55 416) 2728 (1571–4317) 1431 (643–2797) 47 008 (28 553–73 400) 235 (160–328) 547 (232–1011) 50 (29–79) 26 (12–51) 858 (521–1340) 0.5 (0.3–0.7) 3.0 (1.2–5.5) 0.1 (0.0–0.1) 0.1 (0.0–0.1) 0.3 (0.2–0.6)
   Ages ≥65 r 31.9 0.2 (0.1–0.3) 27.5 (25.9–29.1) 13 700 (9123–18 760) 32 147 (13 937–57 165) 2614 (1523–3930) 797 (350–1540) 49 259 (30 216–75 369) 429 (286–587) 1007 (436–1790) 82 (48–123) 25 (11–48) 1543 (946–2360) 0.2 (0.2–0.3) 2.1 (0.9–3.8) 0.0 (0.0–0.1) 0.0 (0.0–0.1) 0.3 (0.2–0.4)
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  Both sexes overall 301 0.4 (0.3–0.5) 26.7 (25.1–28.4) 52 712 (33 555–96 696) 142 050 (60 853–262 431) 11 622 (6767–20 743) 7118 (3074–14 960) 213 503 (125 841–364 758) 162 (103–296) 435 (187–805) 36 (21–64) 22 (9–46) 655 (386–1118) 0.8 (0.4–1.6) 3.0 (1.2–5.6) 0.1 (0.0–0.2) 0.0 (0.0–0.1) 0.3 (0.1–0.5)
Table 4. Continued
Population Characteristics Number of DALYs Attributable to SSBs (95% UI) DALYs per Million Adults Attributable to SSBs (95% UI) Percentage of DALYs Attributable to SSBs (95% UI)
Population
Mean  
SSB Intake 
(Servings/d)
Mean  
BMI (kg/m2) CVD‡ Diabetes Mellitus§ Cancersβ Musculoskeletal¶ Total† CVD‡ Diabetes Mellitus§ Cancersβ Musculoskeletal¶ Total† CVD‡
Diabetes 
Mellitus§ Cancersβ Musculoskeletal¶ Total†
Countries are grouped into regions as follows: Australia/New Zealand – Australia, New Zealand; East/Central Eurasia – Albania, Armenia, Azerbaijan, Bulgaria, Bosnia and 
Herzegovina, Belarus, Czech Republic, Estonia, Georgia, Croatia, Hungary, Kazakhstan, Kyrgyzstan, Lithuania, Latvia, Moldova, Macedonia, Montenegro, Mongolia, Poland, 
Romania, Russian Federation, Serbia, Slovakia, Slovenia, Tajikistan, Turkmenistan, Ukraine, Uzbekistan; East/Southeast Asia – Brunei Darussalam, China, Fiji, Micronesia, 
Indonesia, Japan, Cambodia, Kiribati, Republic of Korea, Lao People’s Democratic Republic, Sri Lanka, Maldives, Marshall Islands, Myanmar, Malaysia, Philippines, Papua 
New Guinea, Democratic People’s Republic of Korea, Singapore, Solomon Islands, Thailand, Timor-Leste, Tonga, Taiwan, Viet Nam, Vanuatu, Samoa; Latin America/Caribbean 
– Argentina, Antigua and Barbuda, Bahamas, Belize, Bolivia, Brazil, Barbados, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, Grenada, Guatemala, 
Guyana, Honduras, Haiti, Jamaica, Saint Lucia, Mexico, Nicaragua, Panama, Peru, Paraguay, El Salvador, Suriname, Trinidad and Tobago, Uruguay, Saint Vincent and the 
Grenadines, Venezuela; North Africa/Middle East – United Arab Emirates, Bahrain, Algeria, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libyan Arab Jamahiriya, Morocco, Oman, 
Occupied Palestinian Territory, Qatar, Saudi Arabia, Syrian Arab Republic, Tunisia, Turkey, Yemen; South Asia – Afghanistan, Bangladesh, Bhutan, India, Nepal, Pakistan; Sub-
Saharan Africa – Angola, Burundi, Benin, Burkina Faso, Botswana, Central African Republic, Côte d’Ivoire, Cameroon, Democratic Republic of the Congo, Congo, Comoros, 
Cape Verde, Djibouti, Eritrea, Ethiopia, Gabon, Ghana, Guinea, Gambia, Guinea-Bissau, Equatorial Guinea, Kenya, Liberia, Lesotho, Madagascar, Mali, Mozambique, Mauritania, 
Mauritius, Malawi, Namibia, Niger, Nigeria, Rwanda, Sudan, Senegal, Sierra Leone, Somalia, São Tomé and Príncipe, Swaziland, Seychelles, Chad, Togo, United Republic of 
Tanzania, Uganda, South Africa, Zambia, Zimbabwe; Western Europe – Andorra, Austria, Belgium, Switzerland, Cyprus, Germany, Denmark, Spain, Finland, France, United 
Kingdom, Greece, Ireland, Iceland, Israel, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Sweden. BMI indicates body mass index; CVD, cardiovascular disease; DALY, 
disability-adjusted life year; SSB, sugar-sweetened beverages; and UI, uncertainty interval.
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  Both sexes overall 786 0.2 (0.1–0.4) 21.2 (19.3–23.2) 2 396 880 (288 098–5 191 455) 541 380 (186 097–1 150 094) 193 494 (17 088–504 117) 179 382 (12 191–482 335) 3 311 136 (643 875–6 636 016) 2554 (307–5531) 577 (198–1225) 206 (18–537) 191 (13–514) 3528 (686–7070) 3.5 (0.3–9.5) 2.3 (0.8–4.9) 0.6 (0.0–1.8) 0.7 (0.0–2.4) 0.8 (0.1–2.0)
Sub-Saharan Africa
  Women
   Ages 20–44 102 0.7 (0.2–1.2) 23.4 (22.0–24.8) 37 029 (6917–111 725) 30 816 (10 209–70 855) 2912 (412–10 073) 3804 (485–13 033) 74 561 (23 857–182 806) 261 (49–789) 218 (72–500) 21 (3–71) 27 (3–92) 526 (168–1291) 2.5 (0.6–8.2) 1.9 (0.6–4.2) 0.2 (0.0–0.7) 0.2 (0.0–0.7) 0.2 (0.1–0.5)
   Ages 45–64 46 0.3 (0.1–0.6) 24.7 (22.9–26.5) 49 411 (5112–166 467) 42 357 (15 102–91 405) 7557 (614–28 181) 15 404 (1348–60 247) 114 729 (28 738–315 748) 1075 (111–3622) 922 (329–1989) 164 (13–613) 335 (29–1311) 2496 (625–6871) 1.4 (0.2–5.4) 2.7 (0.9–5.7) 0.2 (0.0–0.9) 0.6 (0.1–2.5) 0.5 (0.1–1.4)
   Ages ≥65 15.1 0.2 (0.1–0.4) 23.2 (20.0–26.4) 52 327 (3299–1902 99) 31 662 (10 880–68 345) 4481 (259–18 357) 7791 (365–33 591) 96 260 (18 857–288 885) 3466 (219–12 603) 2097 (721–4526) 297 (17–1216) 516 (24–2225) 6375 (1249–19 133) 1.4 (0.1–5.4) 2.6 (0.9–5.6) 0.4 (0.0–1.5) 0.8 (0.0–3.6) 0.7 (0.1–2.1)
   Women overall 163 0.4 (0.1–0.8) 23.6 (21.5–25.8) 138 767 (15 328–468 492) 104 835 (36 190–230 604) 14 950 (1285–56 611) 26 999 (2198–106 871) 285 550 (71 452–787 440) 685 (76–2312) 517 (179–1138) 74 (6–279) 133 (11–527) 1409 (353–3885) 1.8 (0.3–6.3) 2.4 (0.8–5.2) 0.3 (0.0–1.1) 0.5 (0.0–2.3) 0.5 (0.1–1.3)
  Men
   Ages 20–44 103 0.8 (0.2–1.3) 22.1 (20.4–23.7) 57 263 (9026–184 052) 35 051 (11 296–81 630) 3024 (329–12 305) 3166 (357–12 434) 98 504 (28 433–253 567) 400 (63–1286) 245 (79–570) 21 (2–86) 22 (2–87) 688 (199–1772) 3.7 (0.6–11.1) 3.3 (1.1–7.2) 0.3 (0.0–1.2) 0.2 (0.0–0.9) 0.3 (0.1–0.7)
   Ages 45–64 42.5 0.4 (0.1–0.6) 23.0 (21.1–24.8) 78 552 (7711–267 908) 46 511 (16 286–98 467) 8853 (711–34 537) 12 168 (937–49 004) 146 083 (32 801–409 279) 1849 (182–6307) 1095 (383–2318) 208 (17–813) 286 (22–1154) 3439 (772–9635) 2.1 (0.3–8.1) 3.1 (1.1–6.5) 0.4 (0.0–1.9) 0.8 (0.1–3.4) 0.6 (0.1–1.7)
   Ages ≥65 12.3 0.3 (0.1–0.5) 22.2 (19.9–24.6) 55 345 (3270–177 770) 24 201 (8211–51 487) 5327 (287–19 051) 5388 (223–21 842) 90 261 (15 464–248 934) 4495 (266–14 438) 1966 (667–4182) 433 (23–1547) 438 (18–1774) 7331 (1256–20 218) 1.8 (0.1–5.9) 2.3 (0.8–4.9) 0.5 (0.0–1.7) 0.9 (0.0–3.6) 0.7 (0.1–2.0)
   Men overall 158 0.5 (0.1–0.8) 22.4 (20.4–24.3) 191 160 (20 007–629 731) 105 762 (35 794–231 584) 17 203 (1327–65 893) 20 722 (1518–83 280) 334 848 (76 698–911 779) 966 (101–3182) 534 (181–1170) 87 (7–333) 105 (8–421) 1692 (388–4607) 2.6 (0.3–8.4) 2.9 (1.0–6.2) 0.4 (0.0–1.6) 0.6 (0.0–2.6) 0.5 (0.1–1.4)
  Both sexes overall 320 0.5 (0.1–0.8) 23.0 (20.9–25.1) 329 927 (35 336–1 098 222) 210 597 (71 984–462 188) 32 153 (2612–122 505) 47 721 (3715–190 151) 620 398 (148 150–1 699 219) 824 (88–2742) 526 (180–1154) 80 (7–306) 119 (9–475) 1549 (370–4242) 2.2 (0.3–7.3) 2.6 (0.9–5.7) 0.3 (0.0–1.3) 0.6 (0.0–2.5) 0.5 (0.1–1.4)
Western Europe
  Women
   Ages 20–44 57.2 0.6 (0.4–0.7) 24.2 (22.6–25.7) 2785 (1408–7532) 10 643 (4376–20 716) 678 (372–1547) 512 (221–1096) 14 618 (7626–28 381) 40 (20–108) 153 (63–298) 10 (5–22) 7 (3–16) 210 (110–408) 1.7 (0.8–5.0) 2.1 (0.8–4.2) 0.1 (0.1–0.4) 0.0 (0.0–0.1) 0.2 (0.1–0.4)
   Ages 45–64 55.9 0.2 (0.2–0.3) 27.6 (25.7–29.5) 4620 (2981–6824) 19 279 (8111–36 767) 2322 (1474–3444) 2246 (998–4301) 28 468 (16 517–46 842) 83 (53–122) 345 (145–658) 42 (26–62) 40 (18–77) 509 (295–838) 0.5 (0.3–0.7) 2.8 (1.2–5.2) 0.1 (0.1–0.1) 0.1 (0.0–0.1) 0.2 (0.1–0.4)
   Ages ≥65 42.9 0.2 (0.1–0.2) 27.7 (25.4–30.1) 13 062 (7646–37 354) 34 525 (15 355–62 560) 2805 (1576–6691) 1791 (712–4558) 52 183 (30 457–104 202) 305 (178–872) 806 (358–1460) 65 (37–156) 42 (17–106) 1218 (711–2431) 0.3 (0.1–0.7) 2.8 (1.2–4.9) 0.1 (0.0–0.2) 0.1 (0.0–0.2) 0.3 (0.2–0.6)
   Women overall 156 0.4 (0.3–0.5) 26.4 (24.4–28.3) 20 467 (12 035–51 710) 64 447 (27 843–120 044) 5806 (3422–11 682) 4550 (1931–9955) 95 269 (54 601–179 425) 122 (72–307) 383 (165–713) 34 (20–69) 27 (11–59) 566 (324–1066) 0.8 (0.4–2.1) 2.6 (1.1–4.8) 0.1 (0.1–0.3) 0.1 (0.0–0.1) 0.2 (0.1–0.5)
  Men
   Ages 20–44 58.4 0.7 (0.5–0.9) 25.9 (24.7–27.0) 5658 (3637–8272) 15 493 (6339–29 806) 474 (251–814) 340 (150–668) 21 966 (12 471–36 564) 80 (51–116) 218 (89–419) 7 (4–11) 5 (2–9) 309 (175–514) 1.4 (0.9–2.1) 5.4 (2.1–10.1) 0.1 (0.0–0.2) 0.0 (0.0–0.0) 0.3 (0.1–0.5)
   Ages 45–64 54.8 0.3 (0.2–0.3) 28.2 (26.9–29.6) 12 886 (8760–17 955) 29 963 (12 733–55 416) 2728 (1571–4317) 1431 (643–2797) 47 008 (28 553–73 400) 235 (160–328) 547 (232–1011) 50 (29–79) 26 (12–51) 858 (521–1340) 0.5 (0.3–0.7) 3.0 (1.2–5.5) 0.1 (0.0–0.1) 0.1 (0.0–0.1) 0.3 (0.2–0.6)
   Ages ≥65 r 31.9 0.2 (0.1–0.3) 27.5 (25.9–29.1) 13 700 (9123–18 760) 32 147 (13 937–57 165) 2614 (1523–3930) 797 (350–1540) 49 259 (30 216–75 369) 429 (286–587) 1007 (436–1790) 82 (48–123) 25 (11–48) 1543 (946–2360) 0.2 (0.2–0.3) 2.1 (0.9–3.8) 0.0 (0.0–0.1) 0.0 (0.0–0.1) 0.3 (0.2–0.4)
   Men overall 145 0.4 (0.3–0.5) 27.1 (25.7–28.5) 32 245 (21 520–44 986) 77 603 (33 010–142 387) 5817 (3345–9061) 2569 (1143–5005) 118 233 (71 241–185 333) 204 (136–285) 491 (209–902) 37 (21–57) 16 (7–32) 749 (451–1174) 0.7 (0.5–1.1) 3.5 (1.4–6.4) 0.1 (0.0–0.1) 0.0 (0.0–0.1) 0.3 (0.2–0.5)
  Both sexes overall 301 0.4 (0.3–0.5) 26.7 (25.1–28.4) 52 712 (33 555–96 696) 142 050 (60 853–262 431) 11 622 (6767–20 743) 7118 (3074–14 960) 213 503 (125 841–364 758) 162 (103–296) 435 (187–805) 36 (21–64) 22 (9–46) 655 (386–1118) 0.8 (0.4–1.6) 3.0 (1.2–5.6) 0.1 (0.0–0.2) 0.0 (0.0–0.1) 0.3 (0.1–0.5)
Table 4. Continued
Population Characteristics Number of DALYs Attributable to SSBs (95% UI) DALYs per Million Adults Attributable to SSBs (95% UI) Percentage of DALYs Attributable to SSBs (95% UI)
Population
Mean  
SSB Intake 
(Servings/d)
Mean  
BMI (kg/m2) CVD‡ Diabetes Mellitus§ Cancersβ Musculoskeletal¶ Total† CVD‡ Diabetes Mellitus§ Cancersβ Musculoskeletal¶ Total† CVD‡
Diabetes 
Mellitus§ Cancersβ Musculoskeletal¶ Total†
*CVD DALYs include those from ischemic heart disease, ischemic stroke, and hypertensive heart disease.
†Diabetes mellitus DALYs include those from the direct effects of SSBs on diabetes mellitus and the effects of SSBs on diabetes mellitus that are mediated through BMI.
‡Cancer DALYs include those from breast cancer, uterine cancer, esophageal cancer, colon and rectum cancers, pancreatic cancers, kidney cancers, and gall bladder cancer.
§Musculoskeletal DALYS include those from lower back pain and osteoarthritis.
║Total DALYs include those from CVD, diabetes mellitus, and cancers as described above.
(Continued)
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Sugar-sweetened beverages (SSBs) increase obesity and type 2 diabetes mellitus and are now consumed worldwide. Yet, the 
impact of SSBs on global diabetes mellitus– and obesity-related diseases by nation, age, and sex has not been reported. We 
developed a global model incorporating diverse data sources across 187 countries, by age and sex, on the following: SSB intake 
patterns from individual-level dietary surveys and national food availability; effects of SSBs on adiposity and diabetes mel-
litus from meta-analyses of longitudinal cohort studies; impact of adiposity on diabetes mellitus, cardiovascular disease, and 
cancers from meta-analyses of international pooling projects; and numbers of cause-specific national deaths from the Global 
Burden of Diseases study. Using a comparative risk assessment model, in 2010, we estimated ~184 000 deaths/y and 8.5 
million disability-adjusted life-years per year attributable to SSBs worldwide; 75% of deaths and 85% of disability-adjusted 
life-years occurred in low- and middle-income countries. Tremendous geographic variation was evident, with the largest bur-
dens in Latin America and the Caribbean, and the smallest burdens in East Asia. Proportional impacts (percentage of disease 
attributable to SSBs) were highest in young adults, particularly young men. In Mexico, 1 in 3 diabetes mellitus– and obesity-
related deaths in men <44 years of age were attributable to SSBs; and in the United States, 1 in 10 such deaths were attributable 
to SSBs. Given a dramatic inverse gradient between age and SSB intake in most nations, future health burdens could be even 
higher as younger populations age. Our findings highlight the large global health burdens, and the key geographic and demo-
graphic variation, as well, attributable to SSBs, providing the basis for targeted health policy and interventions.
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